"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,A1,US 2013/0124714 A1,061-173-024-799-872,2013-05-16,2013,US 201113294756 A,2011-11-11,US 201113294756 A,2011-11-11,VISUALIZATION OF COMBINED PERFORMANCE METRICS,"Embodiments provide a visualization of combined performance metrics representing the operation of a plurality of computing devices. Sets of host performance metrics corresponding to a plurality of host computing devices are combined to create combined performance metrics, each of which is associated with a performance metric type. The combined performance metrics are plotted in a chart that includes a plurality of axes, each associated with a performance metric type. In addition, a baseline value may be plotted on one or more of the axes. A portion, or the entirety, of the chart may be graphically distinguished when a combined performance metric violates a threshold value.",BEDNAR MARTIN;;VMWARE INC,BEDNAR MARTIN,VMWARE INC (2011-11-03),https://lens.org/061-173-024-799-872,Patent Application,yes,26,82,1,1,0,G06F9/45558;;G06F9/45558;;G06F11/3409;;G06F11/3409;;G06F2009/45591;;G06F2009/45591;;G06F2201/81;;G06F2201/81;;G06F2201/815;;G06F2201/815,G06F15/173,709/224,0,0,,,,DISCONTINUED
2,DE,D1,DE 3486272 D1,190-193-576-876-544,1994-03-24,1994,DE 3486272 T,1984-11-30,US 56663683 A,1983-12-28,Verfahren und Anlage zur auf der Häufigkeit des Vorkommens der Zeichen gegründeten Zeichenerkennung.,,IBM,BEDNAR GREGORY MARTIN,,https://lens.org/190-193-576-876-544,Granted Patent,no,0,0,16,16,0,G06F18/24323;;G06F18/24323,G06F17/30;;G06K9/62;;G06K9/68;;G06K9/70,,0,0,,,,EXPIRED
3,EP,A3,EP 0147657 A3,040-672-047-112-986,1988-07-20,1988,EP 84114430 A,1984-11-30,US 56663683 A,1983-12-28,METHOD AND APPARATUS FOR CHARACTER RECOGNITION BASED UPON THE FREQUENCY OF OCCURRENCE OF CHARACTERS,"The invention relates to a method of processing data for recognising unknown characters of a known character set based in part upon the frequency of occurrence of said characters and to apparatus for performing the method. The method comprises the steps of scanning the unknown characters and generating image data representing the unknown characters, storing the generated image data, and applying to the stored image data discriminating tests for recognition purposes. The method is characterised by the steps of applying to the stored image data a first set of discriminatory tests for identifying whether the image data represents a first group of characters and for recognising the image data that represents characters of the first group of characters. The characters of the first group have a relatively high frequency of occurrence and the first group contains less than all of the characters of the character set. The method also includes subsequently applying to the unrecognised image data a second set of discriminatory tests for identifying whether the unrecognised image data represents a second group of characters and for recognising the image data that represents characters of the second group of characters. The characters of the second group have a lower frequency of occurrence than the characters of the first group and the second group contains at least some characters not in the first group of characters. The method may also include the step of sequentially applying to any unrecognised data from the application of the second set of discriminatory tests at least one additional set of discriminatory tests. Each additional set of discriminatory tests is for identifying the unrecognised image data that represents a respective additional group of characters and for recognising the image data that represents characters of the respective additional group of characters. The characters of each additional group of characters have a lower frequency of occurrence than the characters of the preceding group of characters.",INTERNATIONAL BUSINESS MACHINES CORPORATION,"BEDNAR, GREGORY MARTIN",,https://lens.org/040-672-047-112-986,Search Report,yes,2,0,16,16,0,G06F18/24323;;G06F18/24323,G06F17/30;;G06K9/62;;G06K9/68;;G06K9/70,,2,0,,,"PATENT ABSTRACTS OF JAPAN, vol. 8, no. 153 (P-287)[1590], 17th July 1984; & JP-A-59 052 387 (DENSHI KEISANKI KIHON GIJUTSU KENKIYUU KUMIAI) 26-03-1984;;PATENT ABSTRACTS OF JAPAN, vol. 6, no. 30 (P-103)[908], 23rd February 1982; & JP-A-56 149 676 (NIPPON DENKI K.K.) 19-11-1981",EXPIRED
4,BR,A,BR 8406532 A,162-386-311-713-294,1985-10-15,1985,BR 8406532 A,1984-12-18,US 56663683 A,1983-12-28,METODO E APARELHO PARA O RECONHECIMENTO DE CARACTERES BASEADO NA FREQUENCIA DA OCORRENCIA DOS DITOS CARACTERES,,IBM,BEDNAR GREGORY MARTIN,,https://lens.org/162-386-311-713-294,Patent Application,no,0,0,16,16,0,G06F18/24323;;G06F18/24323,G06F17/30;;G06K9/62;;G06K9/68;;G06K9/70,,0,0,,,,DISCONTINUED
5,EP,B1,EP 0147657 B1,043-486-530-560-375,1994-02-09,1994,EP 84114430 A,1984-11-30,US 56663683 A,1983-12-28,Method and apparatus for character recognition based upon the frequency of occurrence of characters.,,IBM,BEDNAR GREGORY MARTIN,,https://lens.org/043-486-530-560-375,Granted Patent,yes,1,0,16,16,0,G06F18/24323;;G06F18/24323,G06F17/30;;G06K9/62;;G06K9/68;;G06K9/70,,0,0,,,,EXPIRED
6,DE,T2,DE 3486272 T2,105-296-562-686-351,1994-08-11,1994,DE 3486272 T,1984-11-30,US 56663683 A,1983-12-28,Verfahren und Anlage zur auf der Häufigkeit des Vorkommens der Zeichen gegründeten Zeichenerkennung.,,IBM,BEDNAR GREGORY MARTIN,,https://lens.org/105-296-562-686-351,Granted Patent,no,0,0,16,16,0,G06F18/24323;;G06F18/24323,G06F17/30;;G06K9/62;;G06K9/68;;G06K9/70,,0,0,,,,EXPIRED
7,AU,A,AU 1984/034540 A,057-021-624-559-197,1985-07-04,1985,AU 1984/034540 A,1984-10-22,US 56663683 A,1983-12-28,CHARACTER RECOGNITION BASED UPON FREQUENCY OF OCCURRENCE OF CHARACTERS,,IBM,BEDNAR GREGORY MARTIN,,https://lens.org/057-021-624-559-197,Patent Application,no,0,0,16,16,0,G06F18/24323;;G06F18/24323,G06F17/30;;G06K9/62;;G06K9/68;;G06K9/70,,0,0,,,,EXPIRED
8,AU,B2,AU 565704 B2,030-186-246-561-374,1987-09-24,1987,AU 1984/034540 A,1984-10-22,US 56663683 A,1983-12-28,CHARACTER RECOGNITION BASED UPON FREQUENCY OF OCCURRENCE OF CHARACTERS,,IBM,BEDNAR GREGORY MARTIN,,https://lens.org/030-186-246-561-374,Granted Patent,no,0,0,16,16,0,G06F18/24323;;G06F18/24323,G06F17/30;;G06K9/62;;G06K9/68;;G06K9/70,,0,0,,,,EXPIRED
9,EP,A2,EP 0147657 A2,017-809-395-929-985,1985-07-10,1985,EP 84114430 A,1984-11-30,US 56663683 A,1983-12-28,Method and apparatus for character recognition based upon the frequency of occurrence of characters.,"The invention relates to a method of processing data for recognising unknown characters of a known character set based in part upon the frequency of occurrence of said characters and to apparatus for performing the method. The method comprises the steps of scanning the unknown characters and generating image data representing the unknown characters, storing the generated image data, and applying to the stored image data discriminating tests for recognition purposes. The method is characterised by the steps of applying to the stored image data a first set of discriminatory tests for identifying whether the image data represents a first group of characters and for recognising the image data that represents characters of the first group of characters. The characters of the first group have a relatively high frequency of occurrence and the first group contains less than all of the characters of the character set. The method also includes subsequently applying to the unrecognised image data a second set of discriminatory tests for identifying whether the unrecognised image data represents a second group of characters and for recognising the image data that represents characters of the second group of characters. The characters of the second group have a lower frequency of occurrence than the characters of the first group and the second group contains at least some characters not in the first group of characters. The method may also include the step of sequentially applying to any unrecognised data from the application of the second set of discriminatory tests at least one additional set of discriminatory tests. Each additional set of discriminatory tests is for identifying the unrecognised image data that represents a respective additional group of characters and for recognising the image data that represents characters of the respective additional group of characters. The characters of each additional group of characters have a lower frequency of occurrence than the characters of the preceding group of characters.",IBM,BEDNAR GREGORY MARTIN,,https://lens.org/017-809-395-929-985,Patent Application,yes,0,0,16,16,0,G06F18/24323;;G06F18/24323,G06F17/30;;G06K9/62;;G06K9/68;;G06K9/70,,0,0,,,,EXPIRED
10,US,A1,US 2011/0261055 A1,035-617-607-040-640,2011-10-27,2011,US 76416910 A,2010-04-21,US 76416910 A,2010-04-21,Method and Apparatus for Visualizing the Health of Datacenter Objects,"Embodiments of the present invention provide a dashboard that displays an overview of a datacenter's health which helps prioritize, monitor, and troubleshoot problems. In particular, one embodiment is a method for visualizing the health of datacenter objects which includes displaying datacenter objects on a scatterplot of a dashboard wherein one axis of the scatterplot corresponds to problem severity and another axis of the scatterplot corresponds to time.",VMWARE INC,WONG KAREN NATALIE;;BEDNAR MARTIN,VMWARE INC (2010-04-20),https://lens.org/035-617-607-040-640,Patent Application,yes,7,194,2,2,0,G06T11/206;;H04L41/0609;;H04L41/0609;;H04L41/22;;H04L41/22;;H04L43/067;;H04L43/067,G06T11/20,345/440,2,2,127-060-709-317-081;;025-144-524-031-191,10.1109/iv.2007.149;;10.1145/1029208.1029217,"Musa, S.; Parish, D.J.; , ""Visualising Communication Network Security Attacks,"" Information Visualization, 2007. IV '07. 11th International Conference , vol., no., pp.726-733, 4-6 July 2007;;Ball, R., Fink, G. A., & North, C. (2004, October). Home-centric visualization of network traffic for security administration. In Proceedings of the 2004 ACM workshop on Visualization and data mining for computer security (pp. 55-64). ACM.",ACTIVE
11,US,A1,US 2012/0284628 A1,161-357-652-033-423,2012-11-08,2012,US 201113101948 A,2011-05-05,US 201113101948 A,2011-05-05,USER INTERFACE FOR MANAGING MONITORING PROFILES,"A graphical user interface for a virtualized computing environment that includes a plurality of host computers, each having one or more virtual machines running therein, where the virtualized computing environment is configured with one or more monitoring profiles for monitoring a status of objects included in the virtualized computing environment, where the graphical user interface includes a first section and a second section. The first section organizes the one or more monitoring profiles, where each monitoring profile includes one or more rules and each rule corresponds to an action that is performed if the rule is violated. The second section organizes a first set of rules associated with a selected monitoring profile and corresponding actions associated with each rule in the first set of rules.",WONG KAREN NATALIE;;BEDNAR MARTIN;;VMWARE INC,WONG KAREN NATALIE;;BEDNAR MARTIN,VMWARE INC (2011-04-29),https://lens.org/161-357-652-033-423,Patent Application,yes,26,26,2,2,0,H04L43/0817;;H04L41/22;;H04L41/5096;;H04L41/0213;;G06F11/301;;G06F11/3055;;G06F11/3072;;G06F11/32;;G06F11/0709;;G06F11/076;;H04L67/306;;H04L41/40;;H04L43/20;;H04L43/0817;;H04L41/22;;H04L41/5096;;H04L41/0213;;G06F11/301;;G06F11/3055;;G06F11/3072;;G06F11/32;;G06F11/0709;;G06F11/076;;H04L67/306,G06F15/16;;G06F3/048,715/736,2,0,,,"Cisco Systems, Inc.. 2008. ""Cisco Adaptive wIPS Deployment Guide"".;;Lowe, Scott.�Mastering VMware VSphere 4. Indianapolis: Wiley Pub., 2009. Print.",ACTIVE
12,US,B2,US 9124488 B2,118-967-334-907-796,2015-09-01,2015,US 76416910 A,2010-04-21,US 76416910 A,2010-04-21,Method and apparatus for visualizing the health of datacenter objects,"Embodiments of the present invention provide a dashboard that displays an overview of a datacenter's health which helps prioritize, monitor, and troubleshoot problems. In particular, one embodiment is a method for visualizing the health of datacenter objects which includes displaying datacenter objects on a scatterplot of a dashboard wherein one axis of the scatterplot corresponds to problem severity and another axis of the scatterplot corresponds to time.",WONG KAREN NATALIE;;BEDNAR MARTIN;;VMWARE INC,WONG KAREN NATALIE;;BEDNAR MARTIN,VMWARE INC (2010-04-20),https://lens.org/118-967-334-907-796,Granted Patent,yes,7,7,2,2,0,G06T11/206;;H04L41/0609;;H04L41/0609;;H04L41/22;;H04L41/22;;H04L43/067;;H04L43/067,G06T11/00;;G06T11/20;;H04L12/24;;H04L12/26,,2,2,127-060-709-317-081;;025-144-524-031-191,10.1109/iv.2007.149;;10.1145/1029208.1029217,"Musa, S.; Parish, D.J.; , ""Visualising Communication Network Security Attacks,"" Information Visualization, 2007. IV '07. 11th International Conference , vol., No., pp. 726-733, Jul. 4-6, 2007.;;Ball, R., Fink, G. A., & North, C. (Oct. 2004). Home-centric visualization of network traffic for security administration. In Proceedings of the 2004 ACM workshop on Visualization and data mining for computer security (pp. 55-64). ACM.",ACTIVE
13,US,B2,US 9553948 B2,036-941-215-477-852,2017-01-24,2017,US 201113101948 A,2011-05-05,US 201113101948 A,2011-05-05,User interface for managing monitoring profiles,"A graphical user interface for a virtualized computing environment that includes a plurality of host computers, each having one or more virtual machines running therein, where the virtualized computing environment is configured with one or more monitoring profiles for monitoring a status of objects included in the virtualized computing environment, where the graphical user interface includes a first section and a second section. The first section organizes the one or more monitoring profiles, where each monitoring profile includes one or more rules and each rule corresponds to an action that is performed if the rule is violated. The second section organizes a first set of rules associated with a selected monitoring profile and corresponding actions associated with each rule in the first set of rules.",WONG KAREN NATALIE;;BEDNAR MARTIN;;VMWARE INC,WONG KAREN NATALIE;;BEDNAR MARTIN,VMWARE INC (2011-04-29),https://lens.org/036-941-215-477-852,Granted Patent,yes,26,7,2,2,0,H04L43/0817;;H04L41/22;;H04L41/5096;;H04L41/0213;;G06F11/301;;G06F11/3055;;G06F11/3072;;G06F11/32;;G06F11/0709;;G06F11/076;;H04L67/306;;H04L41/40;;H04L43/20;;H04L43/0817;;H04L41/22;;H04L41/5096;;H04L41/0213;;G06F11/301;;G06F11/3055;;G06F11/3072;;G06F11/32;;G06F11/0709;;G06F11/076;;H04L67/306,G06F11/07;;H04L29/08;;G06F11/30;;G06F11/32;;H04L12/24;;H04L12/26,,2,0,,,"Cisco Systems, Inc.. 2008. ""Cisco Adaptive wIPS Deployment Guide"".;;Lowe, Scott. Mastering VMware VSphere 4. Indianapolis: Wiley Pub., 2009. Print.",ACTIVE
14,DE,D1,DE 3485825 D1,051-947-358-981-141,1992-08-27,1992,DE 3485825 T,1984-09-25,US 53728083 A,1983-09-29,VERFAHREN UND ANLAGE FUER DIE SEGMENTIERUNG VON ZEICHENDARSTELLUNGEN.,,IBM,BEDNAR GREGORY MARTIN;;FRYER GEORGE BERNARD,,https://lens.org/051-947-358-981-141,Granted Patent,no,0,0,8,8,0,G06V30/158;;G06V30/10;;G06V30/158;;G06V30/10,G06V30/10,,0,0,,,,EXPIRED
15,EP,B1,EP 0138445 B1,039-114-568-661-807,1992-07-22,1992,EP 84306526 A,1984-09-25,US 53728083 A,1983-09-29,METHOD AND APPARATUS FOR SEGMENTING CHARACTER IMAGES,,INTERNATIONAL BUSINESS MACHINES CORPORATION,"BEDNAR, GREGORY MARTIN;;FRYER, GEORGE BERNARD",,https://lens.org/039-114-568-661-807,Granted Patent,yes,1,1,8,8,0,G06V30/158;;G06V30/10;;G06V30/158;;G06V30/10,G06V30/10,,0,0,,,,EXPIRED
16,WO,A1,WO 2019/105493 A1,043-564-803-121-206,2019-06-06,2019,CZ 2018000056 W,2018-11-29,CZ 2017771 A,2017-12-01,SYSTEM FOR UNWINDING THE COVERING SHEET IN THE BOOT OF A VEHICLE,"The invention relates to a system for unwinding the sheet in the boot of a vehicle. This system consists of a spring (1), a tube (2) connected to the sheet, a profile (3) to be inserted, and a carrier of the spring (1), wherein the spring (1) is arranged inside the profile (3) to be inserted, which is mounted in the tube (2). The spring (1) is secured to the tube (2) by the carrier of the spring (1), wherein the carrier of the spring (1) is simultaneously secured to the lateral inner cladding of the boot. The profile (3) consists of three symmetrical tips and each of the tips has a curved shape. The invention is characterised in that exactly one tip is connected to the second tip by a free end and is connected to the third tip by the second free end, and simultaneously the second and the third tips are not connected to one another. The tip-connection points are in contact with the spring (1), wherein the free ends of the second and third tips are in contact with the spring (1) and pre-tensioned, whereby the spring is fixed in a predetermined position.",SKODA AUTO AS,BEDNAR PAVEL;;KOSTINEC MARTIN;;POLACEK ROMAN,,https://lens.org/043-564-803-121-206,Patent Application,yes,4,0,3,3,0,B60J3/0234;;B60R5/047;;E06B9/42;;B60R5/047;;B60J1/2033;;B60J1/205,B60R5/04;;B60J1/20;;E06B9/60,,0,0,,,,PENDING
17,EP,A3,EP 0138445 A3,006-474-067-764-949,1988-07-27,1988,EP 84306526 A,1984-09-25,US 53728083 A,1983-09-29,METHOD AND APPARATUS FOR SEGMENTING CHARACTER IMAGES,"@ The invention is directed to apparatus for segmenting into individual character images a coded representation of a line of characters printed on a document including a scanner for scanning along the line of characters and for generating data signals representing images of the characters. A profile generator responsive to the data signals generates a line profile segment for each character scanned. Each profile segment extends in a line parallel to the direction of scanning and represents the size of a respective character in the direction of scanning. The apparatus also includes segmentation means which utilises the profile segments to establish in the data signals segmentation points defining boundaries between adjacent character images. The apparatus is characterised in that the segmentation means comprises position determining means for determining the position of the centre of each of said profile segments, a linear function generator for generating a linear function dependent upon the position of the centre of at least one of the profile segments, and analysing means for utilising the linear function to establish the positions of segmentation points. The invention also includes a method of segmenting into individual character images a coded representation of a line of characters printed on a document utilising the above apparatus.",INTERNATIONAL BUSINESS MACHINES CORPORATION,"BEDNAR, GREGORY MARTIN;;FRYER, GEORGE BERNARD",,https://lens.org/006-474-067-764-949,Search Report,yes,2,0,8,8,0,G06V30/158;;G06V30/10;;G06V30/158;;G06V30/10,G06V30/10,,1,0,,,"PATENT ABSTRACTS OF JAPAN, vol. 7, no. 87 (P-190)[1232], 12th April 1983; & JP-A-58 14 281 (TOKYO SHIBAURA DENKI K.K.) 27-01-1983",EXPIRED
18,EP,A2,EP 0138445 A2,028-105-791-908-207,1985-04-24,1985,EP 84306526 A,1984-09-25,US 53728083 A,1983-09-29,Method and apparatus for segmenting character images.,"@ The invention is directed to apparatus for segmenting into individual character images a coded representation of a line of characters printed on a document including a scanner for scanning along the line of characters and for generating data signals representing images of the characters. A profile generator responsive to the data signals generates a line profile segment for each character scanned. Each profile segment extends in a line parallel to the direction of scanning and represents the size of a respective character in the direction of scanning. The apparatus also includes segmentation means which utilises the profile segments to establish in the data signals segmentation points defining boundaries between adjacent character images. The apparatus is characterised in that the segmentation means comprises position determining means for determining the position of the centre of each of said profile segments, a linear function generator for generating a linear function dependent upon the position of the centre of at least one of the profile segments, and analysing means for utilising the linear function to establish the positions of segmentation points. The invention also includes a method of segmenting into individual character images a coded representation of a line of characters printed on a document utilising the above apparatus.",IBM,BEDNAR GREGORY MARTIN;;FRYER GEORGE BERNARD,,https://lens.org/028-105-791-908-207,Patent Application,yes,0,7,8,8,0,G06V30/158;;G06V30/10;;G06V30/158;;G06V30/10,G06V30/10,,0,0,,,,EXPIRED
19,DE,A1,DE 102007011032 A1,187-340-898-563-531,2008-09-11,2008,DE 102007011032 A,2007-03-07,DE 102007011032 A,2007-03-07,"Holding device for galvanically coating common rail lines comprises a contact bolt for contacting with a holding unit of a galvanizing device, a holding dome molded to the contact bolt for fixing a cover and a contact spring","Holding device (1) comprises a contact bolt (2) for contacting with a holding unit of a galvanizing device, a holding dome (7) molded to the contact bolt for fixing a cover (4) and a contact spring (5) via which a pipe a common rail line to be galvanized with the holding device can be shifted.",DAIMLER AG,BAYER SIEGFRIED;;SCHMIDT MATTHIAS;;BEDNAR MARTIN,,https://lens.org/187-340-898-563-531,Patent Application,no,1,0,1,1,0,C25D17/06;;C25D7/04,C25D17/06,,0,0,,,,DISCONTINUED
20,WO,A1,WO 2011/114260 A1,066-950-017-280-234,2011-09-22,2011,IB 2011050987 W,2011-03-09,US 31568210 P,2010-03-19,CEREBROSPINAL FLUID PURIFICATION SYSTEM,Systems and methods the removal of toxins from the cerebrospinal fluid (CSF) are disclosed.,PFIZER;;BEDNAR MARTIN MICHAEL;;MORRISON BRIGGS WILLIAM,BEDNAR MARTIN MICHAEL;;MORRISON BRIGGS WILLIAM,,https://lens.org/066-950-017-280-234,Patent Application,yes,30,28,1,1,0,A61K35/24;;A61K35/30;;A61M27/006;;A61P25/00;;A61P25/16;;A61P25/28;;B01D61/145,A61K35/12;;A61K35/24;;A61K35/30;;A61M1/00;;A61P25/00;;A61P25/16;;A61P25/28,,30,26,019-794-714-899-466;;169-803-183-236-25X;;169-803-183-236-25X;;077-136-988-769-916;;024-394-161-724-540;;135-236-838-817-601;;085-416-221-016-421;;011-131-058-641-230;;016-690-234-524-520;;066-623-345-893-963;;100-155-682-679-032;;022-135-025-220-437;;080-596-108-526-517;;096-217-265-398-991;;018-083-699-336-608;;050-192-968-662-456;;022-811-786-847-614;;055-361-374-348-378;;152-558-422-734-536;;064-444-337-088-757;;120-874-601-772-54X;;120-874-601-772-54X;;052-968-153-379-201;;132-271-934-286-753;;012-914-073-001-191;;027-492-781-913-076,19246392;;10.1073/pnas.0813404106;;pmc2647980;;10.1176/appi.neuropsych.14.3.351;;10.1176/appi.neuropsych.14.3.351;;10.1146/annurev.neuro.26.010302.081142;;12704221;;10.1126/science.1067122;;12065827;;10.1016/s0140-6736(06)69113-7;;16876668;;16481071;;10.1016/j.neurobiolaging.2005.04.017;;17173140;;10.1172/jci28769;;pmc1697799;;10468546;;10.1073/pnas.96.18.9989;;pmc33726;;pmc137821;;10.1073/pnas.242594999;;12391311;;10392578;;10.1038/399a032;;10.1126/science.1087753;;14593166;;10.1126/science.1090349;;14593169;;9804537;;10.1126/science.282.5391.1072;;10.1073/pnas.92.5.1251;;7877963;;pmc42496;;10.1073/pnas.0730423100;;pmc152971;;12655070;;17592131;;pmc1899188;;10.1073/pnas.0704307104;;10.1038/ncpneuro0490;;17479073;;10.1097/01.nrl.0000259483.70041.55;;17495758;;10.1038/35001088;;10688204;;15277677;;pmc509213;;10.1073/pnas.0402391101;;15277677;;pmc509213;;10.1073/pnas.0402391101;;10.1038/399a040;;10392579;;10.1073/pnas.0404874101;;pmc521993;;15306684;;pmc58670;;10.1073/pnas.211430898;;11572956;;11340231;;10.1161/01.str.32.5.1185,"THAKKER ET AL., PROC NATL ACAD SCI U S A., vol. 106, no. 11, 17 March 2009 (2009-03-17), pages 4501 - 6;;BLUMENFELD, H., NEUROANATOMY THROUGH CLINICAL CASES, vol. 951, 2002;;BLUMENFELD, H., NEUROANATOMY THROUGH CLINICAL CASES, 2002;;CAUGHEY, B., P. T. LANSBURY, ANNU REV NEUROSCI, vol. 26, 2003, pages 267 - 98;;CAUGHEY, B., P. T. LANSBURY, ANNU REVNEUROSCI, vol. 26, 2003, pages 267 - 98;;TAYLOR, J. P., J. HARDY ET AL., SCIENCE, vol. 296, no. 5575, 2002, pages 1991 - 5;;BLENNOW, K., M. J. DE LEON ET AL., LANCET, vol. 368, no. 9533, 2006, pages 387 - 403;;GLABE, C. G., NEUROBIOL AGING, vol. 27, no. 4, 2006, pages 570 - 5;;DIAS-SANTAGATA, D., T. A. FULGA ET AL., J CLIN INVEST, vol. 117, no. 1, 2007, pages 236 - 45;;KOO, E. H., T. LANSBURY, JR. ET AL., PROC NATL ACAD SD USA, vol. 96, no. 18, 1999, pages 9989 - 90;;STEECE-COLLIER, K., E. MARIES ET AL., PROC NATL ACAD SCI USA, vol. 99, no. 22, 2002, pages 13972 - 4;;DUNNETT, S. B., A. BJORKLUND, NATURE, vol. 399, no. 6738, 1999, pages A32 - 9;;DAWSON, T. M., V. L. DAWSON, SCIENCE, vol. 302, no. 5646, 2003, pages 819 - 22;;DEKOSKY, S. T., K. MAREK, SCIENCE, vol. 302, no. 5646, 2003, pages 830 - 4;;SHOULSON, I., SCIENCE, vol. 282, no. 5391, 1998, pages 1072 - 4;;ROWLAND, L. P., PROC NATL ACAD SCI USA, vol. 92, no. 5, 1995, pages 1251 - 3;;ROWLAND, L. P., PROC NATL ACAD SCI U S A, vol. 92, no. 5, 1995, pages 1251 - 3;;VALENTINE, J. S., P. J. HART, PROC NATL ACAD SCI USA, vol. 100, no. 7, 2003, pages 3617 - 22;;BANCI, L., I. BERTINI ET AL., PROC NATL ACAD SCI USA, vol. 104, no. 27, 2007, pages 11263 - 7;;MACDONALD, R. L., R. M. PLUTA ET AL., NAT CHN PRACT NEUROL, vol. 3, no. 5, 2007, pages 256 - 63;;VERNINO, S., M. GESCHWIND ET AL., NEUROLOGIST, vol. 13, no. 3, 2007, pages 140 - 7;;PARKHILL, J., B. W. WREN ET AL., NATURE, vol. 403, no. 6770, 2000, pages 665 - 8;;YUKI, N., K. SUSUKI ET AL., PROC NATL ACAD SD USA, vol. 101, no. 31, 2004, pages 11404 - 9;;YUKI, N., K. SUSUKI ET AL., PROC NATL ACAD SCI USA, vol. 101, no. 31, 2004, pages 11404 - 9;;NOSEWORTHY, J. H., NATURE, vol. 399, no. 6738, 1999, pages A40 - 7;;HOHLFELD, R., H. WEKERLE, PROC NATL ACAD SD USA, vol. 101, no. 2, 2004, pages 14599 - 606;;MCCULLOCH, J., D. DEWAR, PROC NATL ACAD SD USA, vol. 98, no. 20, 2001, pages 10989 - 91;;MASCIA, L., L. FEDORKO ET AL., STROKE, vol. 32, no. 5, 2001, pages 1185 - 90;;KESSLER, I. M., Y. G. PACHECO ET AL., SURGNEUROL, vol. 64, no. 1, 2005, pages 1 - 2,5;;KESSLER, I. M., Y. G. PACHECO ET AL., SURG NEUROL, vol. 64, no. 1, 2005",PENDING
21,US,B2,US 9501849 B2,195-994-129-615-416,2016-11-22,2016,US 201213470217 A,2012-05-11,US 201213470217 A,2012-05-11,Multi-dimensional visualization tool for browsing and troubleshooting at scale,"A user interface that allows administrators of a virtualized computing environment to easily navigate to and/or search for specific objects, determine relationships between selected objects, and have visibility into the health status of objects in the virtualized computing environment. Objects within a column may be displayed with names, displayed as bars, or aggregated into groups based on the number of objects in the column. Also, in some embodiments, when a user selects one object, objects in other columns that are related to the selected object may be visually distinguished from the other objects, allowing an administrator to easily navigate to related objects.",WONG KAREN NATALIE;;BEDNAR MARTIN;;SHUKLA MANASWI;;VMWARE INC,WONG KAREN NATALIE;;BEDNAR MARTIN;;SHUKLA MANASWI,VMWARE INC (2012-04-19),https://lens.org/195-994-129-615-416,Granted Patent,yes,99,13,2,2,0,G06T11/206;;G06T11/206,G09G5/22;;G06T11/20,,6,0,,,"Oracle, Financial Reporting Studio Users Guide 9.3.1, 2007, pp. 1-360.;;Bakman-Fig-A (from Bakman, US PGPUB No. 20090307597 A1), 2009.;;Bakman-Fig-B (from Bakman, US PGPUB No. 20090307597 A1), 2009.;;Cranford, How to Produce Excellent Graphs in SAS, 2009.;;Peltier, Clustered and Stacked Column and Bar Charts, Aug. 1, 2011.;;IBM, Show Barchar in TreeTable, 2006.",ACTIVE
22,US,A1,US 2013/0300747 A1,117-487-784-364-005,2013-11-14,2013,US 201213470217 A,2012-05-11,US 201213470217 A,2012-05-11,MULTI-DIMENSIONAL VISUALIZATION TOOL FOR BROWSING AND TROUBLESHOOTING AT SCALE,"A user interface that allows administrators of a virtualized computing environment to easily navigate to and/or search for specific objects, determine relationships between selected objects, and have visibility into the health status of objects in the virtualized computing environment. Objects within a column may be displayed with names, displayed as bars, or aggregated into groups based on the number of objects in the column. Also, in some embodiments, when a user selects one object, objects in other columns that are related to the selected object may be visually distinguished from the other objects, allowing an administrator to easily navigate to related objects.",WONG KAREN NATALIE;;BEDNAR MARTIN;;SHUKLA MANASWI;;VMWARE INC,WONG KAREN NATALIE;;BEDNAR MARTIN;;SHUKLA MANASWI,VMWARE INC (2012-04-19),https://lens.org/117-487-784-364-005,Patent Application,yes,146,81,2,2,0,G06T11/206;;G06T11/206,G06T11/20,345/440.2,6,0,,,"Oracle, Financial Reporting Studio User's Guide 9.3.1, 2007, pp. 1-360;;Bakman_Fig_A (from Bakman, US PGPUB No. 20090307597 A1), 2009;;Bakman_Fig_B (from Bakman, US PGPUB No. 20090307597 A1), 2009;;Cranford, How to Produce Excellent Graphs in SAS, 2009;;Peltier, Clustered and Stacked Column and Bar Charts, 8/1/2011;;IBM, Show Barchar in TreeTable, 2006",ACTIVE
23,CZ,B6,CZ 296849 B6,120-283-198-455-178,2006-07-12,2006,CZ 20012314 A,2001-06-22,CZ 20012314 A,2001-06-22,Machine tool frame and process for producing thereof,"The present invention relates to a machine tool frame consisting of a central tube (1) with radial ribs (2) welded thereto. Parts of a peripheral jacket (3) are welded to free edges of said radial ribs (2) at least in the directions parallel to said central tube (1) longitudinal axis. At least some cavities, extending between the central tube (1) and the peripheral jacket (3), are filled up with rigid foam material (5) exhibiting residual excessive pressure. Disclosed is also a process for producing such a machine tool frame wherein the manufacturing process comprises first welding radial ribs (2) to a central tube (1) (2), subsequently welding a peripheral jacket (3) to free edges of said radial ribs (2), then welding a bottom (4) and a cover (40), and finally filling up at least some cavities, selected symmetrically to some of the frame longitudinal planes passing through said central tube (1) axis, with a filling material which is subsequently let to expand and solidify to form a rigid foam bearing with residual excessive pressure, after hardening, against walls encompassing the foam.",TOS VARNSDORF A S,BEDNAR SLAVOMIR;;MALEK MARTIN;;RYSAVY IVAN;;SMOLAR DANIEL,,https://lens.org/120-283-198-455-178,Granted Patent,no,3,0,2,2,0,,B23Q1/01,,0,0,,,,EXPIRED
24,AU,B2,AU 724449 B2,109-191-561-815-347,2000-09-21,2000,AU 1997/018273 A,1997-01-11,US 58998296 A;;US 9700492 W,1996-01-23,Anti-CD18 antibodies for use against stroke,,GENENTECH INC;;UNIV VERMONT,BEDNAR MARTIN M;;GROSS CORDELL E;;THOMAS G ROGER,,https://lens.org/109-191-561-815-347,Granted Patent,no,0,0,22,22,0,A61K38/00;;A61K39/39541;;A61K2039/505;;C07K16/2845;;A61P7/02;;A61P9/10,G01N33/53;;A61K38/00;;A61K39/395;;A61P7/02;;A61P9/10;;C07K16/28,,2,2,095-311-758-359-733;;010-080-346-309-933,8546211;;pmc1861617;;10.1152/ajpheart.1996.270.1.h53;;8769734,"AM. OF PATH, 148/1 (1996) P.241 GARCIA ET AL;;AM. OF PHYS, 270/1 PT 2 (1996) H53-H64, PEREZ ET AL",EXPIRED
25,WO,A3,WO 2009/050554 A3,166-111-371-435-436,2009-10-15,2009,IB 2008002660 W,2008-10-06,US 98116807 P,2007-10-19,"PYRAZOLO [4, 3D] PYRIMIDINE DERIVATIVES FOR USE IN PROMOTING FUNCTIONAL RECOVERY","The present invention provides for the use of PDE5 inhibitors in methods for treating in a mammal certain central nervous system (CNS) disorders or conditions, including neurodegenerative disorders such as for example Alzheimer's disease or stroke. This invention also pertains to the use of PDE5 inhibitors in methods for promoting in a mammal functional recovery following events such as stroke, such as coronary artery bypass grafting (CABG)-related stroke; craniocerebral trauma; traumatic brain injury; spinal cord trauma; cerebral ischemia, including cerebral ischemia related to CABG; multi-infarct dementia; post-CABG dementia; subdural hematoma; subarachnoid hemorrhage; or any of the wide varieties of brain tumors and/or their removal. The PDE5 inhibitors are compounds of formula (I) or tautomers thereof or pharmaceutically acceptable salts or solvates of said compounds or tautomers.",PFIZER;;BEDNAR MARTIN MICHAEL;;MENNITI FRANK SAMUEL;;TATE BARBARA ANN,BEDNAR MARTIN MICHAEL;;MENNITI FRANK SAMUEL;;TATE BARBARA ANN,,https://lens.org/166-111-371-435-436,Search Report,yes,2,0,2,2,0,A61K31/519;;A61P25/28,A61K31/519;;A61P25/28,,2,2,070-770-191-907-721;;043-854-163-097-003,10.1161/01.str.0000158923.19956.73;;15746452;;10.1016/j.brainres.2006.08.028;;16959227,"ZHANG LI ET AL: ""Functional recovery in aged and young rats after embolic stroke - Treatment with a phosphodiesterase type 5 inhibitor"", STROKE, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 36, no. 4, 1 April 2005 (2005-04-01), pages 847 - 852, XP002404819, ISSN: 0039-2499;;ZHANG L ET AL: ""Tadalafil, a long-acting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke"", BRAIN RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 1118, no. 1, 6 November 2006 (2006-11-06), pages 192 - 198, XP025101612, ISSN: 0006-8993, [retrieved on 20061106]",PENDING
26,EP,A2,EP 0138079 A2,037-827-598-407-217,1985-04-24,1985,EP 84111043 A,1984-09-17,US 53727983 A,1983-09-29,Character recognition apparatus and method for recognising characters associated with diacritical marks.,"The invention relates to character recognition apparatus, for recognising unknown characters of a known character set, some of the characters having diacritical marks associated therewith, which includes storage means for storing character data of an unknown character which may be associated with a diacritical mark, and recognition means for examining the stored character data in order to recognise unknown characters. The recognition means comprises extracting means for extracting from the stored character data the character data corresponding to a predetermined portion of the character which is the expected location of a diacritical mark, and examining means for examining the extracted diacritical mark character data and the rest of the stored character data of the unknown character in order to recognise the unknown character and any diacritical mark associated therewith. The invention also relates to a method of recognising unknown characters using apparatus of the above type.",IBM,BEDNAR GREGORY MARTIN;;FRYER GEORGE BERNARD;;NARASIMHA MANTHRI SELVAPULLAI,,https://lens.org/037-827-598-407-217,Patent Application,yes,2,5,8,8,0,G06V10/10;;G06V30/10;;G06V30/148;;G06V30/15;;G06V10/70;;G06F18/00;;G06V10/10;;G06V30/10;;G06F18/00;;G06V30/148;;G06V30/15;;G06V10/70,G06V10/70;;G06V10/10;;G06V30/10;;G06V30/148,,0,0,,,,EXPIRED
27,WO,A3,WO 1997/026912 A3,169-287-924-010-947,1997-10-09,1997,US 9700492 W,1997-01-11,US 58998296 A,1996-01-23,ANTI-CD18 ANTIBODIES FOR USE AGAINST STROKE,"A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective amount of an anti-CD18 antibody to the mammal, in the absence of removal of the arterial obstruction.",GENENTECH INC;;UNIV VERMONT,BEDNAR MARTIN M;;GROSS CORDELL E;;THOMAS G ROGER,,https://lens.org/169-287-924-010-947,Search Report,yes,1,0,22,22,0,A61K38/00;;A61K39/39541;;A61K2039/505;;C07K16/2845;;A61P7/02;;A61P9/10,A61K38/00;;A61K39/395;;G01N33/53;;A61P7/02;;A61P9/10;;C07K16/28,,6,5,095-311-758-359-733;;010-080-346-309-933;;048-794-669-079-726;;001-812-195-333-366;;097-147-782-576-253,8546211;;pmc1861617;;10.1152/ajpheart.1996.270.1.h53;;8769734;;7860929;;10.1016/0735-1097(94)00443-t;;10.1161/01.str.23.5.712;;1579969;;7908437;;10.2210/pdb2fgw/pdb;;10.1002/prot.340180107,"J. GARCIA ET AL.: ""Effects of CD11b/18 monoclonal antibody on rats with permanent middle cerebral artery occlusion."", AMERICAN JOURNAL OF PATHOLOGY, vol. 148, no. 1, January 1996 (1996-01-01), HAGERSTOWN, MD, USA, pages 241 - 248, XP002036510;;R. PEREZ ET AL.: ""Factors modifying protective effect of anti-CD18 antibodies on myocardial reperfusion injury in dogs."", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 270, no. 1 part 2, 1996, WASHINGTON, DC, USA, pages H53 - H64, XP002036511;;T. AVERSANO ET AL.: ""A chimeric IgG4 monoclonal antibody directed against CD18 reduces infarct size in a primate model of myocardial ischemia and reperfusion."", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 25, no. 3, 1 March 1995 (1995-03-01), NEW YORK, NY, USA, pages 781 - 788, XP002036512;;E. MORI ET AL.: ""Inhibition of polymorphonuclear leukocyte adherence suppresses no-reflow after focal cerebral ischemia in baboons."", STROKE, vol. 23, no. 5, May 1992 (1992-05-01), DALLAS, TX, USA, pages 712 - 718, XP002036513;;M. BEDNAR ET AL.: ""IB4, a monoclonal antibody against the CD18 adhesion complex of leukocytes, attenuates intracranial hypertension in a rabbit stroke model."", STROKE, vol. 23, no. 1, January 1992 (1992-01-01), DALLAS, TX, USA, pages 152, XP002036514;;C. EIGENBROT ET AL.: ""X-ray structures of fragments from binding and nonbinding versions of a humanized anti-CD18 antibody: Structural indications of the key role of VH residues 59 to 65."", PROTEINS: STRUCTURE, FUNCTION, AND GENETICS, vol. 18, no. 1, January 1994 (1994-01-01), NEW YORK, NY, USA, pages 49 - 62, XP000578098",PATENTED
28,EP,A3,EP 0138079 A3,028-224-754-051-381,1988-07-06,1988,EP 84111043 A,1984-09-17,US 53727983 A,1983-09-29,CHARACTER RECOGNITION APPARATUS AND METHOD FOR RECOGNISING CHARACTERS ASSOCIATED WITH DIACRITICAL MARKS,"The invention relates to character recognition apparatus, for recognising unknown characters of a known character set, some of the characters having diacritical marks associated therewith, which includes storage means for storing character data of an unknown character which may be associated with a diacritical mark, and recognition means for examining the stored character data in order to recognise unknown characters. The recognition means comprises extracting means for extracting from the stored character data the character data corresponding to a predetermined portion of the character which is the expected location of a diacritical mark, and examining means for examining the extracted diacritical mark character data and the rest of the stored character data of the unknown character in order to recognise the unknown character and any diacritical mark associated therewith. The invention also relates to a method of recognising unknown characters using apparatus of the above type.",INTERNATIONAL BUSINESS MACHINES CORPORATION,"BEDNAR, GREGORY MARTIN;;FRYER, GEORGE BERNARD;;NARASIMHA, MANTHRI SELVAPULLAI",,https://lens.org/028-224-754-051-381,Search Report,yes,3,0,8,8,0,G06V10/10;;G06V30/10;;G06V30/148;;G06V30/15;;G06V10/70;;G06F18/00;;G06V10/10;;G06V30/10;;G06F18/00;;G06V30/148;;G06V30/15;;G06V10/70,G06V10/70;;G06V30/10;;G06V10/10;;G06V30/148,,0,0,,,,EXPIRED
29,US,A,US 5914112 A,138-226-070-009-112,1999-06-22,1999,US 78880097 A,1997-01-22,US 78880097 A;;US 9303896 P,1996-01-23,Anti-CD18 antibodies in stroke,"A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective amount of an anti-CD18 antibody to the mammal, in the absence of removal of the arterial obstruction.",GENENTECH INC;;UNIV VERMONT,BEDNAR MARTIN M;;GROSS CORDELL E;;THOMAS G ROGER,UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (1997-07-02);;GENENTECH INC (1997-04-25),https://lens.org/138-226-070-009-112,Granted Patent,yes,28,83,1,10,4,A61K38/00;;C07K16/2845;;C07K2317/24;;A61P9/10;;C07K16/2845;;A61K38/00;;C07K2317/24,A61K38/00;;A61P9/10;;C07K16/28,424/144.1;;424/130.1;;424/133.1;;424/141.1;;424/173.1;;424/153.1;;530/387.1;;530/387.3;;530/388.1;;530/388.2;;530/388.22;;530/388.7,48,43,002-259-026-531-084;;001-812-195-333-366;;002-403-986-447-57X;;052-798-529-997-739;;018-838-358-619-397;;037-290-746-113-468;;048-794-669-079-726;;055-030-583-599-951;;045-077-176-392-799;;027-902-851-592-220;;070-469-326-587-575;;110-470-601-227-134;;019-042-311-518-903;;013-965-453-283-510;;078-582-056-407-68X;;000-514-759-673-488;;000-373-170-472-521;;018-347-387-947-035;;000-447-172-519-011;;097-147-782-576-253;;062-864-177-282-080;;055-075-876-593-173;;095-311-758-359-733;;021-293-831-069-96X;;001-228-279-009-210;;012-126-697-378-635;;043-144-105-080-848;;019-703-421-323-539;;027-525-005-713-918;;055-076-506-782-465;;114-088-860-422-258;;021-240-722-422-948;;010-080-346-309-933;;075-799-844-814-006;;061-540-180-605-656;;107-900-380-851-134;;078-429-416-750-81X;;020-476-038-409-995;;004-792-515-132-031;;012-281-537-897-970;;013-408-031-320-797;;045-781-929-029-265;;003-253-722-419-298,10.1080/01616412.1996.11740398;;9162874;;10.1161/01.str.23.5.712;;1579969;;10.3171/jns.1995.82.2.0269;;7815156;;10.1016/0022-510x(94)00203-z;;7722533;;1677219;;10.1161/01.str.22.7.877;;10.1016/0161-5890(89)90060-6;;2698997;;7860929;;10.1016/0735-1097(94)00443-t;;7519330;;10.1080/01616412.1994.11740210;;1987672;;10.1161/01.str.22.1.44;;3336899;;10.1161/01.str.19.1.28;;10.1212/wnl.45.4.815;;7723976;;10.1006/exnr.1993.1023;;8094342;;8154873;;10.1002/ana.410350414;;8160235;;10.1161/01.str.25.4.869;;10.3171/jns.1991.75.4.0623;;1885980;;10.1016/0361-9230(94)90119-8;;7850491;;7541420;;10.1161/01.str.22.10.1276;;1926239;;10.1111/j.1365-3083.1991.tb01773.x;;1707181;;7908437;;10.2210/pdb2fgw/pdb;;10.1002/prot.340180107;;1983768;;7496621;;8546211;;pmc1861617;;7643999;;10.1227/00006123-199506000-00017;;10.1097/00006123-199506000-00017;;8465363;;10.1161/01.str.24.4.558;;10.1002/eji.1830130305;;6339253;;10.1038/348639a0;;2250718;;10.3171/jns.1981.54.6.0773;;7241187;;10.1161/01.str.23.1.93;;1731427;;10.1161/01.str.24.1.117;;8418534;;7820595;;10.1016/0006-8993(94)91478-8;;10.1007/bf00308474;;1557947;;10.1152/ajpheart.1996.270.1.h53;;8769734;;pmc295788;;10.1172/jci115527;;1684364;;7530260;;10.1016/0165-5728(94)90010-8;;1561656;;10.1161/01.str.23.2.247;;pmc53746;;10.1073/pnas.87.7.2643;;1969637;;1436419;;10.1227/00006123-199211000-00016;;10.1097/00006123-199211000-00016;;6999671;;10.1161/01.str.11.5.552;;10.1161/01.str.26.8.1438;;7631350;;10.1016/0006-8993(95)00830-j;;8581506;;7964886;;10.1016/0022-510x(94)90234-8;;7536354;;10.1016/s0039-6060(05)80068-6,"Bednar et al. Neurol. Res. 18:171 175 (1996).;;Mori et al. Stroke 23:712 718 (1992).;;Lindsberg et al. J. Neuro Surg 82:269 277 (1995).;;Kim et al. J. Neurological Sciences 128:45 50 (1995).;;Clark et al. Stroke 22:877 883 (1991).;;Hildreth et al. Mol Immunol. 26:1155 1167 (1989).;;Aversano et al., A Chimeric IgG4 Monolocnal Antibody Directed Against CD18 Reduces Infarct Size in a Primate Model of Myocardial Ischemia and Reperfusion J. Amer. Col. Cardiology 25(3):781 788 (Mar. 1995).;;Bednar et al., Comparison of Triphenyltetrazolium Dye with Light Microscopic Evaluation in a Rabbit Model of Acute Cerebral Ischaemia Neurological Research 16:129 132 (Apr. 1994).;;Bednar et al., IB4, a Monoclonal Antibody Against the CD18 Adhesion Complex of Leukocytes, Attenuates Intracranial Hypertension in a Rabbit Stroke Model Stroke (Abstract Only) 23(1):152 (1992).;;Bednar et al., The Role of Neutrophils and Platelets in a Rabbit Model of Thromboemblic Stroke Stroke 22(1):44 50 (1991).;;Bose et al., Evolving Focal Cerebral Ischemia in Cats: Spatial Correlation of Nuclear Magnetic Resonance Imaging, Cerebral Blood Flow, Tetrazolium Staining, and Histopathology Stroke 19(1):28 37 (Jan. 1988).;;Bowes et al., Monoclonal Antibodies Preventing Leukocyte Activation Reduce Experimental Neurologic Injury and Enhance Efficacy of Thrombolytic Therapy Neurology 45:815 819 (1995).;;Bowes et al., Monoclonal Antibody to the ICAM 1 Adhesion Site Reduces Neurological Damage in a Rabbit Cerebral Embolism Stroke Model Experimental Neurology 119(2):215 219 (1993).;;Chen et al., Anti CD11b Monoclonal Antibody Reduce Ischemic Cell Damage After Transient Focal Cerebral Ischemia in Rat Anti CD11b Monoclonal Antibody Reduces Ischemic Cell Damage After Transient Focal Cerebral Ischemia in Rat Ann. Neurol. 35(4):458 463 (1994).;;Chen et al., Neutropenia Reduces The Volume of Cerebral Infarct After Transient Middle Cerebral Artery Occlusion in the Rat Neuroscience Research Communications 11(2):93 99 (1992).;;Chopp et al., Anti CD11b Monoclonal Antibody (1B6c) Reduces Infarct Size Resulting From Transient but Not Permanent Focal Ischemia in Rat Stroke (Abstract Only) pp. 267 (19th International J) 25(1): (1994).;;Chopp et al., Postischemic Administration of an Anti MAC 1 Antibody Reduces Ischemic Cell Damage After Transient Middle Cerebral Artery Occlusion in Rats Stroke 25(4):869 876 (1993).;;Clark et al., Reduction of Central Nervous System Ischemic Injury by Monoclonal Antibody to Intercellular Adhesion Molecule J. Neurosurg. 75:623 627 (1991).;;Clark et al., Reperfusion Following Focal Stroke Hastens Inflammation and Resolution of Ischemic Injured Tissues Brain Research Bulletin 35(4):387 392 (1994).;;Danilenko et al., A Novel Canine Leukointegrin, d 2 is Expressed by Specific Macrophage Subpopulations in Tissue and a Minor CD8 30 Lymphocyte Subpopulation in Peripheral Blood Journal of Immunology 155:35 44 (1995).;;del Zoppo et al., Polymorphonuclear Leukocytes Occlude Capillaries Following Middle Cerebral Artery Occlusion and Reperfusion in Baboons Stroke 22(10):1276 1283 (1991).;;Desroches et al., Regulation and Functional Involvement of Distinct Determinants of Leucocyte Function Associated Antigen 1 (LFA 1) in T Cell Activation In Vitro Scand. J. Immunol. 33:277 286 (1991).;;Eigenbrot et al., X Ray Structures of Fragments From Binding and Nonbinding Versions of a Humanized Anti CD18 Antibody: Structural Indications of the Key Role of V H Residues 59 to 65 Proteins 18:49 62 (1994).;;Fekete et al., Involvement of Lyphocyte Function Associated Antigen 1 (LFA 1 But Not ICAM 1 in a Radioactive Leukocyte Cell Mediated Immunity (LA CMI) Assay J. Clin. Lab Immunol. 31:145 149 (1990).;;Fisher et al., The Penumbra, Therapeutic Time Window and Acute Ischaemic Stroke Bailliere s Clinical Neurology 4(2):279 295 (Aug. 1995).;;Garcia, Effects of CD11b/18 Monoclonal Antibody on Rats with Permanent Middle Cerebral Artery Occlusion Amer. J. Pathology 148(1):241 248 (Jan. 1996).;;Gross et al., Delayed Tissue Plasminogen Activator Therapy in a Rabbit Model of Thromoembolic Stroke Neurosurgery 36(6):1172 1177 (1995).;;Gross et al., Transforming Growth Factor 1 Reduces Infarct Size After Experimental Cerebral Ischemia in a Rabbit Model Stroke 24(4):558 562 (Apr. 1993).;;Hildreth et al., A Human Lymphocyte associated Antigen Involved in Cell mediated Lympholysis European Journal of Immunology 13:202 208 (1983).;;Hutchings et al., Transfer of Diabetes in Mice Prevented by Blockade of Adhesion Promoting Receptor on Macrophages Nature 348:639 642 (Dec. 13, 1990).;;Jiang et al., Anti CD11b Monoclonal Antibody Reduces Ischemic Cell Damage After Transient (2h) But Not After Permanent MCA Occlusion in the Rat Neuroscience Research Communications 15(2):85 93 1994.;;Jones et al., Thresholds of Focal Cerebral Ischemia in Awake Monkeys Journal of Neurosurgery 54:773 782 (Jun. 1981).;;Kohut et al., Reduction in Ischemic Brain Injury in Rabbits by the Anion Transport Inhibitor L 644,711 Stroke 23(1):93 97 (Jan. 1992).;;Lin et al., Effect of Brain Edema on Infarct Volume in a Focal Cerebral Ischemia Model in Rats Stroke 24(1):117 121 (Jan. 1993).;;Matsuo et al., Role of Cell Adhesion Molecules in Brain Injury After Transient Middle Cerebral Artery Occlusion in the Rat Brain Research 656:344 352 (1994).;;Morioka et al., Progressive Expression of Immunomolecules on Microglial Cells in Rat Dorsal Hippocampus Following Transient Forebrain Ischemia Acta Neuropatholigica , Springer Verlag vol. 83:149 157 (1992).;;Perez et al., Factors modifying protective effect of anti CD18 antibodies on myocardial reperfusion injury in dogs Amer. J. Physiology (Part 2), Washington D.C. 270(1):H53 H64 (1996).;;Saez L1orens et al., Enhanced Attenuation of Meningeal Inflammation and Brain Edema by Concomitant Administration of Anti CD18 Monoclonal Antibodies and Dexamethasone in Experimental Haemophilus Meningitis Journal of Clin. Invest. 88:2003 2009 (Dec. 1991).;;Schroeter et al., Local Immune Responses in the Rat Cerebral Cortex After Middle Cerebral Artery Occlusion Journal of Neuroimmunology , Elsevier Science B.V. vol. 55(2):195 203 (1994).;;Shiga et al., Suppression of Ischemic Brain Edema in Rats by Depletion of Neutrophils Journal of Cerebral Blood Flow and Metabolism (Abstract Only), Ginsberg et al., Supplement 2 edition, New York: Raven Press vol. 11(2):S486 (Jun. 1991).;;Takeshima et al., Monoclonal Leukocyte Antibody Does Not Decrease the Injury of Transient Focal Cerebral Ischemia in Cats Stroke 23(2):247 252 (Feb. 1992).;;Vedder et al., Inhibition of leukocyte adherence by anti CD 18 monoclonal antibody attenuates reperfusion injury in the rabbit ear Proc. Natl. Acad. Sci. USA 87:2643 2646 (Apr. 1990).;;Wilson et al., The Effect of the 21 Aminosteroid U74006F in a Rabbit Model of Thromboembolic Stroke Neurosurgery 31(5):929 934 (Nov. 1992).;;Young et al., H 2 Clearance Measurement of Blood Flow: A Review of Technique and Polargraphic Principles Stroke 11(5):552 564 (Sep. 1980).;;Zhang et al., Anti Intercellular Adhesion Molecule 1 Antibody Reduces Ischemic Cell Damage After Transient But Not Permanent Middle Cerebral Artery Occlusion in the Wistar Rat Stroke 26 (8):1438 1442 (Aug. 1995).;;Zhang et al., Postischemic Treatment (2 4h) with Anti CD11b and Anti CD18 Monclonal Antibodies are Neuroprotective After Transient (2h) Focal Cerebral Ischemia in The Rat Brain Research , Elsevier Science B.V. vol. 698:79 85 (1995).;;Zhang et al., Temporal Profile of Ischemic Tissue Damage, Neutrophil Response, and Vascular Plugging Following Permanent and Transient (2H) Middle Cerebral Artery Occlusion in the Rat Neurological Sciences , Elsevier Science B.V. vol. 125:3 10 (1994).;;Lee et al. Surgery 117 (4):458 465 (1995).",EXPIRED
30,EP,A3,EP 1297847 A3,141-957-956-154-324,2003-05-07,2003,EP 02078486 A,1997-01-11,EP 97903790 A;;US 58998296 A,1996-01-23,Anti-CD18 antibodies in stroke,"A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective amount of an anti-CD18 antibody to the mammal, in the absence of removal of the arterial obstruction.",GENENTECH INC;;UNIV VERMONT,BEDNAR MARTIN M;;GROSS CORDELL E;;THOMAS G ROGER,,https://lens.org/141-957-956-154-324,Search Report,yes,2,0,22,22,0,A61K38/00;;A61K39/39541;;A61K2039/505;;C07K16/2845;;A61P7/02;;A61P9/10,G01N33/53;;A61K38/00;;A61K39/395;;A61P7/02;;A61P9/10;;C07K16/28,,5,5,070-469-326-587-575;;001-812-195-333-366;;048-794-669-079-726;;097-147-782-576-253;;135-761-430-417-685,10.1212/wnl.45.4.815;;7723976;;10.1161/01.str.23.5.712;;1579969;;7860929;;10.1016/0735-1097(94)00443-t;;7908437;;10.2210/pdb2fgw/pdb;;10.1002/prot.340180107;;pmc40279;;10.1073/pnas.92.26.11980;;8618827,"M. BOWES ET AL.: ""Monoclonal antibodies preventing leukocyte activation reduce experimental neurologic injury and enhance efficacy of thrombolytic therapy."", NEUROLOGY, vol. 45, April 1995 (1995-04-01), Cleveland, OH, USA, pages 815 - 819, XP000578301;;E. MORI ET AL.: ""Inhibition of polymorphonuclear leukocyte adherence suppresses no-reflow after focal cerebral ischemia in baboons."", STROKE, vol. 23, no. 5, May 1992 (1992-05-01), Dallas, TX, USA, pages 712 - 718, XP002036513;;T. AVERSANO ET AL.: ""A chimeric IgG4 monoclonal antibody directed against CD18 reduces infarct size in a primate model of myocardial ischemia and reperfusion."", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 25, no. 3, 1 March 1995 (1995-03-01), New York, NY, USA, pages 781 - 788, XP002036512;;C. EIGENBROT ET AL.: ""X-ray structures of fragments from binding and nonbinding versions of a humanized anti-CD18 antibody: structural indications of the key role of VH residues 59 to 65."", PROTEINS: STRUCTURE, FUNCTION, AND GENETICS, vol. 18, no. 1, January 1994 (1994-01-01), New York, NY, USA, pages 49 - 62, XP000578098;;J. HUTCHINS ET AL.: ""Improved biodistribution, tumor targeting, and reduced immunogenicity in mice with a gamma4 variant of Campath-1H."", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE U.S.A., vol. 92, December 1995 (1995-12-01), Washington, DC, USA, pages 11980 - 11984, XP002234019",DISCONTINUED
31,WO,A2,WO 2009/050554 A2,147-671-813-204-798,2009-04-23,2009,IB 2008002660 W,2008-10-06,US 98116807 P,2007-10-19,TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS,"The present invention provides for the use of PDE5 inhibitors in methods for treating in a mammal certain central nervous system (CNS) disorders or conditions, including neurodegenerative disorders such as for example Alzheimer's disease or stroke. This invention also pertains to the use of PDE5 inhibitors in methods for promoting in a mammal functional recovery following events such as stroke, such as coronary artery bypass grafting (CABG)-related stroke; craniocerebral trauma; traumatic brain injury; spinal cord trauma; cerebral ischemia, including cerebral ischemia related to CABG; multi-infarct dementia; post-CABG dementia; subdural hematoma; subarachnoid hemorrhage; or any of the wide varieties of brain tumors and/or their removal. The PDE5 inhibitors are compounds of formula (I) or tautomers thereof or pharmaceutically acceptable salts or solvates of said compounds or tautomers.",PFIZER;;BEDNAR MARTIN MICHAEL;;MENNITI FRANK SAMUEL;;TATE BARBARA ANN,BEDNAR MARTIN MICHAEL;;MENNITI FRANK SAMUEL;;TATE BARBARA ANN,,https://lens.org/147-671-813-204-798,Patent Application,yes,0,3,2,2,0,A61K31/519;;A61P25/28,A61K31/519;;A61P25/28,,0,0,,,,PENDING
32,WO,A3,WO 1997/026912 A3,070-667-926-763-963,1997-07-31,1997,US US9700492,1997-01-11,"US 8/589,982",1996-01-23,ANTI-CD18 ANTIBODIES FOR USE AGAINST STROKE,"A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective amount of an anti-CD18 antibody to the mammal, in the absence of removal of the arterial obstruction.","GENENTECH, INC.;;UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE","BEDNAR, Martin, M.;;GROSS, Cordell, E.;;THOMAS, G., Roger",,https://lens.org/070-667-926-763-963,Search Report,yes,0,0,1,1,0,,A61K38/00;;C07K16/28,,0,0,,,,UNKNOWN
33,AU,A,AU 1997/018273 A,193-191-809-454-255,1997-08-20,1997,AU 1997/018273 A,1997-01-11,US 58998296 A;;US 9700492 W,1996-01-23,Anti-cd18 antibodies for use against stroke,,GENENTECH INC;;UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE THE,BEDNAR MARTIN M;;GROSS CORDELL E;;THOMAS G ROGER,,https://lens.org/193-191-809-454-255,Patent Application,no,0,0,22,22,0,A61K38/00;;A61K39/39541;;A61K2039/505;;C07K16/2845;;A61P7/02;;A61P9/10,G01N33/53;;A61K38/00;;A61K39/395;;A61P7/02;;A61P9/10;;C07K16/28,,0,0,,,,EXPIRED
34,DE,D1,DE 3484890 D1,007-973-521-950-999,1991-09-12,1991,DE 3484890 T,1984-09-17,US 53727983 A,1983-09-29,ZEICHENERKENNUNGSANLAGE UND VERFAHREN ZUM ERKENNEN VON BUCHSTABEN MIT DIAKRITISCHEN ZEICHEN.,,IBM,BEDNAR GREGORY MARTIN;;FRYER GEORGE BERNARD;;NARASIMHA MANTHRI SELVAPULLAI,,https://lens.org/007-973-521-950-999,Granted Patent,no,0,0,8,8,0,G06V10/10;;G06V30/10;;G06V30/148;;G06V30/15;;G06V10/70;;G06F18/00;;G06V10/10;;G06V30/10;;G06F18/00;;G06V30/148;;G06V30/15;;G06V10/70,G06V10/70;;G06V30/10;;G06V10/10;;G06V30/148,,0,0,,,,EXPIRED
35,DK,T3,DK 0877626 T3,037-123-124-124-586,2002-12-30,2002,DK 97903790 T,1997-01-11,US 58998296 A;;US 9700492 W,1996-01-23,Anti-CD18 antistoffer til anvendelse mod slagtilfælde,,UNIV VERMONT;;GENENTECH INC,BEDNAR MARTIN M;;GROSS CORDELL E;;THOMAS G ROGER,,https://lens.org/037-123-124-124-586,Granted Patent,no,0,0,22,22,0,A61K38/00;;A61K39/39541;;A61K2039/505;;C07K16/2845;;A61P7/02;;A61P9/10,G01N33/53;;A61K38/00;;A61K39/395;;A61P7/02;;A61P9/10;;C07K16/28,,0,0,,,,EXPIRED
36,EP,A2,EP 0114996 A2,152-269-905-198-28X,1984-08-08,1984,EP 83112630 A,1983-12-15,US 45301782 A,1982-12-27,Character recognition utilizing transition measurements.,A character recognition system in which a representation of a character is scanned along a plurality of scan lines and measurements are made based on the transitions in each scan line between areas of the character and areas of the background (6). For each scan line a vector is generated based on the transition measurements for the scan line. The vectors are selectively combined logically in order to identify the character (8).,IBM,BEDNAR GREGORY MARTIN;;HARMON JOHN CHARLES;;NARAISMHA MANTHRI SELVAPULLAI,,https://lens.org/152-269-905-198-28X,Patent Application,yes,0,1,4,4,0,G06V30/10;;G06V30/18;;G06V30/184;;G06V30/18076;;G06V30/18;;G06V30/184;;G06V30/10;;G06V30/18076,G06V30/10;;G06V30/18;;G06V30/184,,0,0,,,,DISCONTINUED
37,CA,A1,CA 2242414 A1,075-034-240-320-852,1997-07-31,1997,CA 2242414 A,1997-01-11,US 58998296 A;;US 9700492 W,1996-01-23,ANTI-CD18 ANTIBODIES FOR USE AGAINST STROKE,"A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective amount of an anti-CD18 antibody to the mammal, in the absence of removal of the arterial obstruction.",GENENTECH INC;;UNIV VERMONT,BEDNAR MARTIN M;;GROSS CORDELL E;;THOMAS G ROGER,,https://lens.org/075-034-240-320-852,Patent Application,no,0,0,22,22,16,A61K38/00;;A61K39/39541;;A61K2039/505;;C07K16/2845;;A61P7/02;;A61P9/10,G01N33/53;;A61K38/00;;A61K39/395;;A61P7/02;;A61P9/10;;C07K16/28,,0,0,,,,EXPIRED
38,ES,T3,ES 2183131 T3,175-045-554-047-472,2003-03-16,2003,ES 97903790 T,1997-01-11,US 58998296 A,1996-01-23,ANTICUERPOS ANTI-CD18 UTILIZADOS CONTRA EL ICTUS CEREBRAL.,"SE DESCRIBE UN METODO PARA MEJORAR EL RESULTADO CLINICO EN EL ATAQUE ISQUEMICO FOCAL EN UN MAMIFERO INCREMENTANDO EL FLUJO SANGUINEO CEREBRAL Y/O REDUCIENDO EL TAMAÑO DEL INFARTO, QUE IMPLICA LA ADMINISTRACION DE UNA CANTIDAD EFECTIVA DE UN ANTICUERPO ANTI CD18 AL MAMIFERO, SIN QUE SE HAYA RETIRADO LA OBSTRUCCION ARTERIAL.",GENENTECH INC;;UNIV VERMONT,BEDNAR MARTIN M;;GROSS CORDELL E;;THOMAS G ROGER,,https://lens.org/175-045-554-047-472,Granted Patent,no,0,0,22,22,0,A61K38/00;;A61K39/39541;;A61K2039/505;;C07K16/2845;;A61P7/02;;A61P9/10,A61K38/00;;A61K39/395;;A61P7/02;;G01N33/53;;A61P9/10;;C07K16/28,,0,0,,,,EXPIRED
39,CN,A,CN 114762325 A,064-322-219-579-517,2022-07-15,2022,CN 202080085314 A,2020-12-07,EP 19214486 A;;EP 2020084884 W,2019-12-09,System for monitoring environment of motor vehicle,"The invention relates to a system (1) for monitoring the environment of a motor vehicle (100), in particular an autonomous or semi-autonomous motor vehicle, the system (1) comprising at least one optical image detection device (2) and further comprising an illumination device (3, 4), the optical image detection device (2) being designed to detect a detection region (E1) of the environment, the detection region (E1) can be irradiated at least partially, preferably completely, by the irradiation device (3, 4), and wherein the irradiation device (3, 4) is designed to generate a motor vehicle light distribution or a part of the motor vehicle light distribution. The system (1) comprises at least one optical additional image detection device (5), which is designed to detect a so-called additional detection region (E2), and wherein the system (1) further comprises an additional illumination device (6), which is designed to illuminate the so-called additional detection region (E2). The additional detection region (E2) is irradiated at least partially, preferably completely, also referred to as a second detection region.",ZKW GROUP GMBH,BRANDSTETTER MARTIN;;ALTMANN JOHANN;;SPOHN MARTIN;;BECHMANN HARALD;;BEDNAR INGEBORG;;JACQUEL CHRISTIAN,,https://lens.org/064-322-219-579-517,Patent Application,no,0,0,8,8,0,H04N7/181;;B60R11/04;;B60R2300/103;;B60R2300/105;;B60R2300/301;;B60Q1/0023;;G01S13/867;;B60Q1/18;;G01S13/931;;G01S2013/93277;;G01S17/931;;H04N7/181;;B60Q1/0023;;B60R11/04;;B60Q1/18;;B60Q1/249;;G01S13/931;;G01S17/931;;G01S13/867;;G01S2013/93277;;B60Q2800/10;;B60R2300/301;;B60R2300/105;;B60R2300/103;;G01S17/931;;G01S17/86;;B60W60/001;;H04N23/56;;H04N23/90;;B60Q1/0023;;B60Q1/1415;;G01S13/867;;G01S13/89;;G01S13/931;;G01S17/89;;B60W2420/403;;B60W2420/408,H04N7/18,,0,0,,,,PENDING
40,AT,T1,AT E222774 T1,062-048-903-830-542,2002-09-15,2002,AT 97903790 T,1997-01-11,US 58998296 A;;US 9700492 W,1996-01-23,ANTIKÖRPER GEGEN CD 18 ZUR VERWENDUNG GEGEN GEHIRNSCHLAG,,GENENTECH INC;;UNIV VERMONT,BEDNAR MARTIN M;;GROSS CORDELL E;;THOMAS G ROGER,,https://lens.org/062-048-903-830-542,Granted Patent,no,0,0,22,22,0,A61K38/00;;A61K39/39541;;A61K2039/505;;C07K16/2845;;A61P7/02;;A61P9/10,G01N33/53;;A61K38/00;;A61K39/395;;A61P7/02;;A61P9/10;;C07K16/28,,0,0,,,,PENDING
41,EP,B1,EP 0138079 B1,127-843-296-284-12X,1991-08-07,1991,EP 84111043 A,1984-09-17,US 53727983 A,1983-09-29,CHARACTER RECOGNITION APPARATUS AND METHOD FOR RECOGNISING CHARACTERS ASSOCIATED WITH DIACRITICAL MARKS,,INTERNATIONAL BUSINESS MACHINES CORPORATION,"BEDNAR, GREGORY MARTIN;;FRYER, GEORGE BERNARD;;NARASIMHA, MANTHRI SELVAPULLAI",,https://lens.org/127-843-296-284-12X,Granted Patent,yes,1,1,8,8,0,G06V10/10;;G06V30/10;;G06V30/148;;G06V30/15;;G06V10/70;;G06F18/00;;G06V10/10;;G06V30/10;;G06F18/00;;G06V30/148;;G06V30/15;;G06V10/70,G06V10/70;;G06V30/10;;G06V10/10;;G06V30/148,,0,0,,,,EXPIRED
42,PT,E,PT 877626 E,189-118-222-888-753,2003-01-31,2003,PT 97903790 T,1997-01-11,US 58998296 A,1996-01-23,ANTICORPOS ANTI-CD1S PARA UTILIZACAO CONTRA ICTO,,UNIV VERMONT AND STATE AGRIC C;;GENENTECH INC,BEDNAR MARTIN M;;GROSS CORDELL E;;THOMAS G ROGER,,https://lens.org/189-118-222-888-753,Granted Patent,no,0,0,22,22,0,A61K38/00;;A61K39/39541;;A61K2039/505;;C07K16/2845;;A61P7/02;;A61P9/10,A61K38/00;;A61K39/395;;G01N33/53;;A61P7/02;;A61P9/10;;C07K16/28,,0,0,,,,EXPIRED
43,EP,A2,EP 1297847 A2,101-679-203-438-99X,2003-04-02,2003,EP 02078486 A,1997-01-11,EP 97903790 A;;US 58998296 A,1996-01-23,Anti-CD18 antibodies in stroke,"A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective amount of an anti-CD18 antibody to the mammal, in the absence of removal of the arterial obstruction.",GENENTECH INC;;UNIV VERMONT,BEDNAR MARTIN M;;GROSS CORDELL E;;THOMAS G ROGER,,https://lens.org/101-679-203-438-99X,Patent Application,yes,0,5,22,22,16,A61K38/00;;A61K39/39541;;A61K2039/505;;C07K16/2845;;A61P7/02;;A61P9/10,G01N33/53;;A61K38/00;;A61K39/395;;A61P7/02;;A61P9/10;;C07K16/28,,0,0,,,,DISCONTINUED
44,US,A,US 5945432 A,139-697-090-793-984,1999-08-31,1999,US 64066796 A,1996-05-01,US 64066796 A;;US 57704795 A,1995-12-22,Thrombolytic agents and thienopyridine derivatives in acute stroke,Methods and products are provided for treating thromboembolic stroke. A method involves the administration of a thienopyridine derivative in combination with a thrombolytic agent to a patient suffering from thromboembolic stroke. Preferably the thienopyridine derivative is ticlopidine and the thrombolytic agent is tPA. The method also involves the administration of a thrombolytic agent to a subject who already has circulating plasma levels of a thienopyridine derivative. The product is a pharmaceutical preparation of a thienopyridine derivative and a thrombolytic agent and a pharmaceutically acceptable carrier.,UNIV VERMONT;;GRENENTECH INC,BEDNAR MARTIN M;;KEYT BRUCE A;;GROSS CORDELL E,VERMONT AND STATE AGRICULTURAL COLLEGE UNIVERSITY OF THE (1996-04-05);;VERMONT AND STATE AGRICULTURAL COLLEGE UNIVERISITY OF THE (1996-04-18);;GENENTECH INC (1996-04-17),https://lens.org/139-697-090-793-984,Granted Patent,yes,3,22,1,1,0,A61K38/49;;A61K38/49,A61K38/49,514/301;;514/444;;514/443;;514/663;;514/673;;514/579,43,40,055-581-879-745-672;;105-759-386-342-805;;051-718-574-879-10X;;042-162-505-542-223;;008-693-993-271-134;;081-260-931-798-743;;148-906-241-619-516;;078-303-330-297-002;;079-939-501-286-034;;023-745-071-064-863;;083-636-651-557-668;;030-360-016-713-871;;129-061-344-046-609;;136-899-647-295-963;;011-967-038-340-721;;000-000-654-903-47X;;070-623-504-787-16X;;134-980-095-018-452;;009-303-663-025-395;;023-388-732-376-408;;024-937-417-831-744;;021-293-831-069-96X;;092-917-675-910-435;;041-894-671-213-406;;051-895-539-228-923;;002-734-117-569-969;;090-285-901-027-638;;068-172-563-681-806;;072-996-651-970-575;;054-280-611-471-038;;022-838-256-686-681;;148-286-046-832-149;;031-235-452-095-129;;020-925-422-227-492;;005-287-832-936-294;;017-280-821-066-127;;016-278-107-314-200;;057-743-639-827-531;;065-193-932-623-016;;062-346-498-166-873,8091454;;10.1161/01.str.25.10.2072;;7775709;;10.1016/0735-1097(95)00107-f;;10.1016/0735-1097(95)90011-x;;10.1016/0735-1097(95)00188-a;;7775708;;10.1007/bf01062576;;10603528;;10.1161/01.str.26.6.1039;;7762021;;7778051;;2683695;;10.1517/13543784.4.5.389;;10.1152/ajpheart.1994.267.2.h488;;8067400;;10.1001/archinte.155.2.149;;10.1001/archinte.1995.00430020034005;;7811124;;10.2165/00003495-199549060-00002;;7641602;;10.1097/00002826-199402000-00002;;8149356;;pmc1014125;;2182779;;10.1136/jnnp.53.3.185;;10.2165/00003495-199550010-00002;;7588091;;10.2165/00023210-199503050-00004;;10.1016/0268-9499(93)90051-v;;3810730;;10.1161/01.str.17.6.1254;;1395833;;10.1378/chest.102.4_supplement.529s;;7863971;;10.1016/0002-9149(95)80008-g;;2124736;;10.1161/01.str.21.12.1705;;10.1080/01616412.1993.11740173;;7907409;;7643999;;10.1227/00006123-199506000-00017;;10.1097/00006123-199506000-00017;;10.1080/01616412.1994.11740275;;7708139;;1900516;;10.1016/s0021-9258(19)67773-2;;10.1097/00005344-199312000-00009;;7509901;;2497546;;10.1016/0049-3848(89)90104-7;;3030730;;pmc1167389;;10.1002/j.1460-2075.1986.tb04678.x;;10.1182/blood.v73.7.1842.1842;;2496774;;pmc548919;;2503540;;10.1172/jci114202;;10.1016/s0021-9258(18)83225-2;;2540181;;10.1161/01.cir.81.4.1362;;2107986;;6608420;;10.1161/01.cir.69.5.983;;10.1016/s0021-9258(18)71649-9;;2503511;;10.1161/01.cir.92.10.3032;;7586274;;10.1097/00008506-199604000-00018;;10.1073/pnas.83.13.4670;;pmc323803;;3088564;;10.1055/s-0038-1645686;;2111048;;10.1182/blood.v71.1.216.216;;3120823;;10.1038/nbt0987-953;;10.1016/s0021-9258(19)39394-9;;2108143,"G. Roger Thomas, PhD, Harold Thibodeaux, BS, Carol J. Errett, Julie M. Badillo, BS, Bruce A. Keyt, PhD, Canio J. Refino, BS, Justin A. Zivin, MD, PhD, and William F. Bennett, PhD; A Long Half life and Fibrin Specific Form of Tissue Plasminogen Activator in Rabbit Models of Embolic Stroke and Peripheral Bleeding ; Stroke, vol. 25, No. 10, Oct. 1994, pp. 2072 2079.;;Charles E. Hennekens, MD, Christopher J. O Donnell, MD, Paul M. Ridker, MD, and Victor J. Marder, MD; Current Issues Concerning Thrombolytic Therapy for Acute Myocardial Infarction ; JACC, vol. 25, No. 7 (Supplement), Jun. 1995, pp. 18S 22S.;;David R. Holmes, Jr., MD, Robert M. Califf, MD, and Eric J. Topol, MD; Lessons We Have Learned From the GUSTO Trial ; JACC, vol. 25, No. 7 (Supplemental), Jun. 1995, pp. 10S 17S.;;Martin M. Bednar, Richard H. Dooley, Maziar Zamani, Diantha B. Howard, and Cordell E. Gross; Neutrophil and Platelet Activity and Quantification Following Delayed tPA Therapy in a Rabbit Model of Thromboembolic Stroke ; Journal of Thrombosis and Thrombolysis 1995, pp. 179 185.;;G. Roger Thomas, PhD, Harold Thibodeaux, BS, Carol J. Errett, Martin M. Bednar, MD, PhD, Cordell E. Gross, MD, and William F. Bennett, PhD; Intravenous Aspirin Causes a Paradoxical Attenuation of Cerebrovascular Thrombolysis , Stroke, vol. 26, No. 6, Jun. 1995, pp. 1039 1046.;;Robert G. Hart, MD, Dianne H. Solomon, MD, J. James Rohack, MD, and William M. Feinberg, MD; What s new in stroke ; Texas Medicine, vol. 91, No. 5, May 1995, pp. 46 55.;;Peggy Jo Donahue; Head Off A Stroke; A New Guide To Clot Dissolving Drugs , Prevention Magazine, 1988, pp. 39 45.;;William Feinberg, MD; Antithrombotic Therapy in Stroke and Transient Ischemic Attacks ; AFP, vol. 40, No. 5, (Supplement), Nov. 1989, pp. 53S 59S.;;Jawed Fareed, Demetra D. Callas, Debra Hoppensteadt, Walter Jeske & Jeanine M. Walenga; Recent developments in antithrombotic agents ; Exp. Opin. Invest. Drugs (1995) 4(5), pp. 389 412.;;Sheng Kun Yao, Judy C. Ober, James J. Ferguson, Jean Pierre Maffrand, H. Vernon Anderson, L. Maximilian Buja, and James T. Willerson; Clopidogrel is more effective than aspirin as adjuvant treatment to prevent reocclusion after thrombolysis ; Clopidogrel, Thrombolysis, and Reocclusion, American Physiological Society, 1994, pp. H488 H493.;;Richard C. Becker, MD and Jack Ansell, MD; Antithrombotic Therapy , Arch. Intern. Med., vol. 155, Jan. 23, 1995, pp. 149 161.;;Marc Verstraete and Pierre Zoldhelyi; Novel Antithrombotic Drugs in Development ; Drugs 49(6), 1995, pp. 856 884.;;Joan C. Murray, Michael A. Kelly, and Philip B. Gorelick; Ticlopidine: A New Antiplatelet Agent for the Secondary Prevention of Stroke ; Clinical Neuropharmacology, vol. 17, No. 1, 1994, pp. 23 31.;;Charles Warlow, Ticlopidine, a new antithrombotic drug; but is it better than aspirin for longterm use ; Journal of Neurology, Neurosurgery & Psychiatry, pp. 185 187.;;Karsten Schr o r; Antiplatelet Drugs A Comparative Review ; Drugs 50(1), 1995, pp. 7 28.;;G e rard Besson and Julien Bogousslavsky; Current and Future Options for the Prevention and Treatment of Stroke ; CNS Drugs 3(5), 1995, pp. 351 362.;;A. Bernat, F. Dol, J.M. Herbert, M. Sainte Marie and J.P. Maffrand; Potentiating Effects of Anticoagulants and Antiplatelet Agents on Streptokinase Thrombolysis in the Rabbit ; Fibrinolysis, Gregory No. 7, 1993, pp. 23 30.;;Gregory J. Del Zoppo, MD, Brian R. Copeland, MD, Laurence A. Harker, MD, Thomas A. Waltz, MD, Jack Zyroff, MD and Stephen R. Hanson, PhD; Experimental Acute Thrombotic Stroke in Babboons ; Stroke, vol. 17, No. 6, Nov. Dec. 1986, pp. 1254 1265.;;David G. Sherman, MD, Mark L. Dyken, Jr., MD, Marc Fisher, MD, Michael Gent, PhD, Michael Harrison, MD, and Robert G. Hart, MD; Antithrombotic Therapy for Cerebrovascular Disorders ; Chest, 102, 4, (Supplement), Oct. 1992, pp. 529S 537S.;;Gregory W. Albers; Antithrombotic Agents in Cerebral Ischemia ; The American Journal of Cardiology, vol. 75, Feb. 23, 1995, pp. 34B 38B.;;Martin M. Bednar, MD, Timothy McAuliffe, PhD, Sheila Raymond, AS, and Cordell E. Gross, MD; Tissue Plasminogen Activator Reduces Brain Injury in a Rabbit Model of Thromboembolic Stroke ; Stroke, vol. 21, No. 12, Dec. 1990, pp. 1705 1709.;;Martin M. Bednar, Sheila J. Raymond, and Cordell E. Gross; Tissue plasminogen activator; Comparison of dose and route of administration in a rabbit model of thromboembolic stroke ; 4 pp.;;Cordell E. Gross, MD, Sheila J. Raymond, A.S., Diantha B. Howard, M.S., and Martin J. Bednar, MD; Delayed Tissue Plasminogen Activator Therapy in a Rabbit Model of Thromboembolic Stroke ; Neurosurgery, vol. 36, No. 6, Jun. 1995, pp. 1172 1177.;;Cordell E. Gross, Diantha B. Howard, Richard H. Dooley, Sheila J. Raymond, Susan Fuller and Martin M. Bednar; TGF 1post treatment in a rabbit model of cerebral ischaemia ; 5 pp.;;William F. Bennett, Nicholas F. Paoni, Bruce A. Keyt, David Botstein, Andrew J.S. Jones, Leonard Presta, Florian M. Wurm, and Mark J. Zoller; High Resolution Analysis of Functional Determinants on Human Tissue type Plasminogen Activator ; The Journal of Biological Chemistry, vol. 266, No. 8, Mar. 15, 1991, pp. 5191 5201.;;Suguru Suzuki, Mamoru Saito, Noboru Suzuki, Hiroyuki Kato, Naoko Nagaoka, Shinji Yoshitake, Yoshi Yui, and Chuichi Kawai, Intracoronary Infusion of E6010 has More Potent Thrombolytic Activity Than Tissue Plasminogen Activator (t PA) in Dogs; A Higher Plasma Level of E6010 Than t PA Causes Potent Thrombolytic Activity ; Journal of Cardiovascular Pharmacology, vol. 22, No. 6, 1993, pp. 834 840.;;Peter J. Bugelski, Kei Lai L. Fong, Anne Klinkner, Janice Sowinski, Glenn Rush and D. Gwyn Morgan; Uptake of Human Recombinant Tissue Type Plasminogen Activator by Rat Hepatocytes In Vivo; An Electron Microscope Autoradiographic Study ; Thrombosis Research, vol. 53, No. 3, 1989, pp. 287 303.;;J.H. Verheijen, M.P.M. Caspers, G.T.G. Chang, G.A.W. de Munk, P.H. Pouwels, and B.E. Enger Valk; Involvement of finger domain and kringle 2 domain of tissue type plasminogen activator in fibrin binding and stimulation of activity by fibrin ; The EMBO Journal, vol. 5, No. 13, 1986, pp. 3525 3530.;;Glenn R. Larsen, Mark Metzger, Kimberlee Henson, Yitzhak Blue, and Patricia Horgan; Pharmacokinetic and Distribution Analysis of Variant Forms of Tissue Type Plasminogen Activator With Prolonged Clearance in Rat ; Blood, vol. 73, No. 7, May 15, 1989, pp. 1842 1850.;;Douglas E. Vaughan, Paul J. Declerck, Maria De Mol, and D e sir e Collen; Recombinant Plasminogen Activator Inhibitor 1 Reverses the Bleeding Tendency Associated with the Combined Administration of Tissue type Plasminogen Activator and Aspirin in Rabbits ; J. Clin. Invest., vol. 84, Aug. 1989, pp. 586 591.;;Phillip A. Morton, Dwain A. Owensby, Burton E. Sobel, and Alan L. Schwartz; Catabolism of Tissue type Plasminogen Activator by the Human Hepatoma Cell Line Hep G2 ; The Journal of Biological Chemistry, vol. 264, No. 13, May 5, 1989, pp. 7228 7235.;;Burton E. Sobel, MD, Stanley J. Sarnoff, MD, and Denise A. Nachowiak, BA; Augmented and Sustained Plasma Concentrations After Intramuscular Injections of Molecular Variants and Deglycosylated Forms of Tissue Type Plasminogen Activators ; Circulation, vol. 81, 1990, pp. 1362 1373.;;Burton E. Sobel, MD, Edward M. Geltman, MD, alan J. Tiefenbrunn, MD, Allan S. Jaffe, MD, James J. Spadaro, Jr., MD, Michel M. Ter Pogossian, PhD, D e sir e Collen, MD, and Philip A. Ludbrook, MB, BS; Improvement of regional myocardial metabolism after coronary thrombolysis induced with tissue type plasminogen activator or streptokinase ; Circulation, vol. 69, No. 5, May 1984, pp. 983 990.;;Michael W. Spellman, Louisette J. Basa, Cordelia K. Leonard, John a. Chakel, and John V. O Connor; Susanne Wilson and Herman van Halbeek; Carbohydrate Structures of Human Tissue Plasminogen Activator Expressed in Chinese Hamster Ovary Cells ; The Journal of Biological Chemistry, vol. 264, No. 24, Aug. 25, 1989, pp. 14100 14111.;;Benedict, et al., Circulation, vol. 92, 1995, pp. 3032 3034.;;N. Eng. J. Med. 1995, Dec. 14, vol. 333(24), pp. 1581 1587.;;CA; 120:295826u, 1994.;;Anton Jan van Zonneveld, Harry Veerman, and Hans Pannekoek; Autonomous functions of structural domains on human tissue type plasminogen activator ; Proc. Natl. Acad. Sci., vol. 83, Jul. 1986, pp. 4670 4674.;;M. Johannessen, V. Diness, K. Pingel, L.C. Petersen, D. Rao, P. Lioubin, P. O Hara, and E. Mulvihill; Fibrin Affinity and Clearance of t PA Deletion and Substitution Analogues ; Thrombosis and Haemostasis F.K. Schattauer Verlagsgesellschaft mbH (Stuttgart), vol. 63(1), 1990, pp. 54 59.;;J.H. Verheijen, et al., Sites in Tissue Type Plasminogen Activator Involved in the Interaction with Fibrin, Plasminogen and Low Molecular Weight Ligands ; Glenn R. Larsen, et al.; Pharmacokinetics of Genetically Modified T PA in Rat ; A. Hotchkiss, et al.; The Activity of a Single Chain rt PA Mutant in a Primates and Rabbits ; T. Quertermous, et al.; Expression of a Recombinant Antibody Targeted Thrombolytic Molecule ; Fibrinolysis; Molecular Biology, pp. 491.;;D e sir e Collen, Jean Marie Stassen, and Glenn Larsen; Pharmacokinetics andThrombolytic Properties of Deletion Mutants of Human Tissue Type Plasminogen Activator in Rabbits ; Blood, vol. 71, No. 1, Jan. 1988, pp. 216 219.;;David Lau, Gregory Kuzma, Cha Mer Wei, David Livingston, and Nancy Hsiung, A Modified Human Tissue Plasminogen Activator with Extended Half Life In Vivo ; Bio/Technology, p. 734.;;Tim J. Ahern, George E. Morris, Karen M. Barone, Patricia G. Horgan, Gregg A. Timony, Lauren B. Angus, Kimberlee S. Henson, John B. Stoudemire, Pennina R. Langer Safer, and Glenn R. Larsen; Site directed Mutagenesis in Human Tissue Plasminogen Activator ; The Journal of Biological Chemistry, vol. 265, No. 10, Apr. 5, 1990, pp. 5540 5545.",EXPIRED
45,EP,B1,EP 0877626 B1,144-790-469-498-522,2002-08-28,2002,EP 97903790 A,1997-01-11,US 9700492 W;;US 58998296 A,1996-01-23,ANTI-CD18 ANTIBODIES FOR USE AGAINST STROKE,,GENENTECH INC;;UNIV VERMONT,BEDNAR MARTIN M;;GROSS CORDELL E;;THOMAS G ROGER,,https://lens.org/144-790-469-498-522,Granted Patent,yes,1,0,22,22,0,A61K38/00;;A61K39/39541;;A61K2039/505;;C07K16/2845;;A61P7/02;;A61P9/10,G01N33/53;;A61K38/00;;A61K39/395;;A61P7/02;;A61P9/10;;C07K16/28,,6,0,,,"AMERICAN JOURNAL OF PATHOLOGY, vol. 148, no. 1, January 1996, HAGERSTOWN, MD, USA, pages 241-248, XP002036510 J. GARCIA ET AL.: ""Effects of CD11b/18 monoclonal antibody on rats with permanent middle cerebral artery occlusion."";;AMERICAN JOURNAL OF PHYSIOLOGY, vol. 270, no. 1 part 2, 1996, WASHINGTON, DC, USA, pages H53-H64, XP002036511 R. PEREZ ET AL.: ""Factors modifying protective effect of anti-CD18 antibodies on myocardial reperfusion injury in dogs."";;JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 25, no. 3, 1 March 1995, NEW YORK, NY, USA, pages 781-788, XP002036512 T. AVERSANO ET AL.: ""A chimeric IgG4 monoclonal antibody directed against CD18 reduces infarct size in a primate model of myocardial ischemia and reperfusion."";;STROKE, vol. 23, no. 5, May 1992, DALLAS, TX, USA, pages 712-718, XP002036513 E. MORI ET AL.: ""Inhibition of polymorphonuclear leukocyte adherence suppresses no-reflow after focal cerebral ischemia in baboons."" cited in the application;;STROKE, vol. 23, no. 1, January 1992, DALLAS, TX, USA, page 152 XP002036514 M. BEDNAR ET AL.: ""IB4, a monoclonal antibody against the CD18 adhesion complex of leukocytes, attenuates intracranial hypertension in a rabbit stroke model."" cited in the application;;PROTEINS: STRUCTURE, FUNCTION, AND GENETICS, vol. 18, no. 1, January 1994, NEW YORK, NY, USA, pages 49-62, XP000578098 C. EIGENBROT ET AL.: ""X-ray structures of fragments from binding and nonbinding versions of a humanized anti-CD18 antibody: Structural indications of the key role of VH residues 59 to 65.""",EXPIRED
46,WO,A1,WO 2021/116019 A1,055-365-857-951-866,2021-06-17,2021,EP 2020084884 W,2020-12-07,EP 19214486 A,2019-12-09,SYSTEM FOR MONITORING THE SURROUNDINGS OF A MOTOR VEHICLE,"The invention relates to a system (1) for monitoring the surroundings of a motor vehicle (100), in particular an autonomous or partially autonomous motor vehicle, wherein the system (1) comprises at least one optical image capturing device (2) and also an illumination device (3, 4), wherein the optical image capturing device (2) is designed to capture images of a capture region (E1) of the surroundings, and wherein the capture region (E1) can be illuminated at least partially, preferably completely, by the illumination device (3, 4), and wherein the illumination device (3, 4) is designed to generate a motor vehicle light distribution or a part of a motor vehicle light distribution. The system (1) comprises at least one optical additional image capturing device (5) which is designed to capture images of a so-called additional capture region (E2), and wherein the system (1) also comprises an additional illumination device (6) which is designed to illuminate the additional capture region (E2), also referred to as a second capture region, at least partially, preferably completely.",ZKW GROUP GMBH,BRANDSTETTER MARTIN;;ALTMANN JOHANN;;SPORN MARTIN;;BECHMANN HARALD;;BEDNAR INGEBORG;;JACKL CHRISTIAN,,https://lens.org/055-365-857-951-866,Patent Application,yes,2,0,8,8,0,H04N7/181;;B60R11/04;;B60R2300/103;;B60R2300/105;;B60R2300/301;;B60Q1/0023;;G01S13/867;;B60Q1/18;;G01S13/931;;G01S2013/93277;;G01S17/931;;H04N7/181;;B60Q1/0023;;B60R11/04;;B60Q1/18;;B60Q1/249;;G01S13/931;;G01S17/931;;G01S13/867;;G01S2013/93277;;B60Q2800/10;;B60R2300/301;;B60R2300/105;;B60R2300/103;;G01S17/931;;G01S17/86;;B60W60/001;;H04N23/56;;H04N23/90;;B60Q1/0023;;B60Q1/1415;;G01S13/867;;G01S13/89;;G01S13/931;;G01S17/89;;B60W2420/403;;B60W2420/408,H04N7/18,,0,0,,,,PENDING
47,WO,A2,WO 1997/026912 A2,081-324-318-230-682,1997-07-31,1997,US 9700492 W,1997-01-11,US 58998296 A,1996-01-23,ANTI-CD18 ANTIBODIES FOR USE AGAINST STROKE,"A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective amount of an anti-CD18 antibody to the mammal, in the absence of removal of the arterial obstruction.",GENENTECH INC;;UNIV VERMONT,BEDNAR MARTIN M;;GROSS CORDELL E;;THOMAS G ROGER,,https://lens.org/081-324-318-230-682,Patent Application,no,0,108,22,22,16,A61K38/00;;A61K39/39541;;A61K2039/505;;C07K16/2845;;A61P7/02;;A61P9/10,A61K38/00;;A61K39/395;;G01N33/53;;A61P7/02;;A61P9/10;;C07K16/28,,0,0,,,,PATENTED
48,EP,A2,EP 0877626 A2,108-567-608-533-985,1998-11-18,1998,EP 97903790 A,1997-01-11,US 9700492 W;;US 58998296 A,1996-01-23,ANTI-CD18 ANTIBODIES FOR USE AGAINST STROKE,,GENENTECH INC;;UNIV VERMONT,BEDNAR MARTIN M;;GROSS CORDELL E;;THOMAS G ROGER,,https://lens.org/108-567-608-533-985,Patent Application,yes,0,0,22,22,0,A61K38/00;;A61K39/39541;;A61K2039/505;;C07K16/2845;;A61P7/02;;A61P9/10,G01N33/53;;A61K38/00;;A61K39/395;;A61P7/02;;A61P9/10;;C07K16/28,,0,0,,,,EXPIRED
49,CA,C,CA 2242414 C,137-338-799-489-341,2012-01-03,2012,CA 2242414 A,1997-01-11,US 58998296 A;;US 9700492 W,1996-01-23,ANTI-CD18 ANTIBODIES FOR USE AGAINST STROKE,"A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective amount of an anti-CD18 antibody to the mammal, in the absence of removal of the arterial obstruction.",GENENTECH INC;;UNIV VERMONT,BEDNAR MARTIN M;;GROSS CORDELL E;;THOMAS G ROGER,,https://lens.org/137-338-799-489-341,Granted Patent,no,0,0,22,22,16,A61K38/00;;A61K39/39541;;A61K2039/505;;C07K16/2845;;A61P7/02;;A61P9/10,A61K39/395;;G01N33/53;;A61K38/00;;A61P7/02;;A61P9/10;;C07K16/28,,0,0,,,,EXPIRED
50,ZA,B,ZA 97257 B,161-361-721-296-094,1998-07-14,1998,ZA 97257 A,1997-01-13,US 58998296 A,1996-01-23,Anti-cd18 antibodies in stroke,,GENENTECH INC,BEDNAR MARTIN M;;GROSS CORDELL E;;THOMAS G ROGER,,https://lens.org/161-361-721-296-094,Granted Patent,no,0,0,22,22,0,A61K38/00;;A61K39/39541;;A61K2039/505;;C07K16/2845;;A61P7/02;;A61P9/10,A61K38/00;;A61K39/395;;G01N33/53;;A61P7/02;;A61P9/10;;C07K16/28,,0,0,,,,EXPIRED
51,EP,A1,EP 4074026 A1,010-364-810-829-559,2022-10-19,2022,EP 20817367 A,2020-12-07,EP 19214486 A;;EP 2020084884 W,2019-12-09,SYSTEM FOR MONITORING THE SURROUNDINGS OF A MOTOR VEHICLE,,ZKW GROUP GMBH,BRANDSTETTER MARTIN;;ALTMANN JOHANN;;SPORN MARTIN;;BECHMANN HARALD;;BEDNAR INGEBORG;;JACKL CHRISTIAN,,https://lens.org/010-364-810-829-559,Patent Application,yes,0,0,8,8,0,H04N7/181;;B60R11/04;;B60R2300/103;;B60R2300/105;;B60R2300/301;;B60Q1/0023;;G01S13/867;;B60Q1/18;;G01S13/931;;G01S2013/93277;;G01S17/931;;H04N7/181;;B60Q1/0023;;B60R11/04;;B60Q1/18;;B60Q1/249;;G01S13/931;;G01S17/931;;G01S13/867;;G01S2013/93277;;B60Q2800/10;;B60R2300/301;;B60R2300/105;;B60R2300/103;;G01S17/931;;G01S17/86;;B60W60/001;;H04N23/56;;H04N23/90;;B60Q1/0023;;B60Q1/1415;;G01S13/867;;G01S13/89;;G01S13/931;;G01S17/89;;B60W2420/403;;B60W2420/408,H04N7/18,,0,0,,,,PENDING
52,US,A1,US 2022/0417448 A1,000-848-630-646-657,2022-12-29,2022,US 202017777503 A,2020-12-07,EP 19214486 A;;EP 2020084884 W,2019-12-09,System for Monitoring the Surroundings of a Motor Vehicle,"The invention relates to a system ( 1 ) for monitoring the surroundings of a motor vehicle ( 100 ), in particular an autonomous or semi-autonomous motor vehicle, wherein the system ( 1 ) includes at least one optical image capturing device ( 2 ) as well as further a lighting device ( 3, 4 ), wherein the optical image capturing device ( 2 ) is arranged for capturing an area of coverage (E 1 ) of the surroundings, and wherein the area of coverage (E 1 ) can be illuminated at least partially, preferably completely, by the lighting device ( 3, 4 ), and wherein the lighting device ( 3, 4 ) is arranged for generating a motor vehicle light distribution or part of a motor vehicle light distribution. The system ( 1 ) includes at least one optical additional image capturing device ( 5 ), which is arranged to capture a so-called additional area of coverage (E 2 ), and wherein the system ( 1 ) further includes an additional lighting device ( 6 ), which is arranged to illuminate at least partially, preferably completely, the additional area of coverage (E 2 ), also called the second area of coverage.",ZKW GROUP GMBH,BRANDSTETTER MARTIN;;ALTMANN JOHANN;;SPORN MARTIN;;BECHMANN HARALD;;BEDNAR INGEBORG;;JACKL CHRISTIAN,ZKW GROUP GMBH (2022-04-20),https://lens.org/000-848-630-646-657,Patent Application,yes,4,0,8,8,0,H04N7/181;;B60R11/04;;B60R2300/103;;B60R2300/105;;B60R2300/301;;B60Q1/0023;;G01S13/867;;B60Q1/18;;G01S13/931;;G01S2013/93277;;G01S17/931;;H04N7/181;;B60Q1/0023;;B60R11/04;;B60Q1/18;;B60Q1/249;;G01S13/931;;G01S17/931;;G01S13/867;;G01S2013/93277;;B60Q2800/10;;B60R2300/301;;B60R2300/105;;B60R2300/103;;G01S17/931;;G01S17/86;;B60W60/001;;H04N23/56;;H04N23/90;;B60Q1/0023;;B60Q1/1415;;G01S13/867;;G01S13/89;;G01S13/931;;G01S17/89;;B60W2420/403;;B60W2420/408,B60Q1/00;;G01S13/86;;G01S13/89;;G01S13/931;;G01S17/86,,0,0,,,,PENDING
53,KR,A,KR 20220066353 A,007-522-439-456-673,2022-05-24,2022,KR 20227013230 A,2020-12-07,EP 19214486 A;;EP 2020084884 W,2019-12-09,자동차의 주변환경 모니터링 시스템,"본 발명은 자동차(100), 특히 자율 또는 부분 자율 자동차의 주변환경을 모니터링하기 위한 시스템(1)에 관한 것이며, 상기 시스템(1)은 적어도 하나의 광학 이미지 캡처 장치(2) 및 그 외 조명 장치(3, 4)를 포함하며, 광학 이미지 캡처 장치(2)는 주변환경의 캡처 영역(E1)을 캡처하도록 구성되며, 캡처 영역(E1)은 적어도 부분적으로, 바람직하게는 완전하게 조명 장치(3, 4)에 의해 조명될 수 있으며, 조명 장치(3, 4)는 자동차 광 분포, 또는 자동차 광 분포의 일부분을 생성하도록 구성된다. 상기 시스템(1)은, 이른바 추가 캡처 영역(E2)을 캡처하도록 구성되는 적어도 하나의 광학 추가 이미지 캡처 장치(5)를 포함하며, 상기 시스템(1)은 그 외 제2 캡처 영역으로서도 지칭되는 추가 캡처 영역(E2)을 적어도 부분적으로, 바람직하게는 완전하게 조명하도록 구성되어 있는 추가 조명 장치(6)를 포함한다.",ZKW GROUP GMBH,BRANDSTETTER MARTIN;;ALTMANN JOHANN;;SPORN MARTIN;;BECHMANN HARALD;;BEDNAR INGEBORG;;JACKL CHRISTIAN,,https://lens.org/007-522-439-456-673,Patent Application,no,0,0,8,8,0,H04N7/181;;B60R11/04;;B60R2300/103;;B60R2300/105;;B60R2300/301;;B60Q1/0023;;G01S13/867;;B60Q1/18;;G01S13/931;;G01S2013/93277;;G01S17/931;;H04N7/181;;B60Q1/0023;;B60R11/04;;B60Q1/18;;B60Q1/249;;G01S13/931;;G01S17/931;;G01S13/867;;G01S2013/93277;;B60Q2800/10;;B60R2300/301;;B60R2300/105;;B60R2300/103;;G01S17/931;;G01S17/86;;B60W60/001;;H04N23/56;;H04N23/90;;B60Q1/0023;;B60Q1/1415;;G01S13/867;;G01S13/89;;G01S13/931;;G01S17/89;;B60W2420/403;;B60W2420/408,H04N7/18;;B60Q1/00;;B60Q1/18;;B60Q1/24;;B60R11/04,,0,0,,,,DISCONTINUED
54,EP,A1,EP 3836537 A1,100-863-639-636-034,2021-06-16,2021,EP 19214486 A,2019-12-09,EP 19214486 A,2019-12-09,SYSTEM FOR MONITORING THE SURROUNDINGS OF A MOTOR VEHICLE,"Die Erfindung betrifft ein System (1) zur Überwachung der Umgebung eines Kraftfahrzeuges (100), insbesondere eines autonomen oder teilautonomen Kraftfahrzeuges, wobei das System (1) zumindest eine optische Bilderfassungseinrichtung (2) sowie weiters eine Beleuchtungseinrichtung (3, 4) umfasst, wobei die optische Bilderfassungseinrichtung (2) zur Erfassung eines Erfassungsbereiches (E1) der Umgebung eingerichtet ist, und wobei der Erfassungsbereich (E1) zumindest teilweise, vorzugsweise vollständig, von der Beleuchtungseinrichtung (3, 4) beleuchtet werden kann, und wobei die Beleuchtungseinrichtung (3, 4) zur Erzeugung einer Kraftfahrzeug-Lichtverteilung oder eines Teiles einer Kraftfahrzeug-Lichtverteilung eingerichtet ist. Das System (1) umfasst zumindest eine optische Zusatz-Bilderfassungseinrichtung (5), welche dazu eingerichtet ist, einen sogenannten Zusatz-Erfassungsbereich (E2) zu erfassen, und wobei das System (1) weiters eine Zusatz-Beleuchtungseinrichtung (6) umfasst, welche dazu eingerichtet ist, den Zusatz-Erfassungsbereich (E2), auch als zweiter Erfassungsbereich bezeichnet, zumindest teilweise, vorzugsweise vollständig, zu beleuchten.
",ZKW GROUP GMBH,BRANDSTETTER MARTIN;;ALTMANN JOHANN;;SPORN MARTIN;;BECHMANN HARALD;;BEDNAR INGEBORG;;JACKL CHRISTIAN,,https://lens.org/100-863-639-636-034,Patent Application,yes,2,2,8,8,0,H04N7/181;;B60R11/04;;B60R2300/103;;B60R2300/105;;B60R2300/301;;B60Q1/0023;;G01S13/867;;B60Q1/18;;G01S13/931;;G01S2013/93277;;G01S17/931;;H04N7/181;;B60Q1/0023;;B60R11/04;;B60Q1/18;;B60Q1/249;;G01S13/931;;G01S17/931;;G01S13/867;;G01S2013/93277;;B60Q2800/10;;B60R2300/301;;B60R2300/105;;B60R2300/103;;G01S17/931;;G01S17/86;;B60W60/001;;H04N23/56;;H04N23/90;;B60Q1/0023;;B60Q1/1415;;G01S13/867;;G01S13/89;;G01S13/931;;G01S17/89;;B60W2420/403;;B60W2420/408,H04N7/18,,0,0,,,,DISCONTINUED
55,EP,A3,EP 0114996 A3,188-985-417-313-211,1986-10-29,1986,EP 83112630 A,1983-12-15,US 45301782 A,1982-12-27,CHARACTER RECOGNITION UTILIZING TRANSITION MEASUREMENTS,A character recognition system in which a representation of a character is scanned along a plurality of scan lines and measurements are made based on the transitions in each scan line between areas of the character and areas of the background (6). For each scan line a vector is generated based on the transition measurements for the scan line. The vectors are selectively combined logically in order to identify the character (8).,INTERNATIONAL BUSINESS MACHINES CORPORATION,"BEDNAR, GREGORY MARTIN;;HARMON, JOHN CHARLES;;NARAISMHA, MANTHRI SELVAPULLAI IYENGAR",,https://lens.org/188-985-417-313-211,Search Report,yes,3,0,4,4,0,G06V30/10;;G06V30/18;;G06V30/184;;G06V30/18076;;G06V30/18;;G06V30/184;;G06V30/10;;G06V30/18076,G06V30/10;;G06V30/184;;G06V30/18,,1,0,,,"HET P.T.T. BEDRIJF, vol. 17, no. 4, December 1971, pages 252-276, NL; A.A. SPANJERSBERG: ""A method for the automatic reading of postal giro orders""",DISCONTINUED
56,CZ,U1,CZ 11518 U1,124-535-277-240-494,2001-09-17,2001,CZ 200112122 U,2001-06-22,CZ 200112122 U,2001-06-22,Stojan obráběcího stroje,,TOS VARNSDORF A S,BEDNAR SLAVOMIR ING;;MALEK MARTIN ING;;RYSAVY IVAN;;SMOLAR DANIEL,,https://lens.org/124-535-277-240-494,Limited Patent,no,0,0,1,1,0,,B23Q1/01,,0,0,,,,EXPIRED
57,US,B2,US 7361344 B2,148-065-364-497-746,2008-04-22,2008,US 2571204 A,2004-12-28,US 2571204 A;;US 40428603 A;;US 81138400 A;;US 25165299 A;;US 78880097 A;;US 9303896 P,1996-01-23,Co-administration of a thrombolytic and an-anti-CD18 antibody in stroke,"A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective amount of an anti-CD18 antibody to the mammal, in the absence of removal of the arterial obstruction.",GENENTECH INC,BEDNAR MARTIN M;;GROSS LEGAL REPRESENTATIVE LIN;;THOMAS G ROGER,,https://lens.org/148-065-364-497-746,Granted Patent,yes,29,2,6,10,15,A61K38/49;;A61K39/3955;;A61K2039/505;;C07K16/2821;;C07K16/2845;;C07K2317/24;;C07K2317/54;;C07K2317/76;;A61P9/00;;C07K16/2845;;C07K16/2821;;C07K2317/54;;A61K2039/505;;C07K2317/24;;A61K39/3955;;A61K38/49;;C07K2317/76,A61K39/395;;A61K38/00;;A61K38/18;;A61K38/49;;C07K16/28,424/144.1;;424/130.1;;424/133.1;;424/141.1;;424/153.1;;424/173.1;;424/94.2;;424/94.63;;424/94.64;;514/822;;530/387.1;;530/387.3;;530/388.1;;530/388.2;;530/388.22;;530/388.7,54,49,048-794-669-079-726;;022-345-797-786-049;;055-030-583-599-951;;002-259-026-531-084;;045-077-176-392-799;;027-902-851-592-220;;070-469-326-587-575;;110-470-601-227-134;;019-042-311-518-903;;013-965-453-283-510;;027-943-369-931-942;;078-582-056-407-68X;;018-838-358-619-397;;000-514-759-673-488;;000-373-170-472-521;;018-347-387-947-035;;000-447-172-519-011;;097-147-782-576-253;;062-864-177-282-080;;055-075-876-593-173;;095-311-758-359-733;;021-293-831-069-96X;;001-228-279-009-210;;037-290-746-113-468;;012-126-697-378-635;;043-144-105-080-848;;019-703-421-323-539;;052-798-529-997-739;;027-525-005-713-918;;125-471-240-172-316;;022-418-247-398-548;;055-076-506-782-465;;002-403-986-447-57X;;000-720-141-056-207;;114-088-860-422-258;;001-812-195-333-366;;021-240-722-422-948;;010-080-346-309-933;;075-799-844-814-006;;061-540-180-605-656;;003-613-857-894-471;;107-900-380-851-134;;078-429-416-750-81X;;020-476-038-409-995;;004-792-515-132-031;;012-281-537-897-970;;088-240-275-622-972;;013-408-031-320-797;;045-781-929-029-265,7860929;;10.1016/0735-1097(94)00443-t;;9537341;;10.1161/01.cir.97.12.1150;;7519330;;10.1080/01616412.1994.11740210;;10.1080/01616412.1996.11740398;;9162874;;1987672;;10.1161/01.str.22.1.44;;3336899;;10.1161/01.str.19.1.28;;10.1212/wnl.45.4.815;;7723976;;10.1006/exnr.1993.1023;;8094342;;8154873;;10.1002/ana.410350414;;8160235;;10.1161/01.str.25.4.869;;10494344;;10.1007/978-3-7091-6391-7_11;;10.3171/jns.1991.75.4.0623;;1885980;;1677219;;10.1161/01.str.22.7.877;;10.1016/0361-9230(94)90119-8;;7850491;;7541420;;10.1161/01.str.22.10.1276;;1926239;;10.1111/j.1365-3083.1991.tb01773.x;;1707181;;7908437;;10.2210/pdb2fgw/pdb;;10.1002/prot.340180107;;1983768;;7496621;;8546211;;pmc1861617;;7643999;;10.1227/00006123-199506000-00017;;10.1097/00006123-199506000-00017;;8465363;;10.1161/01.str.24.4.558;;10.1016/0161-5890(89)90060-6;;2698997;;10.1002/eji.1830130305;;6339253;;10.1038/348639a0;;2250718;;10.3171/jns.1981.54.6.0773;;7241187;;10.1016/0022-510x(94)00203-z;;7722533;;10.1161/01.str.23.1.93;;1731427;;10077522;;10.1161/01.cir.99.10.1363;;10229342;;10.1016/s0361-9230(99)00004-0;;10.1161/01.str.24.1.117;;8418534;;10.3171/jns.1995.82.2.0269;;7815156;;9736421;;10.1016/s0049-3848(98)00091-7;;7820595;;10.1016/0006-8993(94)91478-8;;10.1161/01.str.23.5.712;;1579969;;10.1007/bf00308474;;1557947;;10.1152/ajpheart.1996.270.1.h53;;8769734;;pmc295788;;10.1172/jci115527;;1684364;;7530260;;10.1016/0165-5728(94)90010-8;;9667494;;10.1016/s0891-5849(98)00047-1;;1561656;;10.1161/01.str.23.2.247;;pmc53746;;10.1073/pnas.87.7.2643;;1969637;;1436419;;10.1227/00006123-199211000-00016;;10.1097/00006123-199211000-00016;;6999671;;10.1161/01.str.11.5.552;;10.1161/01.str.26.8.1438;;7631350;;9932943;;10.1212/wnl.52.2.273;;10.1016/0006-8993(95)00830-j;;8581506;;7964886;;10.1016/0022-510x(94)90234-8,"Aversano et al., ""A Chimeric IgG4 Monoclonal Antibody Directed Against CD18 Reduces Infarct Size in a Primate Model of Myocardial Ischemia and Reperfusion"" J. Amer. Col. Cardiology 25(3) :781-788 (Mar. 1995).;;Barron et al., ""Use of reperfusion therapy for acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2"" Circulation 97(12):1150-1156 (Mar. 31, 1998).;;Bednar et al., ""Comparison of Triphenyltetrazolium Dye with Light Microscopic Evaluation in a Rabbit Model of Acute Cerebral Ischaemia"" Neurological Research 16:129-132 (Apr. 1994).;;Bednar et al., ""IB4, a Monoclonal Antibody Against the CD18 Adhesion Complex of Leukocytes, Attenuates Intracranial Hypertension in a Rabbit Stroke Model"" Stroke (Abstract Only) 23(1):152 (1992).;;Bednar et al., ""IB4, a monoclonal antibody against the CD18 leukocyte adhesion protein, reduces intracranial pressure following thromboembolic stroke in the rabbit"" Neurological Res. 18:171-175 (Apr. 1996).;;Bednar et al., ""The Role of Neutrophils and Platelets in a Rabbit Model of Thromboembolic Stroke"" Stroke 22(1):44-50 (1991).;;Bose et al., ""Evolving Focal Cerebral Ischemia in Cats: Spatial Correlation of Nuclear Magnetic Resonance Imaging, Cerebral Blood Flow, Tetrazolium Staining, and Histopathology"" Stroke 19(1):28-37 (Jan. 1988).;;Bowes et al., ""Monoclonal Antibodies Preventing Leukocyte Activation Reduce Experimental Neurologic Injury and Enhance Efficacy of Thrombolytic Therapy"" Neurology 45:815-819 (1995).;;Bowes et al., ""Monoclonal Antibody to the ICAM-1 Adhesion Site Reduces Neurological Damage in a Rabbit Cerebral Embolism Stroke Model"" Experimental Neurology 119 (2):215-219 (1993).;;Chen et al., ""Anti-CD11b Monoclonal Antibody Reduce Ischemic Cell Damage After Transient Focal Cerebral Ischemia in Rat Anti-CD11b Monoclonal Antibody Reduces Ischemic Cell Damage After Transient Focal Cerebral Ischemia in Rat"" Ann. Neurol. 35(4):458-463 (1994).;;Chen et al., ""Neutropenia Reduces The Volume of Cerebral Infarct After Transient Middle Cerebral Artery Occlusion in the Rat"" Neuroscience Research Communications 11(2):93-99 (1992).;;Chopp et al., ""Anti-CD11b Monoclonal Antibody (1B6c) Reduces Infarct Size Resulting From Transient but Not Permanent Focal Ischemia in Rat"" Stroke (Abstract Only) pp. 267 (19th International J).;;Chopp et al., ""Postischemic Administration of an Anti-MAC-1 Antibody Reduces Ischemic Cell Damage After Transient Middle Cerebral Artery Occlusion in Rats"" Stroke 25(4):869-876 (1993).;;Chopp et al., ""The clot thickens-thrombolysis and combination therapies"" Acta Neurochirurgica 73(Suppl.):67-71 (1999).;;Clark et al., ""Reduction of Central Nervous System Ischemic Injury by Monoclonal Antibody to Intercellular Adhesion Molecule"" J. Neurosurg. 75:623-627 (1991).;;Clark et al., ""Reduction of Central Nervous System Ischemic Injury in Rabbits Using Leukocyte Adhesion Antibody Treatment"" Stroke 22(7):877-883 (Jul. 1991).;;Clark et al., ""Reperfusion Following Focal Stroke Hastens Inflammation and Resolution of Ischemic Injured Tissue"" Brain Research Bulletin 35(4):387-392 (1994).;;Danilenko et al., ""A Novel Canine Leukointegrin, alpha<SUB>d</SUB>beta<SUB>2</SUB>, is Expressed by Specific Macrophage Subpopulations in Tissue and a Minor CD8+ Lymphocyte Subpopulation in Peripheral Blood"" Journal of Immunology 155:35-44 (1995).;;del Zoppo et al., ""Polymorphonuclear Leukocytes Occlude Capillaries Following Middle Cerebral Artery Occlusion and Reperfusion in Baboons"" Stroke 22(10):1276-1283 (1991).;;Desroches et al., ""Regulation and Functional Involvement of Distinct Determinants of Leucocyte Function-Associated Antigen 1 (LFA-1) in T-Cell Activation In Vitro"" Scand. J. Immunol. 33:277-286 (1991).;;Eigenbrot et al., ""X-Ray Structures of Fragments From Binding and Nonbinding Versions of a Humanized Anti-CD18 Antibody: Structural Indications of the Key Role of V<SUB>H </SUB>Residues 59 to 65"" Proteins: Structure, Function, and Genetics 18:49-62 (1994).;;Fekete et al., ""Involvement of Lymphocyte Function-Associated Antigen-1 (LFA-1) But Not ICAM-1 in a Radioactive Leukocyte Cell-Mediated Immunity (LA-CMI) Assay"" J. Clin. Lab. Immunol. 31:145-149 (1990).;;Fisher et al., ""The Penumbra, Therapeutic Time Window and Acute Ischaemic Stroke"" Bailliere's Clinical Neurology 4(2):279-295 (Aug. 1995).;;Garcia, ""Effects of CD11b/18 Monoclonal Antibody on Rats with Permanent Middle Cerebral Artery Occlusion"" Amer. J. Pathology 148(1):241-248 (Jan. 1996).;;Gross et al., ""Delayed Tissue-Plasminogen Activator Therapy in a Rabbit Model of Thromoembolic Stroke"" Neurosurgery 36(6):1172-1177 (1995).;;Gross et al., ""Transforming Growth Factor-beta1 Reduces Infarct Size After Experimental Cerebral Ischemia in a Rabbit Model"" Stroke 24(4):558-562 (Apr. 1993).;;Hildreth & Hyman, ""Production and characterization of Monoclonal Anti-CD18 Anti-Idiotype Antibodies"" Molecular Immunology 26(12):1155-1167 (1989).;;Hildreth et al., ""A Human Lymphocyte-associated Antigen Involved in Cell-mediated Lympholysis"" European Journal of Immunology 13:202-208 (1983).;;Hutchings et al., ""Transfer of Diabetes in Mice Prevented by Blockade of Adhesion-Promoting Receptor on Macrophages"" Nature 348:639-642 (Dec. 13, 1990).;;Jiang et al., ""Anti-CD11b Monoclonal Antibody Reduces Ischemic Cell Damage After Treatment (2h) But Not After Permanent MCA Occlusion in the Rat"" Neuroscience Research Communications 15(2):85-93 (1994).;;Jones et al., ""Thresholds of Focal Cerebral Ischemia in Awake Monkeys"" Journal of Neurosurgery 54:773-782 (Jun. 1981).;;Kim et al., ""Adhesive Glycoproteins CD11a and CD18 are Upregulated in the Leukocytes from Patients with Ischemic Stroke and Transient Ischemic Attacks"" Journal of the Neurological Sciences 128(1):45-50 (1995).;;Kohut et al., ""Reduction in Ischemic Brain Injury in Rabbits by the Anion Transport Inhibitor L-644, 711"" Stroke 23(2):93-97 (Jan. 1992).;;Kumar et al., ""Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model"" Circulation 99(10):1363-1369 (Mar. 16, 1999).;;Lew et al., ""Complement depletion does not reduce brain injury in a rabbit model of thromboembolic stroke"" Brain Research Bulletin 48(3):325-331 (Feb. 1999).;;Lin et al., ""Effect of Brain Edema on Infarct Volume in a Focal Cerebral Ischemia Model in Rats"" Stroke 24(1):117-121 (Jan. 1993).;;Lindsberg et al., ""Antagonism of Neutrophil Adherence in the Deteriorating Stroke Model in Rabbits"" Journal of Neurosurgery 82:269-277 (1995).;;Link et al., ""Neutrophil adhesion and activation during systemic thrombolysis in acute myocardial infarction"" Thrombosis Research 91(4):183-190 (Aug. 15, 1998).;;Matsuo et al., ""Role of Cell Adhesion Molecules in Brain Injury After Transient Middle Cerebral Artery Occlusion in the Rat"" Brain Research 656:344-352 (1994).;;Mori et al., ""Inhibition of Polymorphonuclear Leukocyte Adherence Suppresses No-Reflow After Focal Cerebral Ischemia in Baboons"" Stroke 23(5):712-718 (May 1992).;;Morioka et al., ""Progressive Expression of Immunomolecules on Microglial Cells in Rat Dorsal Hippocampus Following Transient Forebrain Ischemia"" Acta Neuropatholigica, Springer-Verlag vol. 83:149-157 (1992).;;Perez et al., ""Factors modifying protective effect of anti-CD18 antibodies on myocardial reperfusion injury in dogs"" Amer. J. Physiology (Part 2), Washington, D.C. 270(1):H53-H64 (1996).;;Saez-Llorens et al., ""Enhanced Attenuation of Meningeal Inflammation and Brain Edema by Concomitant Administration of Anti-CD18 Monoclonal Antibodies and Dexamethasone in Experimental Haemophilus Meningitis"" Journal of Clin. Invest. 88:2003-2009 (Dec. 1991).;;Schroeter et al., ""Local Immune Responses in the Rat Cerebral Cortex After Middle Cerebral Artery Occlusion"" Journal of Neuroimmunology, Elsevier Science B.V. vol. 55(2):195-203 (1994).;;Shiga et al., ""Suppression of Ischemic Brain Edema in Rats by Depletion of Neutrophils"" Journal of Cerebral Blood Flow and Metabolism (Abstract Only), Ginsberg et al., Supplement 2 edition, New York:Raven Press vol. 11(2):S486 (Jun. 1991).;;Stringer et al., ""Tissue plasminogen activator (tPA) inhibits interleukin-1 induced acute lung leak"" Free Radical Biology & Medicine 25(2):184-188 (Jul. 15, 1998).;;Takeshima et al., ""Monoclonal Leukocyte Antibody Does Not Decrease the Injury of Transient Focal Cerebral Ischemia in Cats"" Stroke 23(2):247-252 (Feb. 1992).;;Vedder et al., ""Inhibition of leukocyte adherence by anti-CD-18 monoclonal antibody attenates reperfusion injury in the rabbit ear"" Proc. Natl. Acad. Sci. USA 87:2643-2646 (Apr. 1990).;;Wilson et al., ""The Effect of the 21-Aminosteroid U74006F in a Rabbit Model of Thromboembolic Stroke"" Neurosurgery 31(5):929-934 (Nov. 1992).;;Young et al., ""H<SUB>2 </SUB>Clearance Measurement of Blood Flow: A Review of Technique and Polargraphic Principles"" Stroke 11(5):552-564 (Sep. 1980).;;Zhang et al., ""Anti-Intercellular Adhesion Molecule-1 Antibody Reduces Ischemic Cell Damage After Transient But Not Permanent Middle Cerebral Artery Occlusion in the Wistar Rat"" Stroke 26(8):1438-1442 (Aug. 1995).;;Zhang et al., ""Increased therapeutic efficacy with rt-PA and anti-CD18 antibody treatment of stroke in the rat"" Neurology 52(2):273-279 (Jan. 15, 1999).;;Zhang et al., ""Postischemic Treatment (2-4h) with Anti-CD11b and Anti-CD18 Monoclonal Antibodies are Neuroprotective After Transient (2h) Focal Cerebral Ischemia in The Rat"" Brain Research, Elsevier Science B.V. vol. 698:79-85 (1995).;;Zhang et al., ""Temporal Profile of Ischemic Tissue Damage, Neutrophil Response, and Vascular Plugging Following Permanent and Transient (2H) Middle Cerebral Artery Occlusion in the Rat"" Journal of the Neurological Sciences, Elsevier Science B.V. vol. 125:3-10 (1994).",EXPIRED
58,CZ,A3,CZ 20012314 A3,169-440-448-110-629,2003-02-12,2003,CZ 20012314 A,2001-06-22,CZ 20012314 A,2001-06-22,Machine tool frame and process for producing thereof,,TOS VARNSDORF A S,BEDNAR SLAVOMIR ING;;MALEK MARTIN ING;;RYSAVY IVAN;;SMOLAR DANIEL,,https://lens.org/169-440-448-110-629,Patent Application,no,0,1,2,2,0,,B23Q1/01,,0,0,,,,EXPIRED
59,US,B2,US 6903135 B2,146-952-485-780-781,2005-06-07,2005,US 37528703 A,2003-02-27,US 37528703 A;;US 4442401 A;;US 31215999 A;;US 8560298 P,1998-05-15,Methods and products related to 16-HETE analogs,"The present invention includes 16-HETE analogs which are agonists and antagonists of 16-HETE. The compositions may be formulated in pharmaceutically acceptable formulations. The invention also includes methods and products for inhibiting neutrophil adhesion and neutrophil aggregation using the 16-HETE agonists. One method of the invention involves the administration of a 16-HETE agonist in combination with a thrombolytic agent to a patient suffering from, thromboembolic stroke.",UNIV VERMONT,FALCK JOHN R;;BEDNAR MARTIN M;;GROSS CORDELL E;;BALAZY MICHAEL,NEW YORK MEDICAL COLLEGE (1999-06-08);;BOARD OF REGENTS UNIVERSITY OF TEXAS SYSTEMS THE (1999-07-30);;UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE THE (1999-08-03),https://lens.org/146-952-485-780-781,Granted Patent,yes,13,0,12,12,0,A61K31/18;;A61K31/202;;A61K38/49;;C07C311/51;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P29/00;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/10;;Y02A50/30;;C07C311/51;;A61K31/202;;A61K31/18;;A61K38/49;;Y02A50/30,A61K31/18;;A61P7/02;;A61K31/202;;A61K31/215;;A61K38/00;;A61K38/49;;A61P9/00;;A61P9/10;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P29/00;;A61P43/00;;C07C49/24;;C07C59/42;;C07C69/732;;C07C311/51,514/552;;554/213;;554/219;;554/224,21,18,020-205-920-992-394;;042-162-505-542-223;;001-141-180-423-815;;092-917-675-910-435;;052-797-578-454-12X;;113-332-764-920-068;;009-007-873-094-579;;027-327-109-055-430;;065-287-209-794-120;;008-088-831-122-202;;022-072-924-697-540;;017-496-384-730-802;;118-436-646-478-449;;019-835-018-717-583;;030-414-389-472-223;;047-093-158-156-218;;114-704-852-383-435;;057-371-287-458-167,1748634;;10.1016/s0021-9258(18)54320-9;;10.1007/bf01062576;;10603528;;10.1016/s0021-9258(18)86938-1;;2113050;;10.1080/01616412.1994.11740275;;7708139;;10.1111/j.1432-1033.1988.tb14019.x;;3129296;;10.1016/0040-4039(96)00059-7;;10.1002/bms.1200210505;;1525186;;8022420;;pmc1899671;;2820233;;8509425;;10.1016/s0021-9258(18)31472-8;;10.1097/00006534-198605000-00097;;1838897;;10.1007/bf01993227;;1333301;;10.1182/blood.v80.11.2765.2765;;2275817;;10.1146/annurev.cb.06.110190.002043;;pmc1890320;;8080039;;pmc1917898;;2043925;;10.1111/j.1476-5381.1991.tb12160.x;;9721182;;10.1006/abbi.1998.0806;;7721444;;10.1161/01.hyp.25.4.854,"Balazy, M., ""Metabolism of 5,6-Epoxyeicosatrienoic Acid by the Human Platelet, Formation of Novel Thromboxane Analogs"", The Journal of Biological Chemistry, December 15, 1991, pp. 23561-23567, vol. 266, No. 35, The American Society of Biochemistry and Molecular Biology, Inc. USA.;;Bednar, M.M. et al., ""16-HETE: A Novel Arachidonate Metabolite Which Inhibits Human Leukocyte Function"", Jun. 1994, Abstract, Meeting in Florence, Italy.;;Bednar, M.M. et al., ""Neutrophil and Platelet Activity and Quantification Following Delayed tPA Therapy in a Rabbit Model of Thromboembolic Stroke"", Journal of Thrombosis and Thrombolysis, 1995, pp. 179-185, vol. 1, Kluwer Academic Publishers, Boston, Printed: Netherlands.;;Dan, J. et al., ""Constituent acids of Cucumis sativus fruit cutin"", Asian J. Chem., 1995, pp. 381-388, vol. 7, No. 2, Abstract 1995:515704, 123:29628.;;Falck, J.R. et al., ""Cytochrome P-450-dependent Oxidation of Arachidonic Acid to 16-, 17-, and 18-Hydroxyeicosatetraenoic Acids"", The Journal of Biological Chemistry, Jun. 25, 1990, pp. 10244-10249, vol. 265, No. 18, The American Society of Biochemistry and Molecular Biology, Inc. USA.;;Gross, C.E. et al., ""TGF-beta1 post-treatment in a rabbit model of cerbral ischaemia"", Neurological Research, Dec. 1994, pp. 465-470, vol. 16, Forefront Publishing Group.;;Hatzelmann, A. et al., ""The omega-hydroxylation of arachidonic acid by human polymorphonuclear leukocytes"", Eur. J. Biochem., 1988, pp. 445-452, vol. 173, FEBS.;;Heckmann, B. et al., ""Chiral Acetals: Stereocontrolled Syntheses of 16-, 17-, and 18-Hydroxyeicosatetraenoic Acids, Cytochrome P-450 Arachidonate Metabolites"", Tetrahedron Letters, 1996, pp. 1425-1428, vol. 37, No. 9, Elsevier Science Ltd. Great Britain.;;Hill, E. et al., ""Quantitation of 20-Hydroxy-5,8,11,14-eicosatetraenoic Acid (20-HETE) Produced by Human Polymorphonuclear Leukocytes Using Electron Capture Ionization Gas Chromatography/Mass Spectrometry"", Biological Mass Spectrometry, 1992, pp. 249-253, vol. 21, John Wiley & Sons Ltd.;;Knickle, L.C. et al., ""Bioactivation of arachiodonic acid by the cytochrome P450 monooxygenases of guinea pig lung: the ortholog of cytochrome P450 2B4 is solely responsible for formation of epoxyeicosatrienoic acids"", Mol. Pharmacol, 1994, pp. 1273-1280, vol. 45, No. 6, Abstract 1994:474474 121:74474.;;Kraemer, R. et al., ""A Neutrophil-Derived Cytochrome P450-Dependent Metabolite of Arachidonic Acid Modulates Neutrophil Behavior"", American Journal of Pathology, Sep. 1987, pp. 446-454, vol. 128, No. 3, American Association of Pathologists.;;Laethem, R.M. et al., ""Formation of 19(S)-, 19(R)-, and 18(R)-Hydroxyeicosatetraenoic Acids by Alcohol-inducible Cytochrome P450 2EI"", The Journal of Biological Chemistry, Jun. 15, 1993, pp. 12912-12918, vol. 268, No. 17, The American Society for Biochemistry and Molecular Biology, Inc. USA.;;Lee, T.H. et al., ""Effect of Dietary Enrichment with Eicosapentaenoic and Docosahexaenoic Acids on In Vitro Neutrophil and Monocyte Leukotriene Generation and Neutrophil Function"", The New England Journal of Medicine, May 9, 1985, pp. 1217-1224, vol. 312, No. 19.;;Lesch, M.E. et al., ""The effects of (R)-N-(1-methyl-2-phenylethyl) adenosine (L-PIA), a standard A<SUB>1</SUB>-selective adenosine agonist on rat acute models of inflammation and neutrophil function"", Agents and Actions, 1991, pp. 25-27, vol. 34, No. 1/2, Birkauser Verlag, Basel.;;Setty, B.N. et al., ""15-Hydroxyeicosatetraenoic acid-mediated potentiation of thrombin-induced platelet functions occurs via enhanced production of phosphoinositide-derived second messengers-sn-1,2-diacylglycerol and inositol-1,4,5,-trisphosphate"", Blood, Dec. 1, 1992, pp. 2765-2773, vol. 80, No. 11, Abstract 93081777.;;Springer, T.A., ""The Sensation and Regulation of Interactions with the Extracellular Environment: The Cell Biology of Lymphocyte Adhesion Receptors"", Annu. Rev. Cell. Biol., 1990, pp. 359-402, vol. 6, Annual Reviews, Inc.;;Subbaraman, A.S. et al., ""A facile racemic synthesis of eicosane-1, 16-diol, an aglycone of a marine natural product forbesin"", Indian J. Chem., 1992, pp. 262-263, vol. 31B, No. 4, Sect. B, Abstract 1992:214224 116:214224.;;Takata, S. et al., ""15-Hydroxyeicosatetraenoic acid inhibits neutrophil migration across cytokine-activated endothelium"", Am J. Pathol., 1994, pp. 541-549, vol. 145, No. 3, Abstract 1995:138771 122:29618.;;Watanabe, M. et al., ""Stimulation of neutrophil adherence to vascular endothelial cells by histamine and thrombin and its inhibition by PAF antagonists and dexamethasone"", Br. J. Pharmacol., 1991, pp. 239-245, vol. 102, Macmillan Press Ltd.;;Zeldin, L.G. et al., ""Cloning and expression of murine CYP2Cs and their ability to metabolize arachidonic acid"", Archives of Biochemistry & Biophysics, Sep. 1, 1998, pp. 45-57, vol. 357, No. 1, Abstract 98389577.;;Zhu, Y. et al., ""Identification of Arachidonate P-450 Metabolites in Human Platelet Phospholipids"", Hypertension, Apr. 1995, pp. 854-859, vol. 25, No. 4, Part 2.",EXPIRED
60,CA,A1,CA 2332272 A1,155-180-116-686-932,1999-11-25,1999,CA 2332272 A,1999-05-14,US 8560298 P;;US 9910728 W,1998-05-15,NOVEL ANALOGS OF 16-HYDROXYEICOSATETRAENOIC ACID,"The present invention includes 16-HETE analogs of formula (I), wherein R, R2 and R3 have the meanings given in the description, which are agonists and antagoninists of 16-HETE. The compositions may be formulated in pharmaceutically acceptable formulations. The invention also includes methods and products for inhibiting neutrophil adhesion and neutrophil aggregation using the 16-HETE agonists. One method of the invention involves the administration of a 16-HETE agonist in combination with a thrombolytic agent to a patient suffering from thromboembolic stroke.",UNIV VERMONT;;NEW YORK MEDICAL COLLEGE;;UNIV TEXAS,GROSS CORDELL E;;BEDNAR MARTIN M;;FALCK JOHN R;;BALAZY MICHAEL,,https://lens.org/155-180-116-686-932,Patent Application,no,0,0,12,12,0,A61K31/18;;A61K31/202;;A61K38/49;;C07C311/51;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P29/00;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/10;;Y02A50/30;;C07C311/51;;A61K31/202;;A61K31/18;;A61K38/49;;Y02A50/30,A61P7/02;;A61K31/18;;A61K31/202;;A61K31/215;;A61K38/00;;A61K38/49;;A61P9/00;;A61P9/10;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P29/00;;A61P43/00;;C07C49/24;;C07C59/42;;C07C69/732;;C07C311/51,,0,0,,,,DISCONTINUED
61,US,A,US 5753702 A,065-349-100-182-607,1998-05-19,1998,US 65232796 A,1996-05-22,US 65232796 A,1996-05-22,"Arachidonic acid metabolite, 16-hete",The present invention provides methods and products for inhibiting neutrophil adhesion and neutrophil aggregation. The invention includes a method for treating a subject to inhibit neutrophil adhesion and neutrophil aggregation by administering 16-hydroxyeicosatetraenoic acid (16-HETE) to the subject. 16-HETE is an arachidonic acid metabolite. The invention also includes a pharmaceutical preparation of 16-HETE.,UNIV VERMONT,BEDNAR MARTIN M;;GROSS CORDELL E;;BALAZY MICHAEL;;FALCK JOHN R,UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (1996-07-30);;NEW YORK MEDICAL COLLEGE (1996-08-01);;BOARD OF REGENTS (1996-08-02),https://lens.org/065-349-100-182-607,Granted Patent,yes,1,48,7,7,0,A61K31/525;;A61K31/525;;A61K31/20;;A61K31/20;;A61K31/202;;A61K31/202;;A61K31/23;;A61K31/23;;A61K31/35;;A61K31/35;;A61K31/415;;A61K31/415;;A61K31/445;;A61K31/445;;A61K31/60;;A61K31/60;;A61K38/49;;A61K38/49;;A61K45/06;;A61K45/06;;A61P9/10;;Y02A50/30;;Y02A50/30,A61K31/20;;A61K31/202;;A61K31/23;;A61K31/35;;A61K31/415;;A61K31/445;;A61K31/525;;A61K31/60;;A61K38/49;;A61K45/06,514/552,18,13,001-141-180-423-815;;057-371-287-458-167;;092-917-675-910-435;;017-496-384-730-802;;022-072-924-697-540;;009-007-873-094-579;;047-093-158-156-218;;008-088-831-122-202;;020-205-920-992-394;;042-162-505-542-223;;019-835-018-717-583;;065-287-209-794-120;;052-797-578-454-12X,10.1016/s0021-9258(18)86938-1;;2113050;;7721444;;10.1161/01.hyp.25.4.854;;10.1080/01616412.1994.11740275;;7708139;;1838897;;10.1007/bf01993227;;10.1097/00006534-198605000-00097;;10.1002/bms.1200210505;;1525186;;pmc1917898;;2043925;;10.1111/j.1476-5381.1991.tb12160.x;;8509425;;10.1016/s0021-9258(18)31472-8;;1748634;;10.1016/s0021-9258(18)54320-9;;10.1007/bf01062576;;10603528;;2275817;;10.1146/annurev.cb.06.110190.002043;;pmc1899671;;2820233;;10.1111/j.1432-1033.1988.tb14019.x;;3129296,"Chemical Abstracts AN 1995:138771, Takada et al.;;Chemical Abstracts AN 1990:493392, Falck et al.;;Chemical Abstracts AN 1994:474474, Knickle et al.;;Falck, J.R. et al., The Journal of Biological Chemistry, vol. 265 (18):10244 10249 (1990).;;Heckmann, B. et al. . Tetrahadron Letters, vol. 37(9):1425 1428 (1996).;;Bednar, M.M. et al.. Abstract from meeting held in Florence, Italy (Jun. 1994).;;Ying Zhu et al.. Hypertension, vol. 25 (4),Part 2:854 859 (Apr. 1995).;;Gross, C.E. et al. . Neurological Res. , vol. 16:465 470 (Dec. 1994).;;Lesch, M.E. et al. . Agents and Actions, vol. 34:25 27 (1991).;;Lee, T.H. et al. . The New England Journal of Medicine, vol. 312(19):1217 1224 (5/9/85).;;Hill, E. et al. . Biological Mass Spectrometry, vol. 21:249 253 (1992).;;Watanabe, Masako et al. , Br. J. Pharmacol, 102:239 245 (1991).;;Laethem, R.M. et al. , the Journal of Biological Chemistry, vol. 268(17):12912 12918 (1993).;;Balazy, M., The Journal of Biological Chemistry, vol. 266(35):23561 23567 (1991).;;Bednar, M.M. et al., Journal of Thrombosis and Thrombolysis:1:179 185 (1995).;;Springer, T.A. , Annu. Rev. Cell Biol. , 6:359 402 (1990).;;Kraemer, R. et al. , American Journal of Pathology, vol. 128(3):446 454 (1987).;;Hatzelmann A. et al. , Euro. J. Biochem. 173:445 452 (1988).",EXPIRED
62,US,A1,US 2002/0165262 A1,035-804-435-095-55X,2002-11-07,2002,US 4442401 A,2001-11-09,US 4442401 A;;US 31215999 A;;US 8560298 P,1998-05-15,Methods and products relating to 16-HETE analogs,"
   The present invention includes 16-HETE analogs which are agonists and antagonists of 16-HETE. The compositions may be formulated in pharmaceutically acceptable formulations. The invention also includes methods and products for inhibiting neutrophil adhesion and neutrophil aggregation using the 16-HETE agonists. One method of the invention involves the administration of a 16-HETE agonist in combination with a thrombolytic agent to a patient suffering from thromboembolic stroke. 
",UNIV VERMONT,FALCK JOHN R;;BEDNAR MARTIN M;;GROSS CORDELL E;;BALAZY MICHAEL,,https://lens.org/035-804-435-095-55X,Patent Application,yes,0,1,12,12,0,A61K31/18;;A61K31/202;;A61K38/49;;C07C311/51;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P29/00;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/10;;Y02A50/30;;C07C311/51;;A61K31/202;;A61K31/18;;A61K38/49;;Y02A50/30,A61K31/18;;A61K31/202;;A61K31/215;;A61K38/00;;A61P7/02;;A61K38/49;;A61P9/00;;A61P9/10;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P29/00;;A61P43/00;;C07C49/24;;C07C59/42;;C07C69/732;;C07C311/51,5144;;514/464;;514/512;;514/563;;514/419;;514/423,0,0,,,,EXPIRED
63,EP,B1,EP 1077936 B1,190-370-067-120-33X,2005-10-05,2005,EP 99924250 A,1999-05-14,US 9910728 W;;US 8560298 P,1998-05-15,NOVEL ANALOGS OF 16-HYDROXYEICOSATETRAENOIC ACID,"The present invention includes 16-HETE analogs which are agonists and antagonists of 16-HETE. The compositions may be formulated in pharmaceutically acceptable formulations. The invention also includes methods and products for inhibiting neutrophil adhesion and neutrophil aggregation using the 16-HETE agonists. One method of the invention involves the administration of a 16-HETE agonist in combination with a thrombolytic agent to a patient suffering from, thromboembolic stroke.",UNIV VERMONT;;UNIV TEXAS;;NEW YORK MEDICAL COLLEGE,FALCK JOHN R;;BEDNAR MARTIN M;;GROSS CORDELL E;;BALAZY MICHAEL,,https://lens.org/190-370-067-120-33X,Granted Patent,yes,1,1,12,12,0,A61K31/18;;A61K31/202;;A61K38/49;;C07C311/51;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P29/00;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/10;;Y02A50/30;;C07C311/51;;A61K31/202;;A61K31/18;;A61K38/49;;Y02A50/30,A61P7/02;;A61K31/18;;A61K31/202;;A61K31/215;;A61K38/00;;A61K38/49;;A61P9/00;;A61P9/10;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P29/00;;A61P43/00;;C07C49/24;;C07C59/42;;C07C69/732;;C07C311/51,,1,0,,,"HECKMANN, B. ET AL.: ""Chiral Acetals : Stereocontrolled Syntheses of 16-, 17- and 18-Hydroxyeicosatetraenoic Acids, Cytochrome P-450 Arachidonate Metabolites"" TETRAHEDRON LETTERS, vol. 37, no. 9, 1996, pages 1425-1428, XP002115389",EXPIRED
64,EP,A4,EP 0951283 A4,156-666-300-254-511,2002-06-26,2002,EP 97926721 A,1997-05-22,US 9708865 W;;US 65232796 A,1996-05-22,"NOVEL ARACHIDONIC ACID METABOLITE, 16-HETE",,UNIV VERMONT;;UNIV TEXAS;;NEW YORK MEDICAL COLLEGE,BEDNAR MARTIN M;;GROSS CORDELL E;;BALAZY MICHAEL;;FALCK JOHN R,,https://lens.org/156-666-300-254-511,Search Report,no,3,0,7,7,0,A61K31/525;;A61K31/525;;A61K31/20;;A61K31/20;;A61K31/202;;A61K31/202;;A61K31/23;;A61K31/23;;A61K31/35;;A61K31/35;;A61K31/415;;A61K31/415;;A61K31/445;;A61K31/445;;A61K31/60;;A61K31/60;;A61K38/49;;A61K38/49;;A61K45/06;;A61K45/06;;A61P9/10;;Y02A50/30;;Y02A50/30,A61K31/20;;A61K31/202;;A61K31/23;;A61K31/35;;A61K31/415;;A61K31/445;;A61K31/525;;A61K31/60;;A61K38/49;;A61K45/06,,1,0,,,See also references of WO 9744024A1,DISCONTINUED
65,US,B2,US 6562988 B2,041-016-942-918-311,2003-05-13,2003,US 4442401 A,2001-11-09,US 4442401 A;;US 31215999 A;;US 8560298 P,1998-05-15,Methods and products relating to 16-HETE analogs,"
    The present invention includes 16-HETE analogs which are agonists and antagonists of 16-HETE. The compositions may be formulated in pharmaceutically acceptable formulations. The invention also includes methods and products for inhibiting neutrophil adhesion and neutrophil aggregation using the 16-HETE agonists. One method of the invention involves the administration of a 16-HETE agonist in combination with a thrombolytic agent to a patient suffering from thromboembolic stroke. 
",UNIV VERMONT;;UNIV TEXAS;;NEW YORK MEDICAL COLLEGE,FALCK JOHN R;;BEDNAR MARTIN M;;GROSS CORDELL E;;BALAZY MICHAEL,,https://lens.org/041-016-942-918-311,Granted Patent,yes,10,1,12,12,0,A61K31/18;;A61K31/202;;A61K38/49;;C07C311/51;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P29/00;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/10;;Y02A50/30;;C07C311/51;;A61K31/202;;A61K31/18;;A61K38/49;;Y02A50/30,A61K31/18;;A61P7/02;;A61K31/202;;A61K31/215;;A61K38/00;;A61K38/49;;A61P9/00;;A61P9/10;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P29/00;;A61P43/00;;C07C49/24;;C07C59/42;;C07C69/732;;C07C311/51,554/49;;554/43;;554/90;;554/103;;554/104;;558/250;;558/243;;558/308;;562/886;;568/61;;568/69;;568/687,21,18,020-205-920-992-394;;042-162-505-542-223;;001-141-180-423-815;;092-917-675-910-435;;052-797-578-454-12X;;113-332-764-920-068;;009-007-873-094-579;;027-327-109-055-430;;065-287-209-794-120;;008-088-831-122-202;;022-072-924-697-540;;017-496-384-730-802;;118-436-646-478-449;;019-835-018-717-583;;030-414-389-472-223;;047-093-158-156-218;;114-704-852-383-435;;057-371-287-458-167,1748634;;10.1016/s0021-9258(18)54320-9;;10.1007/bf01062576;;10603528;;10.1016/s0021-9258(18)86938-1;;2113050;;10.1080/01616412.1994.11740275;;7708139;;10.1111/j.1432-1033.1988.tb14019.x;;3129296;;10.1016/0040-4039(96)00059-7;;10.1002/bms.1200210505;;1525186;;8022420;;pmc1899671;;2820233;;8509425;;10.1016/s0021-9258(18)31472-8;;10.1097/00006534-198605000-00097;;1838897;;10.1007/bf01993227;;1333301;;10.1182/blood.v80.11.2765.2765;;2275817;;10.1146/annurev.cb.06.110190.002043;;pmc1890320;;8080039;;pmc1917898;;2043925;;10.1111/j.1476-5381.1991.tb12160.x;;9721182;;10.1006/abbi.1998.0806;;7721444;;10.1161/01.hyp.25.4.854,"Balazy, M., ""Metabolism of 5,6-Epoxyeicosatrienoic Acid by the Human Platelet, Formation of Novel Thromboxane Analogs"", The Journal of Biological Chemistry, Dec. 15, 1991, pp. 23561-23567, vol. 266, No. 35, The American Society of Biochemistry and Molecular Biology, Inc. USA.;;Bednar, M.M. et al., ""16-HETE: A Novel Arachidonate Metabolite Which Inhibits Human Leukocyte Function"", Jun. 1994, Abstract, Meeting in Florence, Italy.;;Bednar, M.M. et al., ""Neutrophil and Platelet Activity and Quantification Following Delayed tPA Therapy in a Rabbit Model of Thromboembolic Stroke"", Journal of Thrombosis and Thrombolysis, 1995, pp. 179-185, vol. 1, Kluwer Academic Publishers, Boston, Printed: Netherlands.;;Dan, J. et al., ""Constituent acids of Cucumis sativus fruit cutin"", Asian J. Chem., 1995, pp. 381-388, vol. 7, No. 2, Abstract 1995:515704, 123:29628.;;Falck, J.R. et al., ""Cytochrome P-450-dependent Oxidation of Arachidonic Acid to 16-, 17-, and 18- Hydroxyeicosatetraenoic Acids"", The Journal of Biological Chemistry, Jun. 25, 1990, pp. 10244-10249, vol. 265, No. 18, The American Society of Biochemistry and Molecular Biology, Inc. USA.;;Gross, C.E. et al., ""TGF-beta1 post-treatment in a rabbit model of cerbral ischaemia"", Neurological Research, Dec. 1994, pp. 465-470, vol. 16, Forefront Publishing Group.;;Hatzelmann, A. et al., ""The omega-hydroxylation of arachidonic acid by human polymorphonuclear leukocytes"", Eur. J. Biochem., 1988, pp. 445-452, vol. 173, FEBS.;;Heckmann, B. et al., ""Chiral Acetals: Stereocontrolled Syntheses of 16-, 17-, and 18- Hydroxyeicosatetraenoic Acids, Cytochrome P-450 Arachidonate Metabolites"", Tetrahedron Letters, 1996, pp. 1425-1428, vol. 37, No. 9, Elsevier Science Ltd. Great Britain.;;Hill, E. et al., ""Quantitation of 20-Hydroxy-5,8,11,14-eicosatetraenoic Acid (20-HETE) Produced by Human Polymorphonuclear Leukocytes Using Electron Capture Ionization Gas Chromatography/Mass Spectrometry"", Biological Mass Spectrometry, 1992, pp. 249-253, vol. 21, John Wiley & Sons Ltd.;;Knickle, L.C. et al., ""Bioactivation of arachiodonic acid by the cytochrome P450 monooxygenases of guinea pig lung; the ortholog of cytochrome P450 2B4 is solely responsible for formation of epoxyeicosatrienoic acids"", Mol. Pharmacol, 1994, pp. 1273-1280, vol. 45, No. 6, Abstract 1994:474474 121:74474.;;Kraemer, R. et al., ""A Neutrophil-Derived Cytochrome P450-Dependent Metabolite of Arachidonic Acid Modulates Neutrophil Behavior"", American Journal of Pathology, Sep. 1987, pp. 446-454, vol. 128, No. 3, American Association of Pathologists.;;Laethem, R.M. et al., ""Formation of 19(S)-, 19(R)-, and 18(R)-Hydroxyeicosatetraenoic Acids by Alcohol-inducible Cytochrome P450 2E1"", The Journal of Biological Chemistry, Jun. 15, 1993, pp. 12912-12918, vol. 268, No. 17, The American Society for Biochemistry and Molecular Biology, Inc. USA.;;Lee, T.H. et al., ""Effect of Dietary Enrichment with Eicosapentaenoic and Docosahexaenoic Acids on In Vitro Neutrophil and Monocyte Leukotriene Generation and Neutrophil Function"", The New England Journal of Medicine, May 9, 1985, pp. 1217-1224, vol. 312, No. 19.;;Lesch, M.E. et al., ""The effects of (R)-N-(1-methyl-2-phenylethyl) adenosine (L-PIA), a standard A1-selective adenosine agonist on rat acute models of inflammation and neutrophil function"", Agents and Actions, 1991, pp. 25-27, vol. 34, No. 1/2, Birkauser Verlag, Basel.;;Setty, B.N. et al., ""15-Hydroxyeicosatetraenoic acid-mediated potentiation of thrombin-induced platelet functions occurs via enhanced production of phosphoinositide-derived second messengers-sn-1,2-diacylglycerol and inositol-1,4,5,-trisphosphate"", Blood, Dec. 1, 1992, pp. 2765-2773, vol. 80, No. 11, Abstract 93081777.;;Springer, T.A., ""The Sensation and Regulation of Interactions with the Extracellular Environment: The Cell Biology of Lymphocyte Adhesion Receptors"", Annu. Rev. Cell. Biol., 1990, pp. 359-402, vol. 6, Annual Reviews, Inc.;;Subbaraman, A.S. et al., ""A facile racemic synthesis of eicosane-1,16-diol, an aglycone of a marine natural product forbesin"", Indian J. Chem., 1992, pp. 262-263, vol. 31B, No. 4, Sect. B, Abstract 1992:214224 116:214224.;;Takata, S. et al., ""15-Hydroxyeicosatetraenoic acid inhibits neutrophil migration across cytokine-activated endothelium"", Am J. Pathol., 1994, pp. 541-549, vol. 145, No. 3, Abstract 1995:138771 122:29618.;;Watanabe, M. et al., ""Stimulation of neutrophil adherence to vascular endothelial cells by histamine and thrombin and its inhibition by PAF antagonists and dexamethasone"", Br. J. Pharmacol., 1991, pp. 239-245, vol. 102, Macmillan Press Ltd.;;Zeldin, L.G. et al., ""Cloning and expression of murine CYP2Cs and their ability to metabolize arachidonic acid"", Archives of Biochemistry & Biophysics, Sep. 1, 1998, pp. 45-57, vol. 357, No. 1, Abstract 98389577.;;Zhu, Y. et al., ""Identification of Arachidonate P-450 Metabolites in Human Platelet Phospholipids"", Hypertension, Apr. 1995, pp. 854-859, vol. 25, No. 4, Part 2.",EXPIRED
66,US,A1,US 2003/0176509 A1,061-657-195-137-364,2003-09-18,2003,US 37528703 A,2003-02-27,US 37528703 A;;US 4442401 A;;US 31215999 A;;US 8560298 P,1998-05-15,Methods and products related to 16-HETE analogs,"
   The present invention includes 16-HETE analogs which are agonists and antagonists of 16-HETE. The compositions may be formulated in pharmaceutically acceptable formulations. The invention also includes methods and products for inhibiting neutrophil adhesion and neutrophil aggregation using the 16-HETE agonists. One method of the invention involves the administration of a 16-HETE agonist in combination with a thrombolytic agent to a patient suffering from, thromboembolic stroke. 
",UNIV VERMONT,FALCK JOHN R;;BEDNAR MARTIN M;;GROSS CORDELL E;;BALAZY MICHAEL,NEW YORK MEDICAL COLLEGE (1999-06-08);;BOARD OF REGENTS UNIVERSITY OF TEXAS SYSTEMS THE (1999-07-30);;UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE THE (1999-08-03),https://lens.org/061-657-195-137-364,Patent Application,yes,0,0,12,12,0,A61K31/18;;A61K31/202;;A61K38/49;;C07C311/51;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P29/00;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/10;;Y02A50/30;;C07C311/51;;A61K31/202;;A61K31/18;;A61K38/49;;Y02A50/30,A61K31/18;;A61K31/202;;A61P7/02;;A61K31/215;;A61K38/00;;A61K38/49;;A61P9/00;;A61P9/10;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P29/00;;A61P43/00;;C07C49/24;;C07C59/42;;C07C69/732;;C07C311/51,514/601;;554/43;;554/221,0,0,,,,EXPIRED
67,WO,A1,WO 1999/059964 A1,177-645-675-412-116,1999-11-25,1999,US 9910728 W,1999-05-14,US 8560298 P,1998-05-15,NOVEL ANALOGS OF 16-HYDROXYEICOSATETRAENOIC ACID,"The present invention includes 16-HETE analogs of formula (I), wherein R, R2 and R3 have the meanings given in the description, which are agonists and antagoninists of 16-HETE. The compositions may be formulated in pharmaceutically acceptable formulations. The invention also includes methods and products for inhibiting neutrophil adhesion and neutrophil aggregation using the 16-HETE agonists. One method of the invention involves the administration of a 16-HETE agonist in combination with a thrombolytic agent to a patient suffering from thromboembolic stroke.",UNIV VERMONT;;UNIV TEXAS;;NEW YORK MEDICAL COLLEGE,FALCK JOHN R;;BEDNAR MARTIN M;;GROSS CORDELL E;;BALAZY MICHAEL,,https://lens.org/177-645-675-412-116,Patent Application,yes,1,8,12,12,0,A61K31/18;;A61K31/202;;A61K38/49;;C07C311/51;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P29/00;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/10;;Y02A50/30;;C07C311/51;;A61K31/202;;A61K31/18;;A61K38/49;;Y02A50/30,A61K31/18;;A61K31/202;;A61P7/02;;A61K31/215;;A61K38/00;;A61K38/49;;A61P9/00;;A61P9/10;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P29/00;;A61P43/00;;C07C49/24;;C07C59/42;;C07C69/732;;C07C311/51,,1,1,113-332-764-920-068,10.1016/0040-4039(96)00059-7,"HECKMANN, B. ET AL.: ""Chiral Acetals : Stereocontrolled Syntheses of 16-, 17- and 18-Hydroxyeicosatetraenoic Acids, Cytochrome P-450 Arachidonate Metabolites"", TETRAHEDRON LETTERS, vol. 37, no. 9, 1996, pages 1425 - 1428, XP002115389",PATENTED
68,AU,A,AU 1997/031423 A,182-207-451-621-85X,1997-12-09,1997,AU 1997/031423 A,1997-05-22,US 65232796 A;;US 9708865 W,1996-05-22,"Novel arachidonic acid metabolite, 16-hete",,UNIV TEXAS;;NEW YORK MEDICAL COLLEGE;;UNIVERSITY OF VERMONT THE,BEDNAR MARTIN M;;GROSS CORDELL E;;BALAZY MICHAEL;;FALCK JOHN R,,https://lens.org/182-207-451-621-85X,Patent Application,no,0,0,7,7,0,A61K31/525;;A61K31/525;;A61K31/20;;A61K31/20;;A61K31/202;;A61K31/202;;A61K31/23;;A61K31/23;;A61K31/35;;A61K31/35;;A61K31/415;;A61K31/415;;A61K31/445;;A61K31/445;;A61K31/60;;A61K31/60;;A61K38/49;;A61K38/49;;A61K45/06;;A61K45/06;;A61P9/10;;Y02A50/30;;Y02A50/30,A61K31/20;;A61K31/202;;A61K31/23;;A61K31/35;;A61K31/415;;A61K31/445;;A61K31/525;;A61K31/60;;A61K38/49;;A61K45/06,,0,0,,,,PENDING
69,US,B1,US 6359158 B1,004-284-312-127-485,2002-03-19,2002,US 31215999 A,1999-05-14,US 31215999 A;;US 8560298 P,1998-05-15,Methods and products related to 16-HETE analogs,"
    The present invention includes 16-HETE analogs which are agonists and antagonists of 16-HETE. The compositions may be formulated in pharmaceutically acceptable formulations. The invention also includes methods and products for inhibiting neutrophil adhesion and neutrophil aggregation using the 16-HETE agonists. One method of the invention involves the administration of a 16-HETE agonist in combination with a thrombolytic agent to a patient suffering from thromboembolic stroke. 
",UNIV VERMONT;;UNIV TEXAS;;NEW YORK MEDICAL COLLEGE,FALCK JOHN R;;BEDNAR MARTIN M;;GROSS CORDELL E;;BALAZY MICHAEL,UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (1999-07-30);;NEW YORK MEDICAL COLLEGE (1999-08-06);;BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (1999-07-30);;VERMONT AND STATE UNIVERSITY OF AGRICULTURAL COLLEGE (1999-08-03),https://lens.org/004-284-312-127-485,Granted Patent,yes,10,11,12,12,0,A61K31/18;;A61K31/202;;A61K38/49;;C07C311/51;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P29/00;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/10;;Y02A50/30;;C07C311/51;;A61K31/202;;A61K31/18;;A61K38/49;;Y02A50/30,A61K31/18;;A61P7/02;;A61K31/202;;A61K31/215;;A61K38/00;;A61K38/49;;A61P9/00;;A61P9/10;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P29/00;;A61P43/00;;C07C49/24;;C07C59/42;;C07C69/732;;C07C311/51,554/219;;554/213;;554/224,23,16,027-327-109-055-430;;001-141-180-423-815;;057-371-287-458-167;;092-917-675-910-435;;017-496-384-730-802;;022-072-924-697-540;;009-007-873-094-579;;047-093-158-156-218;;008-088-831-122-202;;020-205-920-992-394;;042-162-505-542-223;;019-835-018-717-583;;065-287-209-794-120;;052-797-578-454-12X;;118-436-646-478-449;;114-704-852-383-435,8022420;;10.1016/s0021-9258(18)86938-1;;2113050;;7721444;;10.1161/01.hyp.25.4.854;;10.1080/01616412.1994.11740275;;7708139;;1838897;;10.1007/bf01993227;;10.1097/00006534-198605000-00097;;10.1002/bms.1200210505;;1525186;;pmc1917898;;2043925;;10.1111/j.1476-5381.1991.tb12160.x;;8509425;;10.1016/s0021-9258(18)31472-8;;1748634;;10.1016/s0021-9258(18)54320-9;;10.1007/bf01062576;;10603528;;2275817;;10.1146/annurev.cb.06.110190.002043;;pmc1899671;;2820233;;10.1111/j.1432-1033.1988.tb14019.x;;3129296;;1333301;;10.1182/blood.v80.11.2765.2765;;9721182;;10.1006/abbi.1998.0806,"Chem. Abstr., 116:214224, 1992.*;;Chem. Abstr., 123:29628, 1995.*;;Knickle, L., et al., Mol Pharmacol, 45:6:1273-80, Abstract.;;Falck, J.R. et al., The Journal of Biological Chemistry, vol. 265 (18):10244-10249 (1990).;;Heckmann, B. et al., Tetrahadron Letters, vol. 37(9):1425-1428 (1996).;;Bednar, M.M et al., Abstract from meeting held in Florence, Italy (Jun. 1994).;;Ying Zhu et al., Hypertension, vol. 25(4),Part 2:854-859 (Apr. 1995).;;Gross, C.E. et al., Neurological Res., vol. 16:465-470 (Dec. 1994).;;Lesch, M.E. et al., Agents and Actions, vol. 34:25-27 (1991).;;Lee, T.H. et al., The New England Journal of Medicine, vol. 312(19):1217-1224 (May 9, 1985).;;Hill, E. et al., Biological Mass Spectrometry, vol. 21:249-253 (1992).;;Watanabe, Masako et al., Br. J. Pharmacol. 102:239-245 (1991).;;Laethem, R.M. et al., The Journal of Biological Chemistry, vol. 268(17):12912-12918 (1993).;;Balazy, M., The Journal of Biological Chemistry, vol. 266(35):23561-23567 (1991).;;Bednar, M.M. et al., Journal of Thrombosis and Thrombolysis:1:179-185 (1995).;;Springer, T.A., Annu. Rev. Cell Biol., 6:359-402 (1990).;;Kraemer, R. et al., American Journal of Pathology, vol. 128(3):446-454 (1987).;;Hatzelmann A. et al., Euro. J. Biochem. 173:445-452 (1988).;;Setty BN, Werner MH, Hannun YA, Stuart MJ; ""15-Hydroxyeicosatetraenoic acid-mediated potentiation of thrombin-induced platelet functions occurs via enhanced production of phosphoinositide-derived second messengers-sn-1,2-diacylglycerol and inositol-1,4,5-trisphosphate.""; Blood; 80(11):2765-73, Dec. 1, 1992.;;Luo G, Zeldin DC, Blaisdell JA, Hodgson E, Goldstein JA; ""Cloning and expression of murine CYP2Cs and their ability to metablolize arachidonic acid,"" Archives of Biochemistry and Biophysics: 357(1):45-57, Sep. 1, 1998.;;Chemical Abstracts AN 1995:138771, Takada et al., Jan. 1994.;;Chemical Abstracts AN 1990:493392, Falck et al., Jan. 1990.;;Chemical Abstracts AN 1994:474474, Knickle et al., Jan. 1994.",EXPIRED
70,US,A,US 6140364 A,072-864-498-479-370,2000-10-31,2000,US 19416699 A,1999-11-26,US 19416699 A;;US 65232796 A;;US 9708865 W,1996-05-22,"Arachidonic acid metabolite, 16-HETE","The present invention provides methods and products for inhibiting neutrophil adhesion and neutrophil aggregation. The invention includes a method for treating a subject to inhibit neutrophil adhesion and neutrophil aggregation by administering 16-hydroxyeicosatetraenoic acid (16-HETE) to the subject. 16-HETE is an arachidonic acid metabolite. The invention also includes a pharmaceutical preparation of 16-HETE. Methods and products are also provided for treating thromboembolic stroke. The method involves the administration of 16-HETE in combination with a thrombolytic agent to a patient suffering from thromboembolic stroke. Preferably, the 16-HETE is 16(R)-HETE and the thrombolytic agent is tPA. The product is a pharmaceutical preparation of 16-HETE and a thrombolytic agent and a pharmaceutically acceptable carrier.",UNIV VERMONT;;NEW YORK MEDICAL COLLEGE;;UNIV TEXAS,FALCK JOHN R;;BEDNAR MARTIN M;;GROSS CORDELL E;;BALAZY MICHAEL,NEW YORK MEDICAL COLLEGE (1999-11-18);;VERMONT UNIVERSITY OF AND STATE AGRICULTURAL COLLEGE THE (1999-10-21);;BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (1999-10-20),https://lens.org/072-864-498-479-370,Granted Patent,yes,10,3,7,7,0,A61K31/525;;A61K31/525;;A61K31/20;;A61K31/20;;A61K31/202;;A61K31/202;;A61K31/23;;A61K31/23;;A61K31/35;;A61K31/35;;A61K31/415;;A61K31/415;;A61K31/445;;A61K31/445;;A61K31/60;;A61K31/60;;A61K38/49;;A61K38/49;;A61K45/06;;A61K45/06;;A61P9/10;;Y02A50/30;;Y02A50/30,A61K31/20;;A61K31/202;;A61K31/23;;A61K31/35;;A61K31/415;;A61K31/445;;A61K31/525;;A61K31/60;;A61K38/49;;A61K45/06,514/552,22,16,001-141-180-423-815;;027-327-109-055-430;;057-371-287-458-167;;118-436-646-478-449;;022-072-924-697-540;;092-917-675-910-435;;017-496-384-730-802;;009-007-873-094-579;;047-093-158-156-218;;008-088-831-122-202;;020-205-920-992-394;;042-162-505-542-223;;019-835-018-717-583;;065-287-209-794-120;;052-797-578-454-12X;;114-704-852-383-435,10.1016/s0021-9258(18)86938-1;;2113050;;8022420;;7721444;;10.1161/01.hyp.25.4.854;;1333301;;10.1182/blood.v80.11.2765.2765;;10.1097/00006534-198605000-00097;;10.1080/01616412.1994.11740275;;7708139;;1838897;;10.1007/bf01993227;;10.1002/bms.1200210505;;1525186;;pmc1917898;;2043925;;10.1111/j.1476-5381.1991.tb12160.x;;8509425;;10.1016/s0021-9258(18)31472-8;;1748634;;10.1016/s0021-9258(18)54320-9;;10.1007/bf01062576;;10603528;;2275817;;10.1146/annurev.cb.06.110190.002043;;pmc1899671;;2820233;;10.1111/j.1432-1033.1988.tb14019.x;;3129296;;9721182;;10.1006/abbi.1998.0806,"Database Chemcial Abstracts on STN, AN 1984:203312, Morita et al, Mechanism of anti thrombogenic effect of eicosapentaenoic acid , Int. Congr. Ser. Excerpta Med. (1983), 623(Perspect. Prostaglandin Res.), 144 9, Jan. 1983.;;Falck, J. R. et al., The Journal of Biological Chemistry, vol. 265 (18):10244 10249 (1990).;;Heckmann, B. et al., Tetrahadron Letters, vol. 37(9):1425 1428 (1996).;;Knickle, L. et al., Mol Pharmacol, 45:6:1273 80, Abstract.;;Bednar, M. M. et al., Abstract from meeting held in Florence, Italy (Jun. 1994).;;Ying Zhu et al., Hypertension, vol. 25 (4), Part 2:854 859 (Apr. 1995).;;Setty, B., et al., Blood, 80:11:2765 73, (1992).;;Lee, T. H. et al., The New England Journal of Medicine, vol. 312(19):1217 1224 (May. 9, 1985).;;Gross, C. E. et al., Neurological Res., vol. 16:465 470 (Dec. 1994).;;Lesch, M. E. et al., Agents and Actions, vol. 34:25 27 (1991).;;Hill, E. et al., Biological Mass Spectrometry, vol. 21:249 253 (1992).;;Watanabe, Masako et al., Br. J. Pharmacol. 102:239 245 (1991).;;Laethem, R. M. et al., The Journal of Biological Chemistry, vol. 268(17):12912 12918 (1993).;;Balazy, M., The Journal of Biological Chemistry, vol. 266(35):23561 23567 (1991).;;Bednar, M. M. et al., Journal of Thrombosis and Thrombolysis:1:179 185 (1995).;;Springer, T. A., Annu. Rev. Cell Biol., 6:359 402 (1990).;;Kraemer, R. et al., American Journal of Pathology, vol. 128(3):446 454 (1987).;;Hatzelmann A. et al., Euro. J. Biochem. 173:445 452 (1988).;;Luo, G., et al., Archives of Biochemistry and biophysics, 357:1:45 57, (1998).;;Takada et al., Chemical Abstracts, 1995:138771, (1994).;;Falck, et al., Chemical Abstracts, 1990:493392, (1990).;;Knickle, et al., Chemical Abstracts, 1994:474474, (1994).",EXPIRED
71,EP,A1,EP 1077936 A1,069-531-837-831-575,2001-02-28,2001,EP 99924250 A,1999-05-14,US 9910728 W;;US 8560298 P,1998-05-15,NOVEL ANALOGS OF 16-HYDROXYEICOSATETRAENOIC ACID,"The present invention includes 16-HETE analogs which are agonists and antagonists of 16-HETE. The compositions may be formulated in pharmaceutically acceptable formulations. The invention also includes methods and products for inhibiting neutrophil adhesion and neutrophil aggregation using the 16-HETE agonists. One method of the invention involves the administration of a 16-HETE agonist in combination with a thrombolytic agent to a patient suffering from, thromboembolic stroke.",UNIV VERMONT;;UNIV TEXAS;;NEW YORK MEDICAL COLLEGE,FALCK JOHN R;;BEDNAR MARTIN M;;GROSS CORDELL E;;BALAZY MICHAEL,,https://lens.org/069-531-837-831-575,Patent Application,yes,0,0,12,12,0,A61K31/18;;A61K31/202;;A61K38/49;;C07C311/51;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P29/00;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/10;;Y02A50/30;;C07C311/51;;A61K31/202;;A61K31/18;;A61K38/49;;Y02A50/30,A61P7/02;;A61K31/18;;A61K31/202;;A61K31/215;;A61K38/00;;A61K38/49;;A61P9/00;;A61P9/10;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P29/00;;A61P43/00;;C07C49/24;;C07C59/42;;C07C69/732;;C07C311/51,,0,0,,,,EXPIRED
72,CA,A1,CA 2256578 A1,099-823-411-775-978,1997-11-27,1997,CA 2256578 A,1997-05-22,US 65232796 A;;US 9708865 W,1996-05-22,"NOVEL ARACHIDONIC ACID METABOLITE, 16-HETE","The present invention provides methods and products for inhibiting neutrophil adhesion and neutrophil aggregation. The invention includes a method for treating a subject to inhibit neutrophil adhesion and neutrophil aggregation by administering 16-hydroxyeicosatetraenoic acid (16-HETE) to the subject. 16HETE is an arachidonic acid metabolite. The invention also includes a pharmaceutical preparation of 16-HETE. Methods and products are also provided for treating thromboembolic stroke. The method involves the administration of 16-HETE in combination with a thrombolytic agent to a patient suffering from thromboembolic stroke. Preferably, the 16-HETE is 16(R)-HETE and the thrombolytic agent is tPA. The product is a pharmaceutical preparation of 16HETE and a thrombolytic agent and a pharmaceutically acceptable carrier.",UNIV TEXAS;;NEW YORK MEDICAL COLLEGE;;UNIV VERMONT,BEDNAR MARTIN M;;BALAZY MICHAEL;;GROSS CORDELL E;;FALCK JOHN R,,https://lens.org/099-823-411-775-978,Patent Application,no,0,0,7,7,0,A61K31/525;;A61K31/525;;A61K31/20;;A61K31/20;;A61K31/202;;A61K31/202;;A61K31/23;;A61K31/23;;A61K31/35;;A61K31/35;;A61K31/415;;A61K31/415;;A61K31/445;;A61K31/445;;A61K31/60;;A61K31/60;;A61K38/49;;A61K38/49;;A61K45/06;;A61K45/06;;A61P9/10;;Y02A50/30;;Y02A50/30,A61K31/20;;A61K31/202;;A61K31/23;;A61K31/35;;A61K31/415;;A61K31/445;;A61K31/525;;A61K31/60;;A61K38/49;;A61K45/06,,0,0,,,,DISCONTINUED
73,EP,A1,EP 0951283 A1,132-530-091-645-319,1999-10-27,1999,EP 97926721 A,1997-05-22,US 9708865 W;;US 65232796 A,1996-05-22,"NOVEL ARACHIDONIC ACID METABOLITE, 16-HETE",,UNIV VERMONT;;UNIV TEXAS;;NEW YORK MEDICAL COLLEGE,BEDNAR MARTIN M;;GROSS CORDELL E;;BALAZY MICHAEL;;FALCK JOHN R,,https://lens.org/132-530-091-645-319,Patent Application,yes,0,0,7,7,0,A61K31/525;;A61K31/525;;A61K31/20;;A61K31/20;;A61K31/202;;A61K31/202;;A61K31/23;;A61K31/23;;A61K31/35;;A61K31/35;;A61K31/415;;A61K31/415;;A61K31/445;;A61K31/445;;A61K31/60;;A61K31/60;;A61K38/49;;A61K38/49;;A61K45/06;;A61K45/06;;A61P9/10;;Y02A50/30;;Y02A50/30,A61K31/20;;A61K31/202;;A61K31/23;;A61K31/35;;A61K31/415;;A61K31/445;;A61K31/525;;A61K31/60;;A61K38/49;;A61K45/06,,0,0,,,,DISCONTINUED
74,WO,A1,WO 1997/044024 A1,018-936-148-399-815,1997-11-27,1997,US 9708865 W,1997-05-22,US 65232796 A,1996-05-22,"NOVEL ARACHIDONIC ACID METABOLITE, 16-HETE","The present invention provides methods and products for inhibiting neutrophil adhesion and neutrophil aggregation. The invention includes a method for treating a subject to inhibit neutrophil adhesion and neutrophil aggregation by administering 16-hydroxyeicosatetraenoic acid (16-HETE) to the subject. 16-HETE is an arachidonic acid metabolite. The invention also includes a pharmaceutical preparation of 16-HETE. Methods and products are also provided for treating thromboembolic stroke. The method involves the administration of 16-HETE in combination with a thrombolytic agent to a patient suffering from thromboembolic stroke. Preferably, the 16-HETE is 16(R)-HETE and the thrombolytic agent is tPA. The product is a pharmaceutical preparation of 16-HETE and a thrombolytic agent and a pharmaceutically acceptable carrier.",UNIV VERMONT;;UNIV TEXAS;;NEW YORK MEDICAL COLLEGE;;BEDNAR MARTIN M;;GROSS CORDELL E;;BALAZY MICHAEL;;FALCK JOHN R,BEDNAR MARTIN M;;GROSS CORDELL E;;BALAZY MICHAEL;;FALCK JOHN R,,https://lens.org/018-936-148-399-815,Patent Application,yes,3,16,7,7,0,A61K31/525;;A61K31/525;;A61K31/20;;A61K31/20;;A61K31/202;;A61K31/202;;A61K31/23;;A61K31/23;;A61K31/35;;A61K31/35;;A61K31/415;;A61K31/415;;A61K31/445;;A61K31/445;;A61K31/60;;A61K31/60;;A61K38/49;;A61K38/49;;A61K45/06;;A61K45/06;;A61P9/10;;Y02A50/30;;Y02A50/30,A61K31/20;;A61K31/202;;A61K31/23;;A61K31/35;;A61K31/415;;A61K31/445;;A61K31/525;;A61K31/60;;A61K38/49;;A61K45/06,,2,1,027-327-109-055-430,8022420,"DATABASE CAPLUS 1 January 1900 (1900-01-01), KNICKLE L C BEND J R: ""Bioactivation of A rachidonic Acid by the Cytochrome p450 Monooxygenases of Guineas Pig Lung:the ortholog of cytochrome p450 2b4 is solely responsible for foprmation of epoxyeicosatrienoic acids"", XP002954913, Database accession no. 1994:474474;;See also references of EP 0951283A4",PENDING
75,AT,T1,AT E305921 T1,192-402-382-462-977,2005-10-15,2005,AT 99924250 T,1999-05-14,US 8560298 P;;US 9910728 W,1998-05-15,NEUE ANALOGA VON 16-HYDROXYEICOSATETRAENSÄURE,"The present invention includes 16-HETE analogs which are agonists and antagonists of 16-HETE. The compositions may be formulated in pharmaceutically acceptable formulations. The invention also includes methods and products for inhibiting neutrophil adhesion and neutrophil aggregation using the 16-HETE agonists. One method of the invention involves the administration of a 16-HETE agonist in combination with a thrombolytic agent to a patient suffering from, thromboembolic stroke.",UNIV VERMONT;;UNIV TEXAS,FALCK JOHN R;;BEDNAR MARTIN M;;GROSS CORDELL E;;BALAZY MICHAEL,,https://lens.org/192-402-382-462-977,Granted Patent,no,0,0,12,12,0,A61K31/18;;A61K31/202;;A61K38/49;;C07C311/51;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P29/00;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/10;;Y02A50/30;;C07C311/51;;A61K31/202;;A61K31/18;;A61K38/49;;Y02A50/30,A61P7/02;;A61K31/18;;A61K31/202;;A61K31/215;;A61K38/00;;A61K38/49;;A61P9/00;;A61P9/10;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P29/00;;A61P43/00;;C07C49/24;;C07C59/42;;C07C69/732;;C07C311/51,,0,0,,,,EXPIRED
76,US,A1,US 2004/0057951 A1,127-372-752-987-702,2004-03-25,2004,US 40428603 A,2003-03-31,US 40428603 A;;US 81138400 A;;US 25165299 A;;US 78880097 A;;US 9303896 P,1996-01-23,Co-administration of a thrombolytic and an anti-CD18 antibody in stroke,"
   A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective amount of an anti-CD18 antibody to the mammal, in the absence of removal of the arterial obstruction. 
",GENENTECH INC,BEDNAR MARTIN M;;GROSS CORDELL E;;THOMAS G ROGER;;GROSS LINDA,,https://lens.org/127-372-752-987-702,Patent Application,yes,9,5,6,10,15,A61K38/49;;A61K39/3955;;A61K2039/505;;C07K16/2821;;C07K16/2845;;C07K2317/24;;C07K2317/54;;C07K2317/76;;A61P9/00;;C07K16/2845;;C07K16/2821;;C07K2317/54;;A61K2039/505;;C07K2317/24;;A61K39/3955;;A61K38/49;;C07K2317/76,A61K38/00;;A61K38/18;;A61K38/49;;A61K39/395;;C07K16/28,424/144.1;;514/12,0,0,,,,DISCONTINUED
77,US,A1,US 2005/0255108 A1,199-417-703-183-263,2005-11-17,2005,US 2571204 A,2004-12-28,US 2571204 A;;US 40428603 A;;US 81138400 A;;US 25165299 A;;US 78880097 A;;US 9303896 P,1996-01-23,Co-administration of a thrombolytic and an-anti-CD18 antibody in stroke,"A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective amount of an anti-CD18 antibody to the mammal, in the absence of removal of the arterial obstruction.",BEDNAR MARTIN M;;GROSS CORDELL E;;GROSS LINDA J;;THOMAS G R,BEDNAR MARTIN M;;GROSS CORDELL E;;GROSS LINDA J;;THOMAS G R,,https://lens.org/199-417-703-183-263,Patent Application,yes,8,0,6,10,15,A61K38/49;;A61K39/3955;;A61K2039/505;;C07K16/2821;;C07K16/2845;;C07K2317/24;;C07K2317/54;;C07K2317/76;;A61P9/00;;C07K16/2845;;C07K16/2821;;C07K2317/54;;A61K2039/505;;C07K2317/24;;A61K39/3955;;A61K38/49;;C07K2317/76,A61K38/00;;A61K38/18;;A61K38/49;;A61K39/395;;C07K16/28,424/144.1;;514/12,0,0,,,,EXPIRED
78,US,A1,US 2002/0081294 A1,056-719-467-822-155,2002-06-27,2002,US 81138400 A,2000-12-20,US 81138400 A;;US 25165299 A;;US 78880097 A;;US 9303896 P,1996-01-23,Co-administration of a thrombolytic and an anti-CD18 antibody in stroke,"
   A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective amount of an ant-CD18 antibody to the mammal, in the absence of removal of the arterial obstruction. 
",GENENTECH INC,BEDNAR MARTIN M;;GROSS CORDELL E;;THOMAS G ROGER;;GROSS LINDA J,GENENTECH INC (2001-06-05),https://lens.org/056-719-467-822-155,Patent Application,yes,0,11,6,10,15,A61K38/49;;A61K39/3955;;A61K2039/505;;C07K16/2821;;C07K16/2845;;C07K2317/24;;C07K2317/54;;C07K2317/76;;A61P9/00;;C07K16/2845;;C07K16/2821;;C07K2317/54;;A61K2039/505;;C07K2317/24;;A61K39/3955;;A61K38/49;;C07K2317/76,A61K38/00;;A61K38/18;;A61K38/49;;A61K39/395;;C07K16/28,424/143.1;;424/131.1;;514/12,0,0,,,,DISCONTINUED
79,US,A1,US 2009/0274689 A1,083-802-805-899-881,2009-11-05,2009,US 10705008 A,2008-04-21,US 10705008 A;;US 2571204 A;;US 40428603 A;;US 81138400 A;;US 25165299 A;;US 78880097 A;;US 9303896 P,1996-01-23,Co-Administration of a Thrombolytic and an Anti-CD18 Antibody in Stroke,"A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective amount of an anti-CD18 antibody to the mammal, in the absence of removal of the arterial obstruction.",BEDNAR MARTIN M;;GROSS CORDELL E;;GROSS LINDA J;;THOMAS G ROGER,BEDNAR MARTIN M;;GROSS CORDELL E;;GROSS LINDA J;;THOMAS G ROGER,,https://lens.org/083-802-805-899-881,Patent Application,yes,1,0,6,10,15,A61K38/49;;A61K39/3955;;A61K2039/505;;C07K16/2821;;C07K16/2845;;C07K2317/24;;C07K2317/54;;C07K2317/76;;A61P9/00;;C07K16/2845;;C07K16/2821;;C07K2317/54;;A61K2039/505;;C07K2317/24;;A61K39/3955;;A61K38/49;;C07K2317/76,A61K39/395;;A61K38/00;;A61K38/18;;A61K38/49;;A61P9/00;;C07K16/28,424/133.1;;424/172.1,0,0,,,,EXPIRED
80,DE,D1,DE 3380325 D1,008-970-369-779-180,1989-09-07,1989,DE 3380325 T,1983-12-15,US 45301882 A,1982-12-27,NORMALISATION OF PRINTED CHARACTER REPRESENTATIONS,,IBM,BEDNAR GREGORY MARTIN;;FITZPATRICK BRIAN EARL;;HARMON JOHN CHARLES;;NARASIMHA MANTHRI SELVAPULLAI,,https://lens.org/008-970-369-779-180,Granted Patent,no,0,0,7,7,0,G06V30/10;;G06V30/166;;G06V30/10;;G06V30/166,G06V30/166;;G06T3/40;;G06V30/10,,0,0,,,,EXPIRED
81,EP,A2,EP 0114305 A2,000-526-462-336-921,1984-08-01,1984,EP 83112631 A,1983-12-15,US 45301882 A,1982-12-27,Normalisation of printed character representations.,"A representation of a printed character having any size is reduced to a standard size. The representation is formed into a matrix of elements having rows and columns. In order to reduce the size of the matrix selected rows are either combined or are deleted. The length of each row is then adjusted. The rules applied for reduction of rows and lengths of rows are based on the overall height and width of the original representation. The representation is initially stored in a buffer 2 and analysed in units 4, 7, 9 and 10 and inserted in normalised form in register 8. The rules for reduction of height and width are stored in tables 5, 12 for look-up.",IBM,BEDNAR GREGORY MARTIN;;FITZPATRICK BRIAN EARL;;HARMON JOHN CHARLES;;NARASIMHA MANTHRI SELVAPULLAI,,https://lens.org/000-526-462-336-921,Patent Application,yes,0,3,7,7,0,G06V30/10;;G06V30/166;;G06V30/10;;G06V30/166,G06T3/40;;G06V30/166;;G06V30/10,,0,0,,,,EXPIRED
82,EP,A3,EP 0114305 A3,136-663-087-136-778,1986-11-12,1986,EP 83112631 A,1983-12-15,US 45301882 A,1982-12-27,NORMALISATION OF PRINTED CHARACTER REPRESENTATIONS,"A representation of a printed character having any size is reduced to a standard size. The representation is formed into a matrix of elements having rows and columns. In order to reduce the size of the matrix selected rows are either combined or are deleted. The length of each row is then adjusted. The rules applied for reduction of rows and lengths of rows are based on the overall height and width of the original representation. The representation is initially stored in a buffer 2 and analysed in units 4, 7, 9 and 10 and inserted in normalised form in register 8. The rules for reduction of height and width are stored in tables 5, 12 for look-up.",INTERNATIONAL BUSINESS MACHINES CORPORATION,"BEDNAR, GREGORY MARTIN;;FITZPATRICK, BRIAN EARL;;HARMON, JOHN CHARLES;;NARASIMHA, MANTHRI SELVAPULLAI IYENGAR",,https://lens.org/136-663-087-136-778,Search Report,yes,2,0,7,7,0,G06V30/10;;G06V30/166;;G06V30/10;;G06V30/166,G06T3/40;;G06V30/166;;G06V30/10,,2,2,048-269-726-617-346;;017-065-889-593-079,10.1109/tc.1972.5008927;;10.1016/0031-3203(76)90042-x,"IEEE TRANSACTIONS ON COMPUTERS, vol. C-21, no. 2, February 1972, pages 201-205, US; A.B. SHAHIDUL HUSSAIN et al.: ""Results obtained using a simple character recognition procedure on Munson's handprinted data"";;PATTERN RECOGNITION, vol. 8, no. 4, October 1976, pages 219-227, Pergamon Press, GB; A. GÜDESEN: ""Quantitative analysis of preprocessing techniques for the recognition of handprinted characters""",EXPIRED
83,EP,B1,EP 0114305 B1,011-532-986-923-182,1989-08-02,1989,EP 83112631 A,1983-12-15,US 45301882 A,1982-12-27,NORMALISATION OF PRINTED CHARACTER REPRESENTATIONS,,INTERNATIONAL BUSINESS MACHINES CORPORATION,"BEDNAR, GREGORY MARTIN;;FITZPATRICK, BRIAN EARL;;HARMON, JOHN CHARLES;;NARASIMHA, MANTHRI SELVAPULLAI IYENGAR",,https://lens.org/011-532-986-923-182,Granted Patent,yes,2,0,7,7,0,G06V30/10;;G06V30/166;;G06V30/10;;G06V30/166,G06T3/40;;G06V30/166;;G06V30/10,,2,0,,,"IEEE TRANSACTIONS ON COMPUTERS, vol. C-21, no. 2, February 1972, pages 201-205, US; A.B. SHAHIDUL HUSSAIN et al.: ""Results obtained using a simple character recognition procedure on Munson's handprinted data"";;PATTERN RECOGNITION, vol. 8, no. 4, October 1976, pages 219-227, Pergamon Press, GB; A. GÜDESEN: ""Quantitative analysis of preprocessing techniques for the recognition of handprinted characters""",EXPIRED
84,US,B2,US 7655230 B2,138-882-721-032-355,2010-02-02,2010,US 10705008 A,2008-04-21,US 10705008 A;;US 2571204 A;;US 40428603 A;;US 81138400 A;;US 25165299 A;;US 78880097 A;;US 9303896 P,1996-01-23,"Co-administration of a tissue plasminogen activator, anti-CD11b antibody and anti-CD18 antibody in stroke","A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective amount of an anti-CD18 antibody to the mammal, in the absence of removal of the arterial obstruction.",GENENTECH INC;;UNIV VERMONT,BEDNAR MARTIN M;;GROSS CORDELL E;;GROSS LEGAL REPRESENTATIVE LINDA J;;THOMAS G ROGER,,https://lens.org/138-882-721-032-355,Granted Patent,yes,30,0,6,10,15,A61K38/49;;A61K39/3955;;A61K2039/505;;C07K16/2821;;C07K16/2845;;C07K2317/24;;C07K2317/54;;C07K2317/76;;A61P9/00;;C07K16/2845;;C07K16/2821;;C07K2317/54;;A61K2039/505;;C07K2317/24;;A61K39/3955;;A61K38/49;;C07K2317/76,A61K39/395;;A61K38/00;;A61K38/18;;A61K38/49;;C07K16/28,424/144.1;;424/130.1;;424/133.1;;424/141.1;;424/153.1;;424/173.1;;424/94.2;;424/94.63;;424/94.64;;514/822;;530/387.1;;530/387.3;;530/388.1;;530/388.2;;530/388.22;;530/388.7,54,49,048-794-669-079-726;;022-345-797-786-049;;055-030-583-599-951;;002-259-026-531-084;;045-077-176-392-799;;027-902-851-592-220;;070-469-326-587-575;;110-470-601-227-134;;019-042-311-518-903;;013-965-453-283-510;;027-943-369-931-942;;078-582-056-407-68X;;018-838-358-619-397;;000-514-759-673-488;;000-373-170-472-521;;018-347-387-947-035;;000-447-172-519-011;;097-147-782-576-253;;062-864-177-282-080;;055-075-876-593-173;;095-311-758-359-733;;021-293-831-069-96X;;001-228-279-009-210;;037-290-746-113-468;;012-126-697-378-635;;043-144-105-080-848;;019-703-421-323-539;;052-798-529-997-739;;027-525-005-713-918;;125-471-240-172-316;;022-418-247-398-548;;055-076-506-782-465;;002-403-986-447-57X;;000-720-141-056-207;;114-088-860-422-258;;001-812-195-333-366;;021-240-722-422-948;;010-080-346-309-933;;075-799-844-814-006;;061-540-180-605-656;;003-613-857-894-471;;107-900-380-851-134;;078-429-416-750-81X;;020-476-038-409-995;;004-792-515-132-031;;012-281-537-897-970;;088-240-275-622-972;;013-408-031-320-797;;045-781-929-029-265,7860929;;10.1016/0735-1097(94)00443-t;;9537341;;10.1161/01.cir.97.12.1150;;7519330;;10.1080/01616412.1994.11740210;;10.1080/01616412.1996.11740398;;9162874;;1987672;;10.1161/01.str.22.1.44;;3336899;;10.1161/01.str.19.1.28;;10.1212/wnl.45.4.815;;7723976;;10.1006/exnr.1993.1023;;8094342;;8154873;;10.1002/ana.410350414;;8160235;;10.1161/01.str.25.4.869;;10494344;;10.1007/978-3-7091-6391-7_11;;10.3171/jns.1991.75.4.0623;;1885980;;1677219;;10.1161/01.str.22.7.877;;10.1016/0361-9230(94)90119-8;;7850491;;7541420;;10.1161/01.str.22.10.1276;;1926239;;10.1111/j.1365-3083.1991.tb01773.x;;1707181;;7908437;;10.2210/pdb2fgw/pdb;;10.1002/prot.340180107;;1983768;;7496621;;8546211;;pmc1861617;;7643999;;10.1227/00006123-199506000-00017;;10.1097/00006123-199506000-00017;;8465363;;10.1161/01.str.24.4.558;;10.1016/0161-5890(89)90060-6;;2698997;;10.1002/eji.1830130305;;6339253;;10.1038/348639a0;;2250718;;10.3171/jns.1981.54.6.0773;;7241187;;10.1016/0022-510x(94)00203-z;;7722533;;10.1161/01.str.23.1.93;;1731427;;10077522;;10.1161/01.cir.99.10.1363;;10229342;;10.1016/s0361-9230(99)00004-0;;10.1161/01.str.24.1.117;;8418534;;10.3171/jns.1995.82.2.0269;;7815156;;9736421;;10.1016/s0049-3848(98)00091-7;;7820595;;10.1016/0006-8993(94)91478-8;;10.1161/01.str.23.5.712;;1579969;;10.1007/bf00308474;;1557947;;10.1152/ajpheart.1996.270.1.h53;;8769734;;pmc295788;;10.1172/jci115527;;1684364;;7530260;;10.1016/0165-5728(94)90010-8;;9667494;;10.1016/s0891-5849(98)00047-1;;1561656;;10.1161/01.str.23.2.247;;pmc53746;;10.1073/pnas.87.7.2643;;1969637;;1436419;;10.1227/00006123-199211000-00016;;10.1097/00006123-199211000-00016;;6999671;;10.1161/01.str.11.5.552;;10.1161/01.str.26.8.1438;;7631350;;9932943;;10.1212/wnl.52.2.273;;10.1016/0006-8993(95)00830-j;;8581506;;7964886;;10.1016/0022-510x(94)90234-8,"Aversano et al., ""A Chimeric IgG4 Monoclonal Antibody Directed Against CD18 Reduces Infarct Size in a Primate Model of Myocardial Ischemia and Reperfusion"" J. Amer. Col. Cardiology 25 (3):781-788 (Mar. 1995).;;Barron et al., ""Use of reperfusion therapy for acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2"" Circulation 97(12):1150-1156 (Mar. 31, 1998).;;Bednar et al., ""Comparison of Triphenyltetrazolium Dye with Light Microscopic Evaluation in a Rabbit Model of Acute Cerebral Ischaemia"" Neurological Research 16:129-132 (Apr. 1994).;;Bednar et al., ""IB4, a Monoclonal Antibody Against the CD18 Adhesion Complex of Leukocytes, Attenuates Intracranial Hypertension in a Rabbit Stroke Model"" Stroke (Abstract Only) 23(1):152 (1992).;;Bednar et al., ""IB4, a monoclonal antibody against the CD18 leukocyte adhesion protein, reduces intracranial pressure following thromboembolic stroke in the rabbit"" Neurological Res. 18:171-175 (Apr. 1996).;;Bednar et al., ""The Role of Neutrophils and Platelets in a Rabbit Model of Thromboembolic Stroke"" Stroke 22(1):44-50 (1991).;;Bose et al., ""Evolving Focal Cerebral Ischemia in Cats: Spatial Correlation of Nuclear Magnetic Resonance Imaging, Cerebral Blood Flow, Tetrazolium Staining, and Histopathology"" Stroke 19(1):28-37 (Jan. 1988).;;Bowes et al., ""Monoclonal Antibodies Preventing Leukocyte Activation Reduce Experimental Neurologic Injury and Enhance Efficacy of Thrombolytic Therapy"" Neurology 45:815-819 (1995).;;Bowes et al., ""Monoclonal Antibody to the ICAM-1 Adhesion Site Reduces Neurological Damage in a Rabbit Cerebral Embolism Stroke Model"" Experimental Neurology 119(2):215-219 (1993).;;Chen et al., ""Anti-CD11b Monoclonal Antibody Reduce Ischemic Cell Damage After Transient Focal Cerebral Ischemia in Rat Anti-CD11b Monoclonal Antibody Reduces Ischemic Cell Damage After Transient Focal Cerebral Ischemia in Rat"" Ann. Neurol. 35(4):458-463 (1994).;;Chen et al., ""Neutropenia Reduces The Volume of Cerebral Infarct After Transient Middle Cerebral Artery Occulsion in the Rat"" Neuroscience Research Communications 11(2):93-99 (1992).;;Chopp et al., ""Anti-CD11b Monoclonal Antibody (1B6c) Reduces Infarct Size Resulting From Transient but Not Permanent Focal Ischemia in Rat"" Stroke (Abstract Only) (19th International J), Stroke 25(1): p. 267, 1994.;;Chopp et al., ""Postischemic Administration of an Anti-MAC-1 Antibody Reduces Ischemic Cell Damage After Transient Middle Cerebral Artery Occlusion in Rats"" Stroke 25(4):869-876 (1993).;;Chopp et al., ""The clot thickens-thrombolysis and combination therapies"" Acta Neurochirurgica 73 (Suppl.):67-71 (1999).;;Clark et al., ""Reduction of Central Nervous System Ischemic Injury by Monoclonal Antibody to Intercellular Adhesion Molecule"" J. Neurosurg. 75:623-627 (1991).;;Clark et al., ""Reduction of Central Nervous System Ischemic Injury in Rabbits Using Leukocyte Adhesion Antibody Treatment"" Stroke 22(7):877-883 (Jul. 1991).;;Clark et al., ""Reperfusion Following Focal Stroke Hastens Inflammation and Resolution of Ischemic Injured Tissue"" Brain Research Bulletin 35(4):387-392 (1994).;;Danilenko et al., ""A Novel Canine Leukointegrin, alphadbeta2, is Expressed by Specific Macrophage Subpopulations in Tissue and a Minor CD8+ Lymphocyte Subpopulation in Peripheral Blood"" Journal of Immunology 155:35-44 (1995).;;del Zoppo et al., ""Polymorphonuclear Leukocytes Occlude Capillaries Following Middle Cerebral Artery Occlusion and Reperfusion in Baboons"" Stroke 22(10):1276-1283 (1991).;;Desroches et al., ""Regulation and Functional Involvement of Distinct Determinants of Leucocyte Function-Associated Antigen 1 (LFA-1) in T-Cell Activation In Vitro"" Scand. J. Immunol. 33:277-286 (1991).;;Eigenbrot et al., ""X-Ray Structures of Fragments From Binding and Nonbinding Versions of a Humanized Anti-CD18 Antibody: Structural Indications of the Key Role of VH Residues 59 to 65"" Proteins: Structure, Function, and Genetics 18:49-62 (1994).;;Fekete et al., ""Involvement of Lymphocyte Function-Associated Antigen-1 (LFA-1) But Not ICAM-1 in a Radioactive Leukocyte Cell-Mediated Immunity (LA-CMI) Assay"" J. Clin. Lab. Immunol. 31:145-149 (1990).;;Fisher et al., ""The Penumbra, Therapeutic Time Window and Acute Ischaemic Stroke"" Bailliere's Clinical Neurology 4(2):279-295 (Aug. 1995).;;Garcia, ""Effects of CD11b/18 Monocloan Antibody on Rats with Permanent Middle Cerebral Artery Occlusion"" Amer. J. Pathology 148(1):241-248 (Jan. 1996).;;Gross et al., ""Delayed Tissue-Plasminogen Activator Therapy in a Rabbit Model of Thromoembolic Stroke"" Neurosurgery 36(6):1172-1177 (1995).;;Gross et al., ""Transforming Growth Factor-beta1 Reduces Infarct Size After Experimental Cerebral Ischemia in a Rabbit Model"" Stroke 24(4):558-562 (Apr. 1993).;;Hildreth & Hyman, ""Production and characterization of Monoclonal Anti-CD18 Anti-Idiotype Antibodies"" Molecular Immunology 26(12):1155-1167 (1989).;;Hildreth et al., ""A Human Lymphoctye-associated Antigen Involved in Cell-mediated Lympholysis"" European Journal of Immunology 13:202-208 (1983).;;Hutchings et al., ""Transfer of Diabetes in Mice Prevented by Blockade of Adhesion-Promoting Receptor on Macrophages"" Nature 348:639-642 (Dec. 13, 1990).;;Jiang et al., ""Anti-CD11b Monoclonal Antibody Reduces Ischemic Cell Damage After Transient (2h) But Not After Permanent MCA Occlusion in the Rat"" Neuroscience Research Communications 15(2):85-93 (1994).;;Jones et al., ""Thresholds of Focal Cerebral Ischemia in Awake Monkeys"" Journal of Neurosurgery 54:773-782 (Jun. 1981).;;Kim et al., ""Adhesive Glycoproteins CD11a are Upregulated in the Leukocytes from Patients with Ischemic Stroke and Transient Ischemic Attacks"" Journal of the Neurological Sciences 128(1):45-50 (1995).;;Kohut et al., ""Reduction in Ischemic Brain Injury in Rabbits by the Anion Transport Inhibitor L-644, 711"" Stroke 23(1):93-97 (Jan. 1992).;;Kumar et al., ""Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model"" Circulation 99(10):1363-1369 (Mar. 16, 1999).;;Lew et al., ""Complement depletion does not reduce brain injury in a rabbit model of thromboembolic stroke"" Brain Research Bulletin 48(3):325-331 (Feb. 1999).;;Lin et al., ""Effect of Brain Edema on Infarct Volume in a Focal Cerebral Ischemia Model in Rats"" Stroke 24(1):117-121 (Jan. 1993).;;Lindsberg et al., ""Antagonism of Neutrophil Adherence in the Deteriorating Stroke Model in Rabbits"" Journal of Neurosurgery 82:269-277 (1995).;;Link et al., ""Neutrophil adhesion and activation during systemic thrombolysis in acute myocardial infarction"" Thrombosis Research 91(4):183-190 (Aug. 15, 1998).;;Matsuo et al., ""Role of Cell Adhesion Molecules in Brain Injury After Transient Middle Cerebral Artery Occlusion in the Rat"" Brain Research 656:344-352 (1994).;;Mori et al., ""Inhibition of Polymorphonuclear Leukoctye Adherence Suppresses No-Reflow After Focal Cerebral Ischemia in Baboons"" Stroke 23(5):712-718 (May 1992).;;Morioka et al., ""Progressive Expression of Immunomolecules on Microglial Cells in Rat Dorsal Hippocampus Following Transient Forebrain Ischemia"" Acta Neuropatholigica, Springer-Verlag vol. 83:149-157 (1992).;;Perez et al., ""Factors modifying protective effect of anti-CD18 antibodies on myocardial repefusion injury in dogs"" Amer. J. Physiology (Part 2), Washington, D.C. 270(1):H53-H64 (1996).;;Saez-Llorens et al., ""Enhanced Attenuation of Meningeal Inflammation and Brain Edema by Concomitant Administration of Anti-CD18 Monoclonal Antibodies and Dexamethasone in Experimental Haemphilus meningitis"" Journal of Clin. Invest. 88:2003-2009 (Dec. 1991).;;Schroeter et al., ""Local Immune Responses in the Rat Cerebral Cortex After Middle Cerebral Artery Occlusion"" Journal of Neuroimmunology, Elsevier Science B.V. vol. 55(2):195-203 (1994).;;Shiga et al., ""Suppression of Ischemic Brain Edema in Rats by Depletion of Neutorphils "" Journal of Cerebral Blood Flow and Metabolism (Abstract Only), Ginsberg et al., Supplement 2 edition, New York:Raven Press vol. 11(2):S486 (Jun. 1991).;;Stringer et al., ""Tissue plasminogen activator (tPA) inhibits interleukin-1 induced acute lung leak"" Free Radical Biology & Medicine 25(2):184-188 (Jul. 15, 1998).;;Takeshima et al., ""Monoclonal Leukocyte Antibody Does Not Decrease the Injury of Transient Focal Cerebral Ischemia in Cats"" Stroke 23(2):247-252 (Feb. 1992).;;Vedder et al., ""Inhibition of leukocyte adherence by anti-CD-18 monoclonal antibody attenuates reperfusion injury in the rabbit ear"" Proc. Natl. Acad. Sci. USA 87:2643-2646 (Apr. 1990).;;Wilson et al., ""The Effect of the 21-Aminosteroid U74006F in a Rabbit Model of Thromboembolic Stroke"" Neurosurgery 31(5):929-934 (Nov. 1992).;;Young et al., ""H2 Clearance Measurement of Blood Flow: A Review of Technique and Polargraphic Principles"" Stroke 11(5):552-564 (Sep. 1980).;;Zhang et al., ""Anti-Intercellular Adhesion Molecule-1 Antibody Reduces Ischemic Cell Damage After Transient But Not Permanent Middle Cerebral Artery Occlusion in the Wistar Rat"" Stroke 26(8):1438-1442 (Aug. 1995).;;Zhang et al., ""Increased therapeutic efficacy with rt-PA and anti-CD18 antibody treatment of stroke in the rat"" Neurology 52(2):273-279 (Jan. 15, 1999).;;Zhang et al., ""Postichemic Treatment (2-4h) with Anti-CD11b and Anti-CD18 Monoclonal Antibodies are Neuroprotective After Transient (2h) Focal Cerebral Ischemia in The Rat"" Brain Research, Elsevier Science B.V. vol. 698:79-85 (1995).;;Zhang et al., ""Temporal Profile of Ischemic Tissue Damage, Neutrophil Response, and Vascular Plugging Following Permanent and Transient (2H) Middle Cerebral Artery Occlusion in the Rat"" Journal of the Neurological Sciences, Elsevier Science B.V. vol. 125:3-10 (1994).",EXPIRED
85,WO,A1,WO 2023/021023 A1,176-194-917-451-155,2023-02-23,2023,EP 2022072839 W,2022-08-16,EP 21191447 A,2021-08-16,COELENTERAZINE-UTILIZING LUCIFERASES WITH STABLE GLOW-TYPE LIGHT EMISSION AND METHODS OF PRODUCING AND USING THEREOF,"The present invention includes polynucleotides that encode novel coelenterazine-utilizing luciferases as well as fragments and mutants thereof having at least 85 % sequence identity. The sequences were generated by ancestral sequence reconstruction combined with single-point mutations and transplantation of important regions from the related Renilla reniformis luciferase protein. The luciferases according to the present invention exhibit modulated properties including at least one of: increased bioluminescence emission stability and half-life; increased affinity towards substrate over the product (suppressed product inhibition); increased thermostability; increased glow-type effectivity; and modulated emission maximum. The present invention also includes polypeptides that are encoded by the provided polynucleotides as well as fragments and mutants thereof having at least 85 % sequence identity, vectors, kits and expression cassettes containing thereof, cells transfected with thereof, and methods of producing and using thereof.",UNIV MASARYKOVA;;FAKULTNI NEMOCNICE U SV ANNY V BRNE,TOUL MARTIN;;SMITH ANDREA;;MAREK MARTIN;;RANGEL PAMPLONA PIZARRO PINTO JOSE GASPAR;;PLANAS-INGLESIAS JOAN;;PLUSKAL DANIEL;;VASINA MICHAL;;BEDNAR DAVID;;PROKOP ZBYNEK;;DAMBORSKY JIRI,,https://lens.org/176-194-917-451-155,Patent Application,yes,0,0,2,2,20,C12N9/0069,C12N9/02;;C12N15/63;;C12Q1/66,,50,40,018-747-321-282-600;;051-364-346-152-720;;011-801-212-377-475;;033-647-553-418-090;;014-044-247-270-866;;051-364-346-152-720;;068-234-384-632-866;;122-015-526-011-632;;051-802-815-302-523;;028-862-168-091-90X;;092-355-429-220-904;;133-251-354-239-916;;013-044-664-386-61X;;022-368-594-985-904;;057-805-537-256-206;;076-801-305-362-457;;050-107-176-956-094;;097-387-576-011-959;;044-347-670-900-42X;;059-932-460-764-361;;033-823-957-760-247;;004-379-052-340-694;;077-418-269-904-400;;085-039-460-117-907;;129-224-547-975-401;;040-363-636-264-022;;007-147-247-240-85X;;028-340-655-656-340;;024-701-421-597-806;;007-344-597-777-510;;036-474-374-641-365;;069-732-171-442-83X;;011-023-804-957-600;;042-868-447-693-676;;053-736-844-144-245;;002-021-250-096-080;;049-405-579-110-966;;047-308-646-101-537;;135-845-473-435-494;;082-151-267-963-934,34127663;;pmc8203615;;10.1038/s41467-021-23450-z;;16857694;;10.1093/protein/gzl023;;17980388;;pmc2700051;;10.1016/j.jmb.2007.09.078;;15158059;;10.1016/j.tibtech.2004.03.011;;10.1016/s0167-7799(04)00085-x;;10524246;;10.1016/s0378-1119(99)00314-5;;16857694;;10.1093/protein/gzl023;;17618292;;10.1038/nmeth1070;;27871386;;10.1016/j.enzmictec.2016.09.009;;10.1021/acscatal.9b01031;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;10.1093/nar/gks1189;;10.1093/bioinformatics/bth444;;15284097;;10.1093/bioinformatics/btl158;;16731699;;pmc517706;;15318951;;10.1186/1471-2105-5-113;;10.1093/sysbio/syq010;;20525638;;16234323;;10.1093/bioinformatics/bti713;;10.1080/10635150390235520;;14530136;;9254330;;10.1093/oxfordjournals.molbev.a025808;;17295320;;10.1002/prot.21313;;10.1007/bf02198858;;8919883;;10.1093/molbev/msm088;;17483113;;10.1093/sysbio/20.4.406;;23939220;;10.1016/j.biochi.2013.07.025;;21460445;;pmc3069742;;10.1107/s0907444910048675;;23793146;;pmc3689523;;10.1107/s0907444913000061;;19461840;;pmc2483472;;10.1107/s0021889807021206;;pmc3069738;;21460441;;10.1107/s0907444910045749;;10.1107/s0907444996012255;;15299926;;10.1107/s0907444909052925;;pmc2815670;;20124702;;25075342;;10.1107/s2052252514009324;;pmc4107921;;10.1110/ps.0350503;;12930986;;pmc2323984;;pmc1160225;;15980491;;10.1093/nar/gki464;;10.1021/acs.jctc.6b00049;;26949976;;26616618;;10.1021/ct900275y;;26574392;;10.1021/ct5010406;;19151095;;pmc2672624;;10.1093/bioinformatics/btp033;;10.1006/jmbi.2000.4042;;10964570;;20124692;;pmc2815665;;10.1107/s0907444909047337;;pmc3193589;;10.1016/j.ymeth.2011.07.005;;21821126;;20383002;;pmc2852313;;10.1107/s0907444910007493,"SCHENKMAYEROVA ANDREA ET AL: ""Engineering the protein dynamics of an ancestral luciferase"", vol. 12, no. 1, 14 June 2021 (2021-06-14), XP055885815, Retrieved from the Internet <URL:https://www.nature.com/articles/s41467-021-23450-z.pdf> DOI: 10.1038/s41467-021-23450-z;;LOENING ANDREAS MARKUS ET AL: ""Consensus guided mutagenesis of Renilla luciferase yields enhanced stability and light output"", PROTEIN ENGINEERING, DESIGN AND SELECTION, OXFORD JOURNAL, LONDON, GB, vol. 19, no. 9, 1 September 2006 (2006-09-01), pages 391 - 400, XP002524403, ISSN: 1741-0126, [retrieved on 20060720], DOI: 10.1093/PROTEIN/GZL023;;LOENING A M ET AL: ""Crystal Structures of the Luciferase and Green Fluorescent Protein from Renilla reniformis"", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 374, no. 4, 7 December 2007 (2007-12-07), pages 1017 - 1028, XP026865862, ISSN: 0022-2836, [retrieved on 20071207], DOI: 10.1016/J.JMB.2007.09.078;;RODA A ET AL: ""Biotechnological applications of bioluminescence and chemiluminescence"", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 22, no. 6, 1 June 2004 (2004-06-01), pages 295 - 303, XP004510121, ISSN: 0167-7799, DOI: 10.1016/J.TIBTECH.2004.03.011;;SCHENKMAYEROVA A: ""Full wwPDB X-ray Structure Validation Report i -"", 23 May 2022 (2022-05-23), XP093004454, Retrieved from the Internet <URL:https://www.ebi.ac.uk/pdbe/entry-files/7ome_full_validation.pdf> [retrieved on 20221202];;LIUESCHER, GENE, vol. 237, 1999, pages 153 - 159;;LOENING ET AL., PROTEIN ENG. DES. SEL., vol. 19, 2006, pages 391 - 400;;LOENINGWUGAMBHIR, NAT. METHODS., vol. 4, 2007, pages 641 - 643;;RAHNAMA, ENZYME MICROB. TECHNOL., vol. 96, 2017, pages 60 - 66;;CHALOUPKOVA ET AL., ACS CATAL., vol. 9, 2019, pages 4810 - 4823;;ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 3402;;NCBI RESOURCE COORDINATORS, NUCLEIC ACIDS RES., vol. 41, 2013, pages D8 - D20;;FRICKEYLUPAS, BIOINFORMATICS, vol. 20, 2004, pages 3702 - 3704;;LIGODZIK, BIOINFORMATICS, vol. 22, 2006, pages 1658 - 1659;;EDGAR, BMC BIOINFORMATICS, vol. 5, 2004, pages 113;;HALL, NUCLEIC ACIDS SYMP. SER., vol. 41, 1999, pages 95 - 98;;GUINDON ET AL., SYST. BIOL., vol. 59, 2010, pages 307 - 321;;LEGASCUEL, MOL. BIOL. EVOL., vol. 25, 2008, pages 1307 - 1320;;HORDIJKGASCUEL, BIOINFORMATICS, vol. 21, 2005, pages 4338 - 4347;;GUINDONGASCUEL, SYST. BIOL., vol. 52, 2003, pages 696 - 704;;MOL. BIOL. EVOL., vol. 14, 1997, pages 685 - 695;;CHOVANCOVA ET AL., PROTEINS, vol. 67, 2007, pages 305 - 316;;KOSHIGOLDSTEIN, J. MOL. EVOL., vol. 42, 1996, pages 313 - 320;;YANG, MOL. BIOL. EVOL., vol. 24, 2007, pages 1586 - 1591;;HANSON-SMITHKOLACZKOWSLDTHORNTON, MOL. BIOL. EVOL., vol. 27, 2010, pages 1988 - 1999;;FITCH, SYST. ZOOL., vol. 20, 1971, pages 406 - 416;;FORTOVA ET AL., BIOCHIMIE, vol. 95, 2013, pages 2091 - 2096;;CHIRASCAN, APPLIED PHOTOPHYSICS;;BATTYE ET AL., ACTA CRYSTALLOGR. D BIOL. CRYSTALLOGR., vol. 67, 2011, pages 271 - 281;;EVANSMURSHUDOV: ""Acta Crystallogr"", D BIOL. CRYSTALLOGR., vol. 69, 2013, pages 1204 - 1214;;MCCOY ET AL., J. APPL. CRYSTALLOGR., vol. 40, 2007, pages 658 - 674;;WINN, ACTA CRYSTALLOGR. D BIOL. CRYSTALLOGR, vol. 67, 2011, pages 235 - 242;;EMSLEYCOWTAN, ACTA CRYSTALLOGR. D BIOL. CRYSTALLOGR, 2004;;MURSHUDOVVAGINDODSON: ""Acta Crystallogr"", D BIOL. CRYSTALLOGR, vol. 53, 1997, pages 240 - 255;;ADAMS: ""Acta Crystallogr."", D BIOL. CRYSTALLOGR, vol. 66, 2010, pages 213 - 221;;JOOSTEN, IUCRJ, vol. 1, 2014, pages 213 - 220;;KANTARDJIEFFRUPP, PROTEIN SCI. PUBL. PROTEIN SOC., vol. 12, 2003, pages 1865 - 1871;;KAVANMAN, HYDROG. EXCH. MASS SPECTROM., vol. 302, 2011, pages 53 - 58;;GORDON ET AL., NUCLEIC ACIDS RES., vol. 33, 2005, pages W368 - W371;;DOERR ET AL., J. CHEM. THEORY COMPUT., vol. 12, 2016, pages 1845 - 1852;;HARVEYGIUPPONIFABRITIIS, J. CHEM. THEORY COMPUT., vol. 5, 2009, pages 2371 - 2377;;HOPKINS ET AL., J. CHEM. THEORY COMPUT., vol. 11, 2015, pages 1864 - 1874;;NARITOMIFUCHIGAMI, J. CHEM. PHYS, 2011;;WATERHOUSE ET AL., BIOINFORMATICS, vol. 25, 2009, pages 1189 - 1191;;NOTREDAMEHIGGINSHERINGA, J. MOL. BIOL., vol. 302, 2000, pages 205 - 217;;KABSCH: ""Acta Crystallogr"", D BIOL. CRYSTALLOGR, vol. 66, 2010, pages 125 - 132;;EVANSMURSHUDOV: ""Acta Crystallogr"", D BIOL. CRYSTALLOGR, vol. 69, 2013, pages 1204 - 1214;;ADAMS ET AL., METHODS STRUCT. PROTEOMICS., vol. 55, 2011, pages 94 - 106;;EMSLEY ET AL.: ""Acta Crystallogr"", D BIOL._ CRYSTALLOGR., vol. 66, 2010, pages 486 - 501;;CHEN ET AL.: ""Acta Crystallogr"", D BIOL. CRYSTALLOGR., vol. 66, 2010, pages 12 - 21",PENDING
86,EP,A1,EP 4137567 A1,088-392-736-972-565,2023-02-22,2023,EP 21191447 A,2021-08-16,EP 21191447 A,2021-08-16,"COELENTERAZINE-UTILIZING LUCIFERASES WITH STABLE GLOW-TYPE LIGHT EMISSION, INCREASED SUBSTRATE AFFINITY, SUPPRESED PRODUCT INHIBITION, AND MODULATED EMISSION WAVELENGTHS, AND METHODS OF PRODUCING AND USING THEREOF","The present invention includes polynucleotides that encode novel coelenterazine-utilizing luciferases as well as fragments and mutants thereof having at least 85 % sequence identity. The sequences were generated by ancestral sequence reconstruction combined with single-point mutations and transplantation of important regions from the related  Renilla reniformis  luciferase protein. The luciferases according to the present invention exhibit modulated properties including at least one of: increased bioluminescence emission stability and half-life; increased affinity towards substrate over product (suppressed product inhibition); increased thermostability; and modulated emission maximum. The present invention also includes polypeptides that are encoded by the provided polynucleotides as well as fragments and mutants thereof having at least 85 % sequence identity, vectors, kits and expression cassettes containing thereof, cells transfected with thereof, and methods of producing and using thereof.",UNIV MASARYKOVA;;FAKULTNI NEMOCNICE U SV ANNY V BRNE,TOUL MARTIN;;SCHENKMAYEROVÁ ANDREA;;MAREK MARTIN;;RANGEL PAMPLONA PIZARRO PINTO JOSE GASPAR;;PLANAS IGLESIAS JOAN;;PLUSKAL DANIEL;;VASINA MICHAL;;BEDNAR DAVID;;PROKOP ZBYNEK;;DAMBORSKÝ JIRÍ,,https://lens.org/088-392-736-972-565,Patent Application,yes,0,0,2,2,20,C12N9/0069,C12N9/02;;C12N15/63;;C12Q1/66,,31,29,018-747-321-282-600;;051-364-346-152-720;;011-801-212-377-475;;033-647-553-418-090;;014-044-247-270-866;;051-364-346-152-720;;068-234-384-632-866;;122-015-526-011-632;;028-862-168-091-90X;;092-355-429-220-904;;133-251-354-239-916;;013-044-664-386-61X;;022-368-594-985-904;;057-805-537-256-206;;128-150-669-127-43X;;059-932-460-764-361;;033-823-957-760-247;;012-023-024-552-430;;077-418-269-904-400;;069-732-171-442-83X;;011-023-804-957-600;;042-868-447-693-676;;053-736-844-144-245;;008-655-309-842-248;;002-021-250-096-080;;049-405-579-110-966;;040-363-636-264-022;;135-845-473-435-494;;082-151-267-963-934,34127663;;pmc8203615;;10.1038/s41467-021-23450-z;;16857694;;10.1093/protein/gzl023;;17980388;;pmc2700051;;10.1016/j.jmb.2007.09.078;;15158059;;10.1016/j.tibtech.2004.03.011;;10.1016/s0167-7799(04)00085-x;;10524246;;10.1016/s0378-1119(99)00314-5;;16857694;;10.1093/protein/gzl023;;17618292;;10.1038/nmeth1070;;27871386;;10.1016/j.enzmictec.2016.09.009;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;10.1093/nar/gks1189;;10.1093/bioinformatics/bth444;;15284097;;10.1093/bioinformatics/btl158;;16731699;;pmc517706;;15318951;;10.1186/1471-2105-5-113;;10.1093/sysbio/syq010;;20525638;;15647292;;10.1093/bioinformatics/bti263;;10.1007/bf02198858;;8919883;;10.1093/molbev/msm088;;17483113;;pmc2922618;;20368266;;10.1093/molbev/msq081;;23939220;;10.1016/j.biochi.2013.07.025;;pmc1160225;;15980491;;10.1093/nar/gki464;;10.1021/acs.jctc.6b00049;;26949976;;26616618;;10.1021/ct900275y;;26574392;;10.1021/ct5010406;;21322734;;10.1063/1.3554380;;19151095;;pmc2672624;;10.1093/bioinformatics/btp033;;10.1006/jmbi.2000.4042;;10964570;;19461840;;pmc2483472;;10.1107/s0021889807021206;;pmc3193589;;10.1016/j.ymeth.2011.07.005;;21821126;;20383002;;pmc2852313;;10.1107/s0907444910007493,"SCHENKMAYEROVA ANDREA ET AL: ""Engineering the protein dynamics of an ancestral luciferase"", NATURE COMMUNICATIONS, vol. 12, no. 1, 14 June 2021 (2021-06-14), XP055885815, Retrieved from the Internet <URL:https://www.nature.com/articles/s41467-021-23450-z.pdf> DOI: 10.1038/s41467-021-23450-z;;LOENING ANDREAS MARKUS ET AL: ""Consensus guided mutagenesis of Renilla luciferase yields enhanced stability and light output"", PROTEIN ENGINEERING, DESIGN AND SELECTION, OXFORD JOURNAL, LONDON, GB, vol. 19, no. 9, 1 September 2006 (2006-09-01), pages 391 - 400, XP002524403, ISSN: 1741-0126, [retrieved on 20060720], DOI: 10.1093/PROTEIN/GZL023;;LOENING A M ET AL: ""Crystal Structures of the Luciferase and Green Fluorescent Protein from Renilla reniformis"", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 374, no. 4, 7 December 2007 (2007-12-07), pages 1017 - 1028, XP026865862, ISSN: 0022-2836, [retrieved on 20071207], DOI: 10.1016/J.JMB.2007.09.078;;RODA A ET AL: ""Biotechnological applications of bioluminescence and chemiluminescence"", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 22, no. 6, 1 June 2004 (2004-06-01), pages 295 - 303, XP004510121, ISSN: 0167-7799, DOI: 10.1016/J.TIBTECH.2004.03.011;;LIUESCHER, GENE, vol. 237, 1999, pages 153 - 159;;LOENING ET AL., PROTEIN ENG. DES. SEL., vol. 19, 2006, pages 391 - 400;;LOENINGWUGAMBHIR, NAT. METHODS., vol. 4, 2007, pages 641 - 643;;RAHNAMA, ENZYME MICROB. TECHNOL., vol. 96, 2017, pages 60 - 66;;NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 3402;;NCBI RESOURCE COORDINATORS, NUCLEIC ACIDS RES., vol. 41, 2013, pages D8 - D20;;FRICKEYLUPAS, BIOINFORMATICS, vol. 20, 2004, pages 3702 - 3704;;LIGODZIK, BIOINFORMATICS, vol. 22, 2006, pages 1658 - 1659;;EDGAR, BMC BIOINFORMATICS., vol. 5, 2004, pages 113;;HALL, NUCLEICACIDS SYMP. SER., vol. 41, 1999, pages 95 - 98;;GUINDON ET AL., SYST. BIOL., vol. 59, 2010, pages 307 - 321;;ABASCAL ET AL., BIOINFORMATICS, vol. 21, 2005, pages 2104 - 2105;;GOLDSTEIN, J. MOL. EVOL., vol. 42, 1996, pages 313 - 320;;YANG, MOL. BIOL. EVOL., vol. 24, 2007, pages 1586 - 1591;;HANSON-SMITH, KOLACZKOWSKITHORNTON, MOL. BIOL. EVOL., vol. 27, 1988;;FORTOVA ET AL., BIOCHIMIE, vol. 95, 2013, pages 2091 - 2096;;KAVANMAN, HYDROG. EXCH. MASS SPECTROM., vol. 302, 2011, pages 53 - 58;;GORDON ET AL., NUCLEICACIDS RES., vol. 33, 2005, pages W368 - W371;;DOERR ET AL., J. CHEM. THEORY COMPUT., vol. 12, 2016, pages 1845 - 1852;;HARVEYGIUPPONIFABRITIIS, J. CHEM. THEORY COMPUT., vol. 5, 2009, pages 2371 - 2377;;HOPKINS ET AL., J. CHEM. THEORY COMPUT., vol. 11, 2015, pages 1864 - 1874;;NARITOMIFUCHIGAMI, J. CHEM. PHYS., vol. 134, 2011, pages 065101;;WATERHOUSE ET AL., BIOINFORMATICS, vol. 25, 2009, pages 1189 - 1191;;NOTREDAME, HIGGINSHERINGA, J. MOL. BIOL., vol. 302, 2000, pages 205 - 217;;MCCOY ET AL., J. APPL. CRYSTALLOGR., vol. 40, 2007, pages 658 - 674;;ADAMS ET AL., METHODS STRUCT. PROTEOMICS., vol. 55, 2011, pages 94 - 106;;EMSLEY ET AL., ACTA CRYSTALLOGR. D BIOL. CRYSTALLOGR., vol. 66, 2010, pages 486 - 501",DISCONTINUED
